other	53	NBK43797|NBK1193|NBK1519|NBK1267|NBK253404|NBK424403|NBK84551|NBK1340|NBK410087|NBK1400|NBK1191|NBK1157|NBK1304|NBK1125|NBK100826|NBK121284|NBK1163|NBK1180|NBK1543|NBK285321|NBK349073|NBK114807|NBK100241|NBK1325|NBK1133|NBK1480|NBK343782|NBK1335|NBK97333|NBK401562|NBK174452|NBK1231|NBK1162|NBK1428|NBK1357|NBK1464|NBK2692|NBK100240|NBK1504|NBK143129|NBK92946|NBK1330|NBK1417|NBK379665|NBK1756|NBK1300|NBK1525|NBK425926|NBK1103|NBK447258|NBK4144|NBK1112|NBK1402	
the following are appropriate:	37	NBK1483|NBK1475|NBK1421|NBK1394|NBK1258|NBK1104|NBK1342|NBK131811|NBK3794|NBK2690|NBK5200|NBK1878|NBK1491|NBK1157|NBK1436|NBK11168|NBK1243|NBK114806|NBK1203|NBK1457|NBK47312|NBK61984|NBK7041|NBK321516|NBK1188|NBK1467|NBK100240|NBK299312|NBK1526|NBK1757|NBK1438|NBK1219|NBK1277|NBK1310|NBK1194|NBK1874|NBK1514	
seizures	22	NBK26471|NBK424403|NBK1293|NBK3794|NBK11167|NBK1191|NBK453432|NBK425540|NBK114458|NBK1150|NBK320989|NBK184570|NBK1173|NBK1428|NBK426063|NBK1115|NBK1195|NBK274566|NBK447257|NBK1220|NBK453434|NBK1183	
hearing loss	16	NBK1117|NBK1263|NBK425540|NBK114458|NBK2534|NBK1443|NBK1121|NBK390670|NBK368476|NBK274565|NBK214367|NBK1162|NBK1415|NBK425723|NBK1295|NBK1445	
skeletal	15	NBK253404|NBK1513|NBK1507|NBK1543|NBK349073|NBK1325|NBK390670|NBK1133|NBK5199|NBK1335|NBK1875|NBK1162|NBK425723|NBK1277|NBK425926	
cardiovascular	12	NBK355754|NBK253404|NBK1279|NBK1462|NBK1133|NBK343782|NBK1335|NBK1162|NBK1412|NBK425723|NBK1277|NBK1249	
respiratory	12	NBK26471|NBK1391|NBK1250|NBK1250|NBK1250|NBK1507|NBK1325|NBK5199|NBK148668|NBK425723|NBK1326|NBK2594	
dental	10	NBK1513|NBK1127|NBK1507|NBK1279|NBK1543|NBK1769|NBK1828|NBK148668|NBK1412|NBK425926	
treatment includes the following:	10	NBK154653|NBK333438|NBK1206|NBK114458|NBK1136|NBK1198|NBK1472|NBK24676|NBK1422|NBK1412	
gastrointestinal	9	NBK26471|NBK1250|NBK1157|NBK1279|NBK343782|NBK1412|NBK425723|NBK100240|NBK1249	
hearing	9	NBK1544|NBK5199|NBK148668|NBK425723|NBK1201|NBK1448|NBK1265|NBK1341|NBK1397	
the following are indicated:	9	NBK1536|NBK1272|NBK47079|NBK1354|NBK84258|NBK52787|NBK185329|NBK1353|NBK1445	
neurologic	8	NBK355754|NBK26468|NBK349073|NBK390803|NBK174452|NBK1412|NBK100240|NBK378974	
treatment is symptomatic	8	NBK355518|NBK1358|NBK1285|NBK201366|NBK1340|NBK236968|NBK447152|NBK9673	
motor dysfunction	8	NBK424403|NBK453432|NBK425540|NBK201978|NBK447920|NBK426063|NBK447257|NBK453434	
gross motor dysfunction	8	NBK424403|NBK453432|NBK425540|NBK201978|NBK447920|NBK426063|NBK447257|NBK453434	
consider use of durable medical equipment as needed (e	8	NBK424403|NBK453432|NBK425540|NBK201978|NBK447920|NBK426063|NBK447257|NBK453434	
fine motor dysfunction	8	NBK424403|NBK453432|NBK425540|NBK201978|NBK447920|NBK426063|NBK447257|NBK453434	
oral motor dysfunction	8	NBK424403|NBK453432|NBK425540|NBK201978|NBK447920|NBK426063|NBK447257|NBK453434	
eyes	8	NBK1409|NBK1180|NBK1287|NBK349072|NBK390670|NBK1480|NBK5199|NBK1397	
skin	8	NBK1157|NBK1304|NBK1125|NBK1543|NBK1287|NBK1769|NBK349072|NBK1397	
developmental pediatricians can provide assistance with transition to adulthood	8	NBK453432|NBK425540|NBK201978|NBK425723|NBK447920|NBK426063|NBK447257|NBK453434	
some issues to consider:	8	NBK453432|NBK425540|NBK201978|NBK425723|NBK447920|NBK426063|NBK447257|NBK453434	
renal disease	7	NBK1267|NBK410087|NBK1292|NBK114458|NBK53700|NBK1325|NBK401562	
eye	7	NBK253404|NBK1543|NBK1769|NBK1133|NBK1335|NBK148668|NBK1464	
sensorineural hearing loss	7	NBK2591|NBK201366|NBK1876|NBK57098|NBK1331|NBK201365|NBK378974	
nutrition	7	NBK247162|NBK97260|NBK305870|NBK320989|NBK1176|NBK1370|NBK1352	
growth	7	NBK1398|NBK1544|NBK1507|NBK390610|NBK148668|NBK1324|NBK1756	
ophthalmologic	7	NBK1216|NBK1462|NBK1325|NBK1162|NBK1412|NBK100240|NBK1302	
manifestation	7	NBK453432|NBK425540|NBK425128|NBK447920|NBK426063|NBK447257|NBK453434	
treatment	7	NBK453432|NBK425540|NBK425128|NBK447920|NBK426063|NBK447257|NBK453434	
communication issues	7	NBK453432|NBK425540|NBK201978|NBK447920|NBK426063|NBK447257|NBK453434	
and	6	NBK1517|NBK3789|NBK1124|NBK1166|NBK1283|NBK1382	
craniofacial	6	NBK1513|NBK1455|NBK1133|NBK425723|NBK1277|NBK1302	
hypothyroidism	6	NBK1110|NBK1332|NBK185066|NBK247161|NBK174451|NBK378974	
treatment is supportive	6	NBK396257|NBK195853|NBK1473|NBK373578|NBK1319|NBK327267	
forearm crutches or canes for gait stability	6	NBK1539|NBK1285|NBK1511|NBK1468|NBK153601|NBK169431	
special shoes, including those with good ankle support	6	NBK1205|NBK1285|NBK1511|NBK201366|NBK1468|NBK169431	
5 g/m2	6	NBK1458|NBK1458|NBK1458|NBK1458|NBK97260|NBK97260	
table 3	6	NBK453432|NBK97260|NBK174884|NBK447920|NBK426063|NBK447257	
considerations/other	6	NBK453432|NBK425540|NBK425128|NBK447920|NBK426063|NBK447257	
standard recommendations may vary from country to country	6	NBK453432|NBK201978|NBK425723|NBK447920|NBK426063|NBK447257	
ages 0-3 years	6	NBK453432|NBK425540|NBK201978|NBK425723|NBK447920|NBK453434	
ages 3-5 years	6	NBK453432|NBK425540|NBK201978|NBK425723|NBK447920|NBK453434	
ages 5-21 years	6	NBK453432|NBK425540|NBK201978|NBK425723|NBK447920|NBK453434	
all ages	6	NBK453432|NBK425540|NBK201978|NBK425723|NBK447920|NBK453434	
liver transplantation	6	NBK26372|NBK114807|NBK100241|NBK92947|NBK154378|NBK1515	
canes and walkers help prevent falls	6	NBK1184|NBK1225|NBK1399|NBK1275|NBK1471|NBK1256	
no specific therapy is available	5	NBK355518|NBK169825|NBK236968|NBK9673|NBK9673	
renal	5	NBK1207|NBK1157|NBK5199|NBK1326|NBK1445	
cardiomyopathy	5	NBK1267|NBK1261|NBK320989|NBK97333|NBK1173	
intellectual disability	5	NBK2591|NBK1191|NBK1484|NBK214367|NBK1183	
ataxia	5	NBK2591|NBK338165|NBK184570|NBK247161|NBK3795	
special education	5	NBK326661|NBK2587|NBK43417|NBK1535|NBK1277	
failure to thrive	5	NBK1110|NBK1332|NBK390670|NBK1280|NBK1525	
developmental delay	5	NBK1110|NBK1332|NBK425128|NBK1415|NBK274566	
1-0	5	NBK99496|NBK1474|NBK1180|NBK1283|NBK2692	
treatment is symptomatic and may include the following:	5	NBK1205|NBK1511|NBK1468|NBK153601|NBK169431	
dystonia	5	NBK1216|NBK453432|NBK320989|NBK1173|NBK378974	
in the united states:	5	NBK453432|NBK201978|NBK447920|NBK447257|NBK453434	
consider evaluation for alternative means of communication (e	5	NBK453432|NBK425540|NBK201978|NBK447257|NBK453434	
yes	5	NBK1283|NBK1283|NBK1283|NBK1283|NBK1283	
short stature	4	NBK1152|NBK84550|NBK1215|NBK425926	
endocrine	4	NBK1267|NBK390670|NBK1249|NBK378974	
neurologic manifestations	4	NBK333437|NBK115333|NBK435692|NBK1376	
pulmonary	4	NBK26468|NBK343782|NBK100240|NBK1352	
cancer	4	NBK26468|NBK1398|NBK22301|NBK1237	
physical therapy	4	NBK247162|NBK1279|NBK453432|NBK1121	
renal anomalies	4	NBK1380|NBK114806|NBK390670|NBK274566	
deafness	4	NBK22925|NBK2689|NBK3795|NBK274566	
5-1	4	NBK1156|NBK1319|NBK1319|NBK1319	
treatment follows routine practices	4	NBK304142|NBK4144|NBK4144|NBK4144	
speech therapy	4	NBK1168|NBK201366|NBK43417|NBK1214	
some individuals require forearm crutches or canes for gait stability	4	NBK1358|NBK1187|NBK1340|NBK1374	
cardiac	4	NBK1507|NBK5199|NBK148668|NBK1427	
caregivers	4	NBK385626|NBK367946|NBK385627|NBK379665	
heart defects	4	NBK1373|NBK114806|NBK274566|NBK1445	
psychotropic medication may also be indicated	4	NBK327268|NBK327268|NBK327268|NBK327268	
constipation	4	NBK327268|NBK1132|NBK426063|NBK453434	
antiepileptic drugs	4	NBK25442|NBK453432|NBK1214|NBK453434	
musculoskeletal	4	NBK1462|NBK368476|NBK148668|NBK1412	
spasticity	4	NBK453432|NBK338165|NBK184570|NBK247161	
global developmental disability / intellectual disability educational issues	4	NBK453432|NBK425540|NBK201978|NBK453434	
private supportive therapies based on the affected individual’s needs	4	NBK453432|NBK447920|NBK426063|NBK447257	
medications	4	NBK1163|NBK1135|NBK1121|NBK299312	
0-3	4	NBK1368|NBK1319|NBK1319|NBK1148	
developmental	4	NBK114806|NBK390670|NBK1412|NBK100240	
8-2	4	NBK1133|NBK1319|NBK1319|NBK1319	
gerd = gastroesophageal reflux disease	4	NBK426063|NBK426063|NBK447257|NBK447257	
hydrocephalus	3	NBK1419|NBK1152|NBK1484	
adrenal insufficiency	3	NBK1431|NBK190103|NBK174451	
hypertension	3	NBK1193|NBK1180|NBK1246	
liver disease	3	NBK1519|NBK1250|NBK1250	
hepatic disease	3	NBK1267|NBK100826|NBK121284	
pulmonary disease	3	NBK1267|NBK1370|NBK1122	
renal manifestations	3	NBK333437|NBK3789|NBK1376	
hyperlipidemia	3	NBK208534|NBK305870|NBK1370	
bleeding	3	NBK208534|NBK1287|NBK1370	
dialysis	3	NBK100238|NBK1283|NBK2692	
surgical stabilization of the spine may be required	3	NBK253404|NBK1133|NBK1335	
pectus excavatum can be severe	3	NBK253404|NBK1133|NBK1335	
optic atrophy	3	NBK2591|NBK1876|NBK4144	
appropriate treatment includes the following:	3	NBK169615|NBK269029|NBK7050	
diabetes mellitus	3	NBK1398|NBK4144|NBK378974	
for ages 0-3 years	3	NBK424403|NBK426063|NBK447257	
for ages 3-5 years	3	NBK424403|NBK426063|NBK447257	
for ages 5-21 years	3	NBK424403|NBK426063|NBK447257	
for all ages	3	NBK424403|NBK426063|NBK447257	
social/behavioral difficulties	3	NBK424403|NBK447920|NBK447257	
05-0	3	NBK1171|NBK1361|NBK1319	
weight control to avoid obesity	3	NBK1385|NBK1476|NBK1408	
feeding difficulties	3	NBK1391|NBK1191|NBK1183	
osteopenia	3	NBK1110|NBK425926|NBK1416	
management is supportive	3	NBK1544|NBK185330|NBK1140	
development	3	NBK1544|NBK174452|NBK1464	
exocrine pancreatic insufficiency	3	NBK1250|NBK1250|NBK1250	
anemia	3	NBK84550|NBK1364|NBK1351	
malignancy	3	NBK84550|NBK1176|NBK1246	
exercise within the individual's capability	3	NBK1205|NBK1285|NBK1511	
fewer than 5% need wheelchairs	3	NBK1285|NBK1187|NBK1374	
symptomatic treatment	3	NBK201366|NBK5201|NBK431123	
5-0	3	NBK3794|NBK1361|NBK1283	
0 g/m2	3	NBK1458|NBK1458|NBK97260	
audiologic	3	NBK1216|NBK1875|NBK1302	
fitting with appropriate hearing aids	3	NBK1536|NBK1272|NBK1383	
enrollment in an appropriate educational program for the hearing impaired	3	NBK1536|NBK1272|NBK1383	
growth hormone deficiency	3	NBK327268|NBK247161|NBK1324	
tolerance to different primary layers varies	3	NBK1157|NBK1304|NBK1125	
nonstick products (e	3	NBK1157|NBK1125|NBK1369	
silicone-based products without adhesive (e	3	NBK1157|NBK1304|NBK1125	
rolls of gauze (e	3	NBK1157|NBK1304|NBK1125	
cleft palate	3	NBK1263|NBK368476|NBK1407	
table 5	3	NBK425540|NBK1319|NBK453434	
neutropenia	3	NBK425540|NBK285321|NBK1364	
physical therapy is recommended to maximize mobility	3	NBK425540|NBK447257|NBK453434	
no specific treatment is available	3	NBK1384|NBK1384|NBK1384	
prevention of secondary manifestations	3	NBK1281|NBK1313|NBK1463	
ketogenic diet	3	NBK1318|NBK1430|NBK379665	
7-2	3	NBK1312|NBK1312|NBK1319	
pediatric issues	3	NBK1404|NBK1495|NBK7014	
liver	3	NBK390610|NBK1448|NBK1326	
sodium benzoate	3	NBK97260|NBK1357|NBK154378	
table 4	3	NBK97260|NBK425128|NBK1319	
orthopedic	3	NBK1769|NBK184570|NBK2594	
supportive therapy includes the following:	3	NBK2587|NBK43417|NBK1535	
use of respiratory aids when indicated	3	NBK1476|NBK1408|NBK1303	
genitourinary abnormalities	3	NBK190103|NBK368476|NBK1324	
epilepsy	3	NBK274565|NBK1284|NBK3795	
see hereditary hearing loss and deafness	3	NBK274565|NBK201365|NBK378974	
supportive and symptomatic management is indicated	3	NBK1828|NBK1875|NBK24701	
9-2	3	NBK1319|NBK1319|NBK1319	
2(1	3	NBK1319|NBK1319|NBK1319	
0(1	3	NBK1319|NBK1319|NBK1319	
5-2	3	NBK1319|NBK1319|NBK1319	
7-4	3	NBK1319|NBK1319|NBK1319	
surgery	3	NBK1414|NBK196157|NBK3822	
dysphagia	3	NBK1126|NBK1115|NBK378974	
vision	3	NBK1448|NBK1265|NBK1341	
hypogonadism	3	NBK247161|NBK1330|NBK378974	
care by a pediatric endocrinologist is recommended	3	NBK174451|NBK174451|NBK174451	
standard management	3	NBK426063|NBK426063|NBK453434	
craniosynostosis	2	NBK1419|NBK1415	
org)	2	NBK1418|NBK196157	
obesity	2	NBK1152|NBK1267	
obstructive sleep apnea	2	NBK1152|NBK425128	
ocular	2	NBK355754|NBK1207	
cleft lip/palate	2	NBK43797|NBK268648	
chronic treatment	2	NBK1431|NBK1353	
hypogonadotropic hypogonadism	2	NBK1431|NBK174451	
other treatments	2	NBK1193|NBK1143	
movement disorder	2	NBK26471|NBK3794	
lung disease	2	NBK1519|NBK1180	
no definitive treatments for the limb-girdle muscular dystrophies exist	2	NBK114459|NBK1408	
thrombocytopenia	2	NBK208534|NBK1364	
reducing the risk of neurologic damage	2	NBK1159|NBK154378	
see deafness and hereditary hearing loss overview, management	2	NBK2591|NBK1876	
immunodeficiency	2	NBK26468|NBK1287	
some symptoms (e	2	NBK1241|NBK1178	
bone marrow transplantation	2	NBK1426|NBK1271	
symptoms typically resolve within days	2	NBK169615|NBK320989	
bone marrow transplantation (bmt)	2	NBK1398|NBK1364	
education of parents regarding common seizure presentations is appropriate	2	NBK424403|NBK350554	
, contractures, scoliosis, hip dislocation)	2	NBK424403|NBK201978	
parkinsonism	2	NBK424403|NBK47027	
other features	2	NBK424403|NBK114806	
ovarian insufficiency	2	NBK1441|NBK242617	
infertility	2	NBK1441|NBK22925	
cardiac defects are managed in a routine manner	2	NBK373577|NBK214367	
the following are recommended:	2	NBK284774|NBK349072	
precocious puberty	2	NBK1171|NBK274564	
physical therapy and rehabilitation to improve motor function	2	NBK326661|NBK43417	
they can tolerate carbohydrates, fats, and protein	2	NBK1110|NBK1332	
oral motor dysfunction with persistent vomiting	2	NBK1110|NBK1332	
consultation with a gastroenterologist and nutritionist is often necessary	2	NBK1110|NBK1332	
"infantile catastrophic phase	2	NBK1110|NBK1332	
strabismus	2	NBK1110|NBK1332	
stroke-like episodes	2	NBK1110|NBK1332	
coagulopathy	2	NBK1110|NBK1332	
deep venous thrombosis (dvt)	2	NBK1110|NBK1332	
independent living issues	2	NBK1110|NBK1332	
0-2	2	NBK1156|NBK1319	
ocular manifestations	2	NBK154652|NBK1331	
aeruginosa in airway cultures	2	NBK1250|NBK1250	
bronchodilator	2	NBK1250|NBK1250	
hypertonic saline	2	NBK1250|NBK1250	
dornase alfa	2	NBK1250|NBK1250	
airway clearance	2	NBK1250|NBK1250	
fertility	2	NBK1250|NBK1547	
refractive errors may be managed with spectacles or contact lenses	2	NBK1348|NBK1190	
to improve alignment in primary gaze position	2	NBK1348|NBK1190	
colitis	2	NBK99496|NBK1287	
antidepressants are often required to treat concurrent depression	2	NBK304142|NBK5942	
ocular abnormalities	2	NBK5188|NBK1415	
services provided vary based on age and needs	2	NBK1337|NBK1222	
physical and occupational therapy	2	NBK1168|NBK1203	
ventilatory support	2	NBK1168|NBK1427	
daily heel cord stretching exercises to prevent achilles tendon shortening	2	NBK1539|NBK1511	
orthopedic surgery	2	NBK45014|NBK1393	
fewer than 5% of individuals need wheelchairs	2	NBK1358|NBK1205	
respiratory dysfunction	2	NBK201366|NBK1443	
odontoid hypoplasia	2	NBK201366|NBK148668	
exercise within the individual's capability to remain physically active	2	NBK1468|NBK169431	
hearing aids as needed	2	NBK131811|NBK321516	
management includes the following:	2	NBK1482|NBK453433	
0 mm in diameter	2	NBK7046|NBK1246	
pharmacologic treatment	2	NBK410087|NBK1295	
central nervous system	2	NBK1507|NBK1480	
cognitive	2	NBK1507|NBK1828	
endocrinopathies	2	NBK1507|NBK274564	
spine	2	NBK1455|NBK1180	
sodium benzoate: 250 mg/kg or 5	2	NBK1458|NBK1458	
sodium phenylacetate: 250 mg/kg or 5	2	NBK1458|NBK1458	
10% arginine hcl: 600 mg/kg or 12	2	NBK1458|NBK1458	
reversal of catabolism	2	NBK1458|NBK154378	
gastroesophageal reflux should be addressed in a standard manner	2	NBK1191|NBK1183	
ophthalmologic abnormalities are treated in the standard manner	2	NBK1191|NBK1183	
skeletal abnormalities (e	2	NBK1191|NBK1183	
hearing loss is treated with a trial of hearing aids	2	NBK1191|NBK1183	
infants benefit from enrollment in an early-intervention program	2	NBK1158|NBK390803	
pulmonary fibrosis	2	NBK22301|NBK1287	
thiamine	2	NBK220444|NBK1282	
riboflavin	2	NBK220444|NBK299312	
initial treatment	2	NBK1447|NBK1375	
long-term medical management	2	NBK1447|NBK1375	
levodopa	2	NBK1508|NBK1489	
treatment of psychiatric problems with appropriate psychotropic medications	2	NBK1491|NBK1438	
adaptation of environment and care to the level of dementia	2	NBK1491|NBK1438	
individuals with severe heart block may require pacemaker implantation	2	NBK1373|NBK1111	
growth retardation	2	NBK1373|NBK1370	
feeding therapy	2	NBK327268|NBK447257	
oral medications are usually tried first:	2	NBK1492|NBK378974	
baclofen (lioresal®)	2	NBK1492|NBK378974	
benzodiazepines	2	NBK1492|NBK1318	
primary layers include the following:	2	NBK1157|NBK1125	
, telfa®, n-terface®)	2	NBK1157|NBK1125	
, mepitel®, mepilex®)	2	NBK1157|NBK1125	
, kerlix®) are commonly used	2	NBK1125|NBK1369	
hypotrichosis	2	NBK1200|NBK1112	
see prevention of primary manifestations	2	NBK1279|NBK6816	
hematologic	2	NBK1279|NBK1237	
treatment of manifestations in individuals with ethylmalonic encephalopathy	2	NBK453432|NBK453432	
gorman et al [2016]	2	NBK453432|NBK453432	
enrollment in developmental disabilities administration (dda) is recommended	2	NBK453432|NBK447257	
hernia	2	NBK54467|NBK1277	
arterial abnormalities	2	NBK54467|NBK5201	
acute photosensitivity	2	NBK100826|NBK121284	
grey or smoke-colored filters provide only partial protection	2	NBK100826|NBK121284	
topical sunscreens are typically not useful	2	NBK100826|NBK121284	
close monitoring is warranted	2	NBK100826|NBK121284	
treatment of thrombosis in children	2	NBK1368|NBK1148	
antoun et al [2016]	2	NBK425540|NBK425540	
huemer et al [2015]	2	NBK425540|NBK425540	
the following measures are appropriate:	2	NBK1676|NBK385289	
referral of the family to support groups and other resources	2	NBK114458|NBK1526	
cryptorchidism	2	NBK114458|NBK268648	
dental problems	2	NBK114458|NBK1132	
pain	2	NBK1443|NBK1525	
thus, good sleep hygiene should be encouraged	2	NBK1318|NBK379665	
corticosteroids	2	NBK1318|NBK379665	
immunoglobulins	2	NBK1318|NBK379665	
educational programming directed to the specific disabilities identified	2	NBK1198|NBK24676	
cardiac manifestations	2	NBK115333|NBK373578	
intramuscular injections should be avoided unless under factor coverage	2	NBK1404|NBK1495	
dermatologic	2	NBK390610|NBK1237	
cataract	2	NBK390610|NBK1237	
250 mg/kg/day	2	NBK97260|NBK97260	
sodium phenylacetate	2	NBK97260|NBK154378	
mechanisms of drug action in treatment of hyperammonemia	2	NBK97260|NBK97260	
raises insulin levels	2	NBK97260|NBK97260	
induces anabolic state	2	NBK97260|NBK97260	
causes protein sparing effect from skeletal muscle amino acids	2	NBK97260|NBK97260	
stimulates secretion of insulin	2	NBK97260|NBK97260	
eliminates one amino group in the urine	2	NBK97260|NBK97260	
eliminates two amino groups in the urine	2	NBK97260|NBK97260	
a non-essential amino acid in humans	2	NBK97260|NBK97260	
surgical management	2	NBK1375|NBK196157	
renal and liver function	2	NBK100241|NBK100241	
full blood count	2	NBK100241|NBK100241	
psychological support	2	NBK1150|NBK1416	
table 7	2	NBK1338|NBK1283	
principles of treatment for individuals with hokpp	2	NBK1338|NBK1338	
add 0	2	NBK1338|NBK1338	
3 meq/kg/h	2	NBK1338|NBK1338	
(2) in the work setting	2	NBK1338|NBK1338	
myopathy	2	NBK1338|NBK1476	
behavior	2	NBK1769|NBK390803	
drugs to reduce muscle spasticity (e	2	NBK1509|NBK247161	
, oxybutynin)	2	NBK1509|NBK247161	
cd46	2	NBK1367|NBK1367	
cfh	2	NBK1367|NBK1367	
dgke	2	NBK1367|NBK1367	
thbd	2	NBK1367|NBK1367	
hyperuricemia/gout	2	NBK53700|NBK1356	
lifelong therapy with allopurinol may be required	2	NBK53700|NBK1356	
the transplanted kidney does not develop the disease	2	NBK53700|NBK1356	
current recommended drug therapies for adults with fh	2	NBK174884|NBK174884	
15% 1, 3	2	NBK174884|NBK174884	
50% 5	2	NBK174884|NBK174884	
often ineffective in hofh	2	NBK174884|NBK174884	
kastelein et al [2008]	2	NBK174884|NBK174884	
rader et al [2003]	2	NBK174884|NBK174884	
approved only for adults with hofh	2	NBK174884|NBK174884	
cuchel et al [2014]	2	NBK174884|NBK174884	
raal & santos [2012]	2	NBK174884|NBK174884	
physical therapy to improve motor function	2	NBK2587|NBK1535	
pharmacologic treatment of spasticity and seizures	2	NBK1675|NBK121988	
maintenance therapy	2	NBK1170|NBK1349	
genital anomalies	2	NBK114806|NBK390670	
surgery as required	2	NBK114806|NBK1324	
routine management	2	NBK114806|NBK426063	
thyroid hormone replacement as needed	2	NBK114806|NBK390670	
treatment of manifestations in individuals with kcnk9 imprinting syndrome	2	NBK425128|NBK425128	
standard treatment for scoliosis	2	NBK425128|NBK1457	
developmental disabilities administration (dda) enrollment is recommended	2	NBK201978|NBK453434	
social/behavioral issues	2	NBK201978|NBK425723	
therapeutic management of the sleep disorder	2	NBK47079|NBK1310	
management of seizures in accordance with standard practice	2	NBK47079|NBK1310	
auditory amplification if hearing loss is identified	2	NBK47079|NBK1310	
gonadotropin therapy	2	NBK1334|NBK1334	
spastic paraplegia	2	NBK1484|NBK1284	
general guidelines can be followed	2	NBK1484|NBK1284	
antiepileptic drugs (aed) if epileptic seizures are present	2	NBK43417|NBK1535	
acidosis	2	NBK320989|NBK1173	
psychological support for the affected individual and family is essential	2	NBK320989|NBK1173	
feeding	2	NBK184570|NBK5199	
psychomotor development	2	NBK368476|NBK1177	
gerd	2	NBK368476|NBK426063	
neurobehavioral symptoms	2	NBK1149|NBK1195	
the choice should be left to personal preference	2	NBK1133|NBK1335	
dural ectasia is usually asymptomatic	2	NBK1133|NBK1335	
no effective therapies for symptomatic dural ectasia currently exist	2	NBK1133|NBK1335	
hernias tend to recur after surgical intervention	2	NBK1133|NBK1335	
long-term treatment	2	NBK1361|NBK154378	
genitourinary	2	NBK343782|NBK1412	
joint contractures	2	NBK97333|NBK1525	
developmental delay/cognitive impairment	2	NBK97333|NBK4144	
specialized learning programs to meet individual needs	2	NBK84258|NBK52787	
no specific antiepileptic or antipsychotic medications are indicated	2	NBK84258|NBK52787	
cardiac malformations	2	NBK274565|NBK349624	
treatment should follow standard practice	2	NBK401562|NBK401562	
see hereditary hearing loss and deafness overview	2	NBK214367|NBK1302	
congenital heart defects	2	NBK1502|NBK1403	
stretching exercises are ineffective and painful	2	NBK1828|NBK1875	
the following treatment is appropriate:	2	NBK1214|NBK26373	
joints	2	NBK373578|NBK1302	
reasons for 28 hospitalizations in 15 infants with msud	2	NBK1319|NBK1319	
strauss et al [2010]	2	NBK1319|NBK1319	
4(2	2	NBK1319|NBK1319	
3(1	2	NBK1319|NBK1319	
1(1	2	NBK1319|NBK1319	
5-6	2	NBK1319|NBK1103	
3-9	2	NBK1319|NBK1319	
3-1	2	NBK1319|NBK1515	
0(3	2	NBK1319|NBK1319	
7(3	2	NBK1319|NBK1319	
7-7	2	NBK1319|NBK1319	
2(5	2	NBK1319|NBK1319	
50(0	2	NBK1319|NBK1319	
43-0	2	NBK1319|NBK1319	
58)	2	NBK1319|NBK1319	
from strauss et al [2010]	2	NBK1319|NBK1319	
with permission from elsevier	2	NBK1319|NBK1319	
acute pancreatitis	2	NBK1319|NBK190101	
infection	2	NBK1319|NBK1178	
see hirschsprung disease overview	2	NBK1412|NBK1427	
cataracts	2	NBK2689|NBK1417	
deep brain stimulation (dbs)	2	NBK1414|NBK1489	
cataracts can be removed if they impair vision	2	NBK1165|NBK1466	
other tumors	2	NBK1201|NBK196157	
photodysphoria (discomfort in bright light	2	NBK1166|NBK1232	
orthopedic treatment	2	NBK1295|NBK83985	
dental treatment	2	NBK1295|NBK83985	
treatment of decreased visual acuity is symptomatic (e	2	NBK1248|NBK4144	
, low-vision aids)	2	NBK1248|NBK4144	
250 mg/kg	2	NBK154378|NBK154378	
5,500 mg/m2	2	NBK154378|NBK154378	
batshaw et al [2001]	2	NBK154378|NBK154378	
loading dose given over 90 to 120 minutes	2	NBK154378|NBK154378	
maintenance dose given over 24 hours	2	NBK154378|NBK154378	
the typical dilution is 1:10	2	NBK154378|NBK154378	
arginine infusion not to exceed 150mg/kg/h	2	NBK154378|NBK154378	
surgery has been reported to be helpful by many patients	2	NBK190101|NBK84399	
fecal elastase-1 analysis (schebo® biotech ag	2	NBK190101|NBK84399	
, cck-8) or receptor agonists (e	2	NBK190101|NBK84399	
their nature (e	2	NBK190101|NBK84399	
blocking of pancreatic lipase (e	2	NBK190101|NBK84399	
diseases of the intestinal mucosa	2	NBK190101|NBK84399	
diffusion-weighted mri	2	NBK190101|NBK84399	
monitoring for glucose intolerance	2	NBK190101|NBK84399	
hypoventilation	2	NBK47027|NBK426063	
consider aspirin treatment	2	NBK395975|NBK395975	
severe atp8b1 deficiency	2	NBK1297|NBK1297	
mild atp8b1 deficiency	2	NBK1297|NBK1297	
reduction of calcium oxalate supersaturation	2	NBK1283|NBK2692	
organ transplantation	2	NBK1283|NBK2692	
only if affected person is known to be b6 responsive	2	NBK1283|NBK1283	
from cochat et al [2012]	2	NBK1283|NBK1283	
recommendations assume the availability of facilities	2	NBK1283|NBK1283	
pox= plasma oxalate	2	NBK1283|NBK1283	
see note	2	NBK1266|NBK1266	
visual impairment	2	NBK247161|NBK1300	
cys282tyr / p	2	NBK143129|NBK143129	
treatment of medical manifestations in individuals with ptls	2	NBK447920|NBK447920	
standard treatment as recommended by dentist/orthodontist	2	NBK447920|NBK447257	
poor weight gain / failure to thrive	2	NBK447920|NBK447257	
global developmental delay / intellectual disability educational issues	2	NBK447920|NBK447257	
, orthotics, adaptive strollers)	2	NBK447920|NBK447257	
chemotherapy	2	NBK196157|NBK196157	
5 years	2	NBK196157|NBK1112	
joint pain	2	NBK327267|NBK425926	
see published guidelines/consensus statements	2	NBK1148|NBK1377	
treatment of manifestations in individuals with pura-related neurodevelopmental disorders	2	NBK426063|NBK426063	
scoliosis	2	NBK426063|NBK148820	
sleep	2	NBK1115|NBK2594	
skeletal abnormalities	2	NBK1324|NBK1756	
treatments include the following:	2	NBK6803|NBK425223	
standard treatment with antiepileptic drugs for seizures	2	NBK6803|NBK425223	
physical, occupational, and speech therapies, if necessary	2	NBK26373|NBK55062	
standard treatment is indicated	2	NBK1403|NBK1403	
treatment of manifestations in individuals with trio-related intellectual disability	2	NBK447257|NBK447257	
treatment of manifestations in individuals with unc80 deficiency	2	NBK453434|NBK453434	
see retinitis pigmentosa overview, management	2	NBK1265|NBK1341	
educational support	2	NBK1874|NBK148820	
hearing impairment	2	NBK4144|NBK349624	
medical measures	1	NBK1396	
early use of antibiotics for bacterial infections	1	NBK1396	
insertion	1	NBK1396	
physiotherapy including hydrotherapy to avoid strain on the joints	1	NBK1396	
use of a wheelchair if necessary	1	NBK1396	
orthopedic intervention if necessary	1	NBK1396	
special shoes may help with ankle and foot support	1	NBK1396	
therefore, ventriculocaval shunts are preferred	1	NBK1396	
educational opportunities/social considerations	1	NBK1396	
use of sign language in individuals with significant hearing loss	1	NBK1396	
early educational intervention for development of social skills	1	NBK1396	
speech therapy to improve speech	1	NBK1396	
special education to maximize learning	1	NBK1396	
planning housing for possible future wheelchair use	1	NBK1396	
hbh disease	1	NBK1435	
cortisol deficiency	1	NBK1419	
genital abnormalities	1	NBK1419	
hypospadias and cryptorchidism may be corrected with surgery	1	NBK1419	
vaginal reconstruction may be performed in females with vaginal hypoplasia	1	NBK1419	
ovarian cysts	1	NBK1419	
nasal stints or tracheotomy may be required	1	NBK1419	
joint contractures and elbow synostosis	1	NBK1419	
early developmental/educational intervention is appropriate for cognitive delays	1	NBK1372	
low-dose neuroleptics may be useful for psychiatric manifestations	1	NBK1372	
referral for psychiatric evaluation is appropriate	1	NBK1372	
low vision aids include high-powered magnifiers for reading	1	NBK1418	
achromat	1	NBK1418	
provide palliative care for viable newborns	1	NBK1516	
only modest effects on adult stature seem to accrue	1	NBK1152	
measures to avoid obesity should start in early childhood	1	NBK1152	
craniocervical junction constriction	1	NBK1152	
the best predictors of need for suboccipital decompression include:	1	NBK1152	
lower-limb hyperreflexia or clonus	1	NBK1152	
central hypopnea demonstrated by polysomnography	1	NBK1152	
treatment may include the following:	1	NBK1152	
adenotonsillectomy	1	NBK1152	
weight reduction	1	NBK1152	
continuous positive airway pressure	1	NBK1152	
tracheostomy for extreme cases	1	NBK1152	
middle ear dysfunction	1	NBK1152	
varus deformity	1	NBK1152	
various interventions may be elected (e	1	NBK1152	
kyphosis	1	NBK1152	
spinal stenosis	1	NBK1152	
socialization	1	NBK1152	
desferrioxamine	1	NBK1493	
treatment with iron chelating agents (i	1	NBK1493	
deferasirox	1	NBK1493	
deferiprone	1	NBK1493	
fresh-frozen human plasma	1	NBK1493	
if the serum potassium concentration is low (<3	1	NBK1264	
treatment for actg2-related disorders remains supportive	1	NBK299311	
urologic manifestations	1	NBK299311	
management of bladder dysfunction by an urologist is recommended	1	NBK299311	
gastrointestinal manifestations	1	NBK299311	
however, bladder catheterization was still required	1	NBK299311	
prophylaxis for pneumocystis jiroveci	1	NBK1483	
intravenous immunoglobulin (ivig)	1	NBK1483	
cutaneous/cranial	1	NBK355754	
wounds without calvarial involvement	1	NBK355754	
plastic wrap (e	1	NBK355754	
, duoderm®)	1	NBK355754	
other less preferred, less costly dressings are:	1	NBK355754	
wounds with calvarial defects: acute care	1	NBK355754	
wounds with calvarial defects: late calvarial reconstruction	1	NBK355754	
limb	1	NBK355754	
early physiotherapy can maximize motor function and range of motion	1	NBK355754	
management of seizures is per routine	1	NBK355754	
if typical signs (e	1	NBK84111	
medication has been variably effective in suppressing debilitating symptoms	1	NBK263441	
j friedman, personal observation]	1	NBK263441	
fm hisama, personal observation]	1	NBK263441	
stress management	1	NBK263441	
intrafamilial variation in pharmaco-responsiveness occurs	1	NBK1169	
therefore, all appropriate aeds should be tried	1	NBK1169	
speech, occupational, and physical therapy	1	NBK355518	
specialized learning programs depending on individual needs	1	NBK355518	
nutritional support if necessary	1	NBK355518	
routine treatment of cardiac and ophthalmologic findings	1	NBK355518	
ankyloblepharon filiforme adnatum	1	NBK43797	
larger ones may require surgical separation by an ophthalmologist	1	NBK43797	
ectodermal defects	1	NBK43797	
skin erosions	1	NBK43797	
empiric treatment (i	1	NBK43797	
clefting should be addressed as soon as developmentally possible	1	NBK43797	
chest physiotherapy and vigorous treatment of respiratory complications	1	NBK1475	
management of seizures using standard protocols	1	NBK1475	
acute episodes	1	NBK1431	
correction of hyperkalemia may be needed	1	NBK1431	
, solu-cortef®)	1	NBK1431	
adequate sodium must be provided	1	NBK1431	
treatment during stress	1	NBK1431	
, intercurrent illness, surgery, trauma)	1	NBK1431	
glucose and sodium may be needed	1	NBK1431	
parents should have access to rapid medical advice	1	NBK1431	
guidelines for hospital admission should be clear	1	NBK1431	
acth levels should normalize when replacement therapy is adequate	1	NBK1431	
acute neurovisceral attack	1	NBK1193	
clinical assessment should include a full neurologic evaluation	1	NBK1193	
investigations should include:	1	NBK1193	
full blood count (fbc)	1	NBK1193	
serum and urine osmolality	1	NBK1193	
urine sodium concentration if hyponatremic	1	NBK1193	
, crp, blood cultures, ck, magnesium	1	NBK1193	
mri should be considered if cns symptoms are present	1	NBK1193	
general measures	1	NBK1193	
see agents/circumstances to avoid	1	NBK1193	
restore energy balance using an enteral route if possible	1	NBK1193	
treat intercurrent infections and other diseases promptly	1	NBK1193	
supportive treatment	1	NBK1193	
pain relief	1	NBK1193	
nausea and vomiting	1	NBK1193	
prochloperazine, promazine or ondansetron are considered safe	1	NBK1193	
beta blockers are considered safe	1	NBK1193	
fluid balance and electrolytes	1	NBK1193	
dextrose saline is preferred	1	NBK1193	
specific treatment	1	NBK1193	
it is infused over at least 30 minutes	1	NBK1193	
recurrent acute attacks	1	NBK1193	
gynecological review and bone density monitoring are recommended	1	NBK1193	
prophylactic hemin infusion	1	NBK1193	
however, evidence for clinical efficacy remains elusive	1	NBK1193	
, medicalert® or similar)	1	NBK1193	
see resources	1	NBK1193	
liver transplantation for end-stage liver disease has an 80	1	NBK1273	
cardiac involvement is treated in a standard manner	1	NBK1273	
renal anomalies are treated in a standard manner	1	NBK1273	
vascular accidents should be treated in a standard manner	1	NBK1273	
head injuries and neurologic symptoms should be evaluated aggressively	1	NBK1273	
ophthalmologic abnormalities rarely need intervention	1	NBK1273	
vertebral anomalies are rarely symptomatic	1	NBK1273	
no specific therapy is currently available for alexander disease	1	NBK1172	
neuroblastoma and ganglioneuroblastoma	1	NBK24599	
aortic stenosis may necessitate valve replacement	1	NBK1454	
treatment is limited to symptom management and supportive care	1	NBK26471	
alpers-huttenlocher syndrome	1	NBK26471	
family education is critical	1	NBK26471	
supportive therapies	1	NBK26471	
hepatic	1	NBK26471	
treatment with cpap or bipap as indicated is appropriate	1	NBK26471	
seizure control is a goal of treatment	1	NBK26471	
other phenotypes	1	NBK26471	
gastrostomy may be required to provide adequate nutrition	1	NBK26471	
surgery for ptosis may provide symptomatic relief for some	1	NBK26471	
, influenza and pneumococcal)	1	NBK1519	
controls	1	NBK1519	
recommend intravenous aat augmentation therapy for individuals with established emphysema	1	NBK1519	
, fev1 35%-60% predicted)	1	NBK1519	
2 months post-liver transplant and not achieving statistical significance	1	NBK1519	
panniculitis	1	NBK1519	
hypertensive individuals should receive appropriate management	1	NBK1207	
male relative without hematuria	1	NBK1207	
male relative with hematuria	1	NBK1207	
female relative without hematuria	1	NBK1207	
female relative with hematuria (i	1	NBK1207	
, heterozygous female)	1	NBK1207	
cochlear	1	NBK1207	
hearing aids should be prescribed when appropriate	1	NBK1207	
some individuals develop cataracts that interfere with vision	1	NBK1207	
these should be extracted when necessary	1	NBK1207	
diffuse leiomyomatosis	1	NBK1207	
symptomatic leiomyomas may require surgical intervention	1	NBK1207	
monitoring for and treatment of lymphoproliferation and hypersplenism	1	NBK1108	
however, sirolimus is not without side effects	1	NBK1108	
treatment of lymphoma is according to conventional protocols	1	NBK1108	
treatment of cytopenias and other autoimmune diseases	1	NBK1108	
caregiver and patient support groups are valuable	1	NBK268647	
options include:	1	NBK268647	
ssris	1	NBK268647	
venlafaxine	1	NBK268647	
however, weakness and lethargy are common side effects	1	NBK1450	
low-tech (e	1	NBK1450	
, alphabet board) and high-tech (i	1	NBK1450	
no therapy exists to prevent the progressive organ involvement	1	NBK1267	
rod-cone dystrophy	1	NBK1267	
progressive sensorineural hearing loss	1	NBK1267	
hearing can be maximized with bilateral digital hearing aids	1	NBK1267	
exercise	1	NBK1267	
and metformin	1	NBK1267	
hypertriglyceridemia	1	NBK1267	
pancreatitis should be treated as in the general population	1	NBK1267	
urologic	1	NBK1267	
prevention of primary complications	1	NBK1267	
depression and seizures should be treated with appropriate medications	1	NBK1236	
the first such drug was tacrine	1	NBK1161	
however, this agent is also hepatotoxic	1	NBK1161	
antidepressant medication may improve associated depression	1	NBK1161	
seizures have occurred in some affected infants	1	NBK1365	
assignment of sex of rearing	1	NBK1429	
even in cais this may not always be easy	1	NBK1429	
cais	1	NBK1429	
however, the issue of gonadectomy is controversial	1	NBK1429	
pais with predominantly female genitalia (incomplete ais)	1	NBK1429	
pais with ambiguous genitalia or predominantly male genitalia	1	NBK1429	
gynecomastia that develops in puberty eventually requires reduction mammoplasty	1	NBK1429	
mais	1	NBK1429	
the customary medical treatment (i	1	NBK1144	
sometimes fundoplication as required	1	NBK1144	
no one drug has proven superior	1	NBK1144	
medications used for minor motor seizures (e	1	NBK1144	
hypermotoric behaviors are typically resistant to behavioral therapies	1	NBK1144	
unstable or nonambulatory children may benefit from physical therapy	1	NBK1144	
individualization and flexibility in the school are important educational strategies	1	NBK1144	
administration of 0	1	NBK1144	
strabismus may require surgical correction	1	NBK1144	
aniridia	1	NBK1360	
simple measures are often the most important:	1	NBK1360	
regular eye examinations and correction of refractive errors	1	NBK1360	
occlusion therapy for anisometropic amblyopia or strabismic amblyopia in childhood	1	NBK1360	
advice and help with schooling	1	NBK1360	
social support	1	NBK1360	
lens	1	NBK1360	
children rarely require surgery (lens aspiration or lensectomy)	1	NBK1360	
in adults, phacoemulsification can be successful	1	NBK1360	
intraocular pressure	1	NBK1360	
glaucoma is usually initially treated with topical anti-glaucoma medication	1	NBK1360	
trabeculectomy with or without antimetabolites (e	1	NBK1360	
medical treatment is generally ineffective and surgery is required	1	NBK1360	
cornea	1	NBK1360	
aniridic fibrosis syndrome	1	NBK1360	
wilms tumor	1	NBK1360	
see wilms tumor overview	1	NBK1360	
the need for orthoses or other assistive devices varies individually	1	NBK114459	
most patients remain ambulatory without assistance for decades	1	NBK114459	
provide palliative care for the viable newborn	1	NBK1317	
educational support (e	1	NBK1154	
, behavioralists) who can provide the following:	1	NBK5300	
gait safety devices including canes and wheel chairs	1	NBK5300	
behavioral modification and cognitive aids as needed	1	NBK5300	
there are no formal management guidelines for apoe p	1	NBK208534	
leu167del-related lipid disorders	1	NBK208534	
in patients with fasting triglyceride levels:	1	NBK208534	
splenomegaly	1	NBK208534	
splenectomy should be avoided as it may worsen hyperlipidemia	1	NBK208534	
liver function abnormalities	1	NBK208534	
persistent nausea	1	NBK208534	
vomiting	1	NBK208534	
abdominal pain	1	NBK208534	
yellow discoloration of the skin	1	NBK208534	
bruising	1	NBK208534	
any new petechial rash	1	NBK208534	
allopurinol	1	NBK100238	
febuxostat	1	NBK100238	
treatment of esrd	1	NBK100238	
kidney transplantation	1	NBK100238	
arginine supplementation is obviously contraindicated	1	NBK1159	
rapidly reducing plasma ammonia concentration	1	NBK1159	
pharmacologic management to allow alternative pathway excretion of excess nitrogen	1	NBK1159	
in early treatment, feeding 1	1	NBK1159	
0 to 1	1	NBK1159	
older children require and tolerate lower protein intake	1	NBK1159	
seizures are easily treated by phenobarbital or carbamazepine	1	NBK1159	
discontinuing oral protein intake	1	NBK51784	
intravenous nitrogen scavenging therapy	1	NBK51784	
ammonia levels usually normalize with therapy	1	NBK51784	
nitrogen scavenging therapy needs to be continued during hemodialysis	1	NBK51784	
curative therapy is not available	1	NBK1255	
clinical history studies are limited	1	NBK253404	
aneurysms and focal stenoses are amenable to surgical intervention	1	NBK253404	
hernias may recur after surgical repair	1	NBK253404	
emphysema is treated symptomatically	1	NBK253404	
, swimming) performed in moderation	1	NBK253404	
no treatment is available	1	NBK2591	
see hereditary ataxias, management	1	NBK2591	
beta blockers are considered first line therapy	1	NBK1131	
however, individual responses to specific medications (e	1	NBK26468	
(see also therapies under investigation	1	NBK26468	
speech therapy may benefit persons with dysarthria	1	NBK1138	
one of the following vitamin e preparations is used:	1	NBK1241	
the naturally occurring form, rrr-α-tocopherol	1	NBK1241	
thalassemia major	1	NBK1426	
transfusions are usually given every two to three weeks	1	NBK1426	
thalassemia intermedia	1	NBK1426	
cord blood transplantation	1	NBK1426	
uveal melanoma	1	NBK390611	
malignant mesothelioma	1	NBK390611	
thus, a cure is unlikely	1	NBK390611	
there is no specific treatment of bwcff syndrome	1	NBK327153	
symptomatic management involves the following	1	NBK327153	
ptosis may require surgical treatment	1	NBK327153	
hearing loss may require routine care including hearing aids	1	NBK327153	
epilepsy is treated using standard protocols	1	NBK327153	
management of heart failure	1	NBK247162	
management of neutropenia	1	NBK247162	
78 ± 0	1	NBK247162	
45-12	1	NBK247162	
8 years, with an average exposure of 7	1	NBK247162	
3 years	1	NBK247162	
educational support in school	1	NBK247162	
, renal or hepatic dysfunction)	1	NBK1363	
indicators are functional interference and poorly fitting footwear	1	NBK1363	
dental extractions are appropriate as required for dental crowding	1	NBK1363	
insertion of grommets is commonplace	1	NBK1363	
manifestations should be treated by specialists (e	1	NBK1151	
keratocysts usually require surgical excision	1	NBK1151	
systemic treatment with retinoids (e	1	NBK1151	
bethlem myopathy	1	NBK1503	
ullrich cmd	1	NBK1503	
contractures tend to be aggressive and may require surgery	1	NBK1503	
kcnq2-bfne	1	NBK32534	
refractory seizures are uncommon in kcnq2-related bfne	1	NBK32534	
kcnq2-nee	1	NBK32534	
augmentative communication techniques can be valuable for many patients	1	NBK32534	
antiepileptic treatment for seizures	1	NBK1421	
symptomatic treatment for headaches	1	NBK1421	
biotin and thiamine therapy	1	NBK169615	
biotin and thiamine need to be given lifelong	1	NBK169615	
in the acute stage empiric treatment with antimicrobial/antiviral agents	1	NBK169615	
fever control	1	NBK169615	
antiepileptic drugs for effective control of seizures	1	NBK169615	
symptomatic treatment of dystonia, including administration of l-dopa	1	NBK169615	
rehabilitation, physiotherapy, occupational therapy, and speech therapy	1	NBK169615	
educational programs adapted to individual needs	1	NBK169615	
therefore, renal tumors greater than 3	1	NBK1522	
no treatment for bcd currently exists	1	NBK91457	
psychosocial	1	NBK1398	
milunsky et al [2011] provided management guidelines	1	NBK55063	
see table iii)	1	NBK55063	
they should not be cauterized	1	NBK55063	
most larger skin defects require surgical excision	1	NBK55063	
recommended treatment:	1	NBK1380	
second branchial arch anomalies	1	NBK1380	
excise branchial cleft cysts/fistulae	1	NBK1380	
otologic anomalies	1	NBK1380	
fit with appropriate aural habilitation as indicated	1	NBK1380	
enroll in an appropriate educational program for the hearing impaired	1	NBK1380	
consider canaloplasty to correct an atretic canal	1	NBK1380	
treat urologic and renal abnormalities in the standard manner	1	NBK1380	
if renal anomalies (e	1	NBK1380	
if esrd develops, consider renal transplantation	1	NBK1380	
global developmental disability/intellectual disability	1	NBK424403	
disordered sleep	1	NBK424403	
ophthalmologic findings	1	NBK424403	
eye findings are treated in a routine manner	1	NBK424403	
regular pulmonary hygiene to manage risk for pulmonary complications	1	NBK424403	
tracheostomy as indicated when secretions are difficult to manage	1	NBK424403	
eyelid surgery	1	NBK1441	
timing of eyelid surgery is controversial	1	NBK1441	
however, it remains controversial	1	NBK1441	
hormone replacement therapy (hrt)	1	NBK1441	
it is important to:	1	NBK1517	
controversy exists regarding the treatment of asymptomatic individuals	1	NBK1517	
treatment of craniofacial manifestations (e	1	NBK373577	
there are no reports on the use of aflibercept	1	NBK1167	
the cnv regressed and the subretinal hemorrhage resolved	1	NBK1167	
genetic counseling and occupational counseling should be offered	1	NBK1167	
abdominal wall repair for omphalocele soon after birth	1	NBK1394	
generally, this surgery is well tolerated	1	NBK1394	
management of difficulties arising from macroglossia:	1	NBK1394	
some children benefit from tongue reduction surgery	1	NBK1394	
orthodontic intervention as needed in later childhood/adolescence	1	NBK1394	
assessment of speech difficulties	1	NBK1394	
management of cleft palate following standard protocols	1	NBK1394	
referral to a craniofacial surgeon if facial hemihyperplasia is significant	1	NBK1394	
treatment of neoplasias following standard pediatric oncology protocols	1	NBK1394	
, nephrocalcinosis)	1	NBK1394	
management of cardiac problems following standard protocols	1	NBK1394	
during acute episodes	1	NBK284774	
restrict protein intake if plasma ammonia is elevated	1	NBK284774	
without carglumic acid, hyperammonemia persisted longer (i	1	NBK284774	
, an additional 1-2 days)	1	NBK284774	
there is no treatment of proven efficacy for cadasil	1	NBK1500	
classic 21-ohd cah	1	NBK1171	
glucocorticoid replacement therapy	1	NBK1171	
the use of oral hydrocortisone suspension is discouraged	1	NBK1171	
during periods of stress (e	1	NBK1171	
affected individuals should carry medical information regarding emergency steroid dosing	1	NBK1171	
mineralocorticoid replacement therapy	1	NBK1171	
sodium chloride supplementation may not be necessary after infancy	1	NBK1171	
feminizing genitoplasty	1	NBK1171	
the systematic evidence for this belief is lacking	1	NBK1171	
testicular adrenal rest tumors	1	NBK1171	
transition from adolescence to adulthood	1	NBK1171	
women with classic cah had increased diastolic blood pressure	1	NBK1171	
subjective health status was significantly impaired and fertility compromised	1	NBK1171	
adrenalectomy	1	NBK1171	
non-classic 21-ohd cah	1	NBK1171	
most survivors with cd require orthopedic care	1	NBK1760	
club feet require surgical correction	1	NBK1760	
the hips should be checked for luxation	1	NBK1760	
bracing is usually not helpful	1	NBK1760	
neonatal/infantile canavan disease	1	NBK1234	
seizures may be treated with antiepileptic drugs (aeds)	1	NBK1234	
diamox® seems to reduce intracranial pressure	1	NBK1234	
botox® injections may be used to relieve spasticity	1	NBK1234	
mild/juvenile canavan disease	1	NBK1234	
scoliosis may require bracing or surgical correction	1	NBK246980	
personality change may require antipsychotic medication	1	NBK32533	
a wig or hairpiece may be helpful for alopecia	1	NBK32533	
the following interventions are routine:	1	NBK1286	
cardiac myxoma	1	NBK1286	
open-heart surgery	1	NBK1286	
cutaneous and mammary myxoma	1	NBK1286	
surgical excision	1	NBK1286	
cushing syndrome	1	NBK1286	
bilateral adrenalectomy	1	NBK1286	
pituitary adenoma	1	NBK1286	
transsphenoidal surgery	1	NBK1286	
thyroid adenomas	1	NBK1286	
surgery if cancerous	1	NBK1286	
lccsct	1	NBK1286	
pms	1	NBK1286	
surgery to remove primary and/or metastatic lesions	1	NBK1286	
no specific treatment is currently available for caveolinopathies	1	NBK1385	
management should include the following:	1	NBK1385	
infants are started with daily 1	1	NBK1328	
0 mg intramuscular or subcutaneous injections	1	NBK1328	
acute metabolic decompensation	1	NBK1328	
long-term management	1	NBK1328	
these are accomplished by:	1	NBK1328	
parenteral ohcbl	1	NBK1328	
0 mg (~0	1	NBK1328	
betaine	1	NBK1328	
optimal dosing and monitoring have not been adequately established	1	NBK1328	
folate and folinic acid	1	NBK1328	
the adult dose of folate is 1	1	NBK1328	
5 mg for maintenance	1	NBK1328	
dietary management	1	NBK1328	
other therapeutic considerations that have not been fully validated:	1	NBK1328	
methionine supplementation	1	NBK1328	
pyridoxine	1	NBK1328	
levocarnitine	1	NBK1328	
indicated for low plasma carnitine levels	1	NBK1328	
supportive therapy includes the following as needed:	1	NBK326661	
treatment of headache	1	NBK326661	
guidance for visual impairment	1	NBK326661	
classic cca	1	NBK1386	
this type of therapy is best instituted in childhood	1	NBK1386	
surgical release of contractures may be necessary	1	NBK1386	
consultation with an orthopedist is encouraged	1	NBK1386	
severe/lethal cca	1	NBK1386	
no general recommendations exist	1	NBK1386	
speech therapy may be required during periods of dental treatment	1	NBK1513	
sinus and middle ear infections require aggressive and timely treatment	1	NBK1513	
helmets may be advised for high-risk activities	1	NBK1513	
the treatment of cataracts is surgical	1	NBK25565	
regular rehabilitation can prevent or postpone osteoporosis	1	NBK25565	
recurrent hemorrhage or mass effect	1	NBK1293	
neuropsychological testing may be considered prior to any neurosurgical procedure	1	NBK1293	
microsurgical techniques rely on intraoperative examination for precise localization	1	NBK1293	
headaches	1	NBK1293	
neurologic deficits	1	NBK1293	
hypotonia and weakness	1	NBK1391	
patients may benefit from physical therapy	1	NBK1391	
scoliosis and joint contractures	1	NBK1391	
patients with more severe symptoms may require respiratory support	1	NBK1391	
peginterferon-α2b has also been given once a week	1	NBK5313	
the mechanism behind this response is unknown	1	NBK5313	
splenectomy is of unproved value	1	NBK5313	
orthopedic issues—thorax shortening, scoliosis/kyphosis	1	NBK1110	
occasionally, surgical treatment of spinal curvature is warranted	1	NBK1110	
others may have a more refractory course	1	NBK1332	
renal issues	1	NBK1332	
immunologic status	1	NBK1332	
most individuals affected with cdgs have functional immune systems	1	NBK1332	
additional management issues of adults with cdg	1	NBK1332	
orthopedic issues — thorax shortening, scoliosis/kyphosis	1	NBK1332	
recently, therapy may start in the prenatal period	1	NBK1359	
postnatal treatment	1	NBK1359	
emphasis must be on preventing secondary lung injury	1	NBK1359	
it is unclear whether ecmo improves survival in cdh	1	NBK1359	
prenatal treatment	1	NBK1359	
surgical correction of intestinal malrotation if present	1	NBK1104	
alternative communicative methods (e	1	NBK1104	
standard treatment for hearing loss	1	NBK1104	
standard interventions for cardiac defects	1	NBK1104	
appropriate treatment for seizures	1	NBK1104	
antibiotic prophylaxis and follow up for vesicoureteral reflux	1	NBK1104	
orchiopexy if cryptorchidism is present	1	NBK1104	
standard intervention for bicornuate uterus, if present	1	NBK1104	
cervical spine stenosis may require decompression	1	NBK1544	
thoracic and lumbar spine (for scoliosis)	1	NBK1544	
l-carnitine supplementation	1	NBK84551	
l-carnitine supplementation has relatively few side effects:	1	NBK84551	
hypoglycemic episodes are treated with intravenous dextrose infusion	1	NBK84551	
cardiomyopathy requires management by specialists in cardiology	1	NBK84551	
correction of polydactyly (optional)	1	NBK154653	
orthopedic care as required (e	1	NBK154653	
, for hip dysplasia)	1	NBK154653	
dental care	1	NBK154653	
standard treatment for renal and liver abnormalities	1	NBK154653	
pneumonia should be treated with antibiotics	1	NBK154653	
asthma can be treated with steroids	1	NBK154653	
standard treatment for cardiac abnormalities	1	NBK154653	
no consensus management guidelines have been developed to date	1	NBK1156	
improving gait, exercise tolerance, and flexion contractures	1	NBK1156	
unsuccessful steroid therapy was reported in one adult	1	NBK1156	
less symptomatic individuals can be started on 0	1	NBK1156	
0 mg/kg every other day	1	NBK1156	
higher-dose steroids may help with acute pain crises	1	NBK1156	
calcitonin	1	NBK1156	
losartan	1	NBK1156	
pain in the tibia resolved completely following the surgery	1	NBK1156	
corticosteroids may delay skull hyperostosis and cranial nerve impingement	1	NBK1156	
three underwent internal auditory canal decompression with mixed results	1	NBK1156	
celiac disease	1	NBK1727	
a dietitian experienced in treating celiac disease should be involved	1	NBK1727	
, 100 mg) can damage the small intestine	1	NBK1727	
note that a slice of bread contains approximately 2	1	NBK1727	
5 grams of gluten	1	NBK1727	
some hidden sources of gluten:	1	NBK1727	
non-starchy foods such as soy sauce and beer	1	NBK1727	
, lipstick)	1	NBK1727	
refractory sprue or celiac disease	1	NBK1727	
cutaneous photosensitivity	1	NBK154652	
reflectant sunscreens containing zinc oxide or titanium dioxide	1	NBK154652	
skin trauma should be avoided	1	NBK154652	
wound care is essential to prevent infection of opened blisters	1	NBK154652	
laser hair removal can be used to treat facial hypertrichosis	1	NBK154652	
topical antibiotics for corneal ulcers, scleritis, and blepharitis	1	NBK154652	
bone manifestations	1	NBK154652	
hemolytic anemia	1	NBK154652	
consider blood transfusions when hemolysis is significant	1	NBK154652	
cystic fibrosis (cf)	1	NBK1250	
inhaled dornase alfa in all individuals age ≥6 years	1	NBK1250	
inhaled hypertonic saline in all individuals age ≥6 years	1	NBK1250	
recommended sequence for inhaled medications:	1	NBK1250	
an aerosolized antibiotic	1	NBK1250	
gly551asp and other specific pathogenic variants	1	NBK1250	
phe508del	1	NBK1250	
lung or heart/lung transplantation	1	NBK1250	
an option for some individuals with severe disease	1	NBK1250	
oral pancreatic enzyme replacement with meals	1	NBK1250	
congenital absence of the vas deferens (cavd)	1	NBK1250	
prevention of primary manifestations – cystic fibrosis	1	NBK1250	
aerosolized antibiotic	1	NBK1250	
all routine immunizations should be given at the recommended times	1	NBK1250	
pancreatic enzyme replacement and supplementation of fat-soluble vitamins	1	NBK1250	
high-calorie, high-fat nutritional supplements	1	NBK1250	
consultation with a nutritionist specializing in cf	1	NBK1250	
surveillance – cystic fibrosis	1	NBK1250	
culture respiratory tract secretions at least four times yearly	1	NBK1250	
75 g/kg, or 75 g maximum	1	NBK1250	
evaluate bone mineral density in adolescence	1	NBK1250	
agents/circumstances to avoid – cystic fibrosis	1	NBK1250	
avoid the following:	1	NBK1250	
respiratory irritants (e	1	NBK1250	
, smoke, dust)	1	NBK1250	
individuals with respiratory infections	1	NBK1250	
dehydration	1	NBK1250	
increasing caloric intake may be of benefit	1	NBK1186	
constipation affects the majority of individuals	1	NBK1186	
seizures are treated as in the general population	1	NBK1186	
recurrent otitis media may require placement of pe tubes	1	NBK1186	
hyperkeratoses are treated as in the general population	1	NBK1186	
nonsurgical treatment of ophthalmologic findings:	1	NBK1348	
correction of ptosis	1	NBK1348	
eye muscle surgery	1	NBK1348	
to correct or improve a compensatory head posture	1	NBK1348	
to improve ambulation and gross motor development in young children	1	NBK1348	
principles of surgical approach:	1	NBK1348	
profound weakening procedures (e	1	NBK1348	
orthodontic evaluation and appropriate intervention may be necessary	1	NBK1259	
treatment of colitis in cgd can be difficult	1	NBK99496	
corticosteroid treatment of heightened inflammatory response	1	NBK99496	
granulocyte infusions	1	NBK99496	
granulocyte infusions are generally well tolerated	1	NBK99496	
males with x-linked cgd	1	NBK99496	
, they are kell negative)	1	NBK99496	
kell-negative blood products are rarely available	1	NBK99496	
splints can be tried for foot drop	1	NBK1387	
choanal atresia	1	NBK1117	
feeding/swallowing dysfunction	1	NBK1117	
renal evaluation	1	NBK1117	
renal ultrasound examination is recommended in all children	1	NBK1117	
endocrine evaluation	1	NBK1117	
coloboma	1	NBK1117	
hearing loss should be assumed until proven otherwise	1	NBK1117	
communication	1	NBK1117	
deaf-blind service referral	1	NBK1117	
referral to deafblind education services (e	1	NBK1117	
frequent rest breaks may be needed	1	NBK1117	
myofacial release can improve posture and flexibility	1	NBK1117	
occasionally, sleep studies show obstructive apnea	1	NBK1117	
gi consultation is often indicated	1	NBK1117	
obsessive-compulsive disorder	1	NBK1117	
pervasive developmental disorder	1	NBK1117	
sensory processing issues are likely implicated	1	NBK1117	
attention-deficit hyperactivity disorder	1	NBK1117	
understanding this is critical to devising appropriate interventional strategies	1	NBK1117	
general	1	NBK304142	
adequate nutrition and weight maintenance are essential	1	NBK304142	
appropriate bracing and stretching can minimize contractures	1	NBK304142	
mitochondrial myopathy	1	NBK304142	
assistance with ambulation and posture	1	NBK304142	
surgical correction of ptosis as needed	1	NBK304142	
amyotrophic lateral sclerosis	1	NBK304142	
(als)	1	NBK304142	
frontotemporal dementia (ftd)	1	NBK304142	
spinal motor neuronopathy	1	NBK304142	
seizures should be managed by an experienced pediatric neurologist	1	NBK333201	
hematologic and immunologic defects	1	NBK5188	
select individuals may also receive intrathecal methotrexate and prednisilone	1	NBK5188	
once remission occurs, prompt hsct is recommended	1	NBK5188	
correction of refractive errors may improve visual acuity	1	NBK5188	
skin hypopigmentation	1	NBK5188	
skin protection varies depending on the degree of hypopigmentation	1	NBK5188	
neurologic abnormalities	1	NBK5188	
skeletal dysplasia	1	NBK84550	
orthopedic surgery may be complicated by low bone density	1	NBK84550	
immunodeficiency and infection	1	NBK84550	
nutrition and ocular health have become increasingly topical:	1	NBK1337	
preparedness for appropriate countermeasures (e	1	NBK52917	
an apnea monitor is recommended	1	NBK52917	
anticonvulsants may be required	1	NBK52917	
surgical instrumentation or prolonged	1	NBK52917	
bracing may be required to correct a progressive thoracolumbar scoliosis	1	NBK52917	
paradoxical sweating	1	NBK52917	
treatment should be reserved for adults and older children	1	NBK52917	
clonidine	1	NBK52917	
oral clonidine, at starting doses of 0	1	NBK52917	
05 mg to 0	1	NBK52917	
1 mg four times daily may be required	1	NBK52917	
abrupt cessation of clonidine can lead to prominent hypertension	1	NBK52917	
moxonidine was well tolerated in the short term	1	NBK52917	
however, long-term observations are not yet available	1	NBK52917	
niccd	1	NBK1181	
the treatment with therapeutic formulas is not lifelong	1	NBK1181	
fttdcd	1	NBK1181	
ctln2	1	NBK1181	
other treatments include the following:	1	NBK1181	
saheki et al 2010	1	NBK1181	
yazaki et al 2010	1	NBK1181	
ohura et al, personal communication	1	NBK1181	
okano et al, personal communication]	1	NBK1181	
aro	1	NBK1127	
adoii	1	NBK1127	
orthopedic treatment is often required for fractures and arthritis	1	NBK1127	
no specific dietary or other metabolic treatment is available	1	NBK396257	
a trial of antiepileptic drugs (aeds) (e	1	NBK1346	
treatment of behavioral problems is standard and requires periodic reassessment	1	NBK1346	
no definitive treatments exist for the congenital muscular dystrophies	1	NBK1291	
speech therapy may be indicated	1	NBK1291	
close attention to oral hygiene is indicated	1	NBK1291	
medical treatment	1	NBK1168	
acetylcholineesterase (ache) inhibitors (pyridostigmine)	1	NBK1168	
3,4-diaminopyridine (3,4-dap)	1	NBK1168	
quinidine, fluoxetine	1	NBK1168	
however, it may induce suicidal ideation	1	NBK1168	
non-medical treatment	1	NBK1168	
orthotics or a wheelchair	1	NBK1168	
a percutaneous gastric tube	1	NBK1168	
exercise within the affected individual's capability	1	NBK1539	
note: (1) fatigue may improve with exercise	1	NBK1539	
wheelchair for mobility because of gait instability	1	NBK1539	
lower urinary tract involvement [krhut et al 2014]	1	NBK1539	
vocal cord paresis	1	NBK1539	
treatment may include:	1	NBK45014	
ankle/foot orthoses	1	NBK45014	
forearm crutches or canes	1	NBK45014	
rarely, wheelchairs	1	NBK45014	
career and employment counseling	1	NBK45014	
anticipatory counseling is appropriate	1	NBK1358	
forearm crutches or canes for gait stability for some individuals	1	NBK1205	
many remain physically active	1	NBK1205	
the following may be indicated:	1	NBK1285	
wheelchairs for mobility because of gait instability	1	NBK1511	
for treatment of findings common to all	1	NBK201366	
trpv4-associated disorders	1	NBK201366	
pain and depression	1	NBK201366	
neuropathy	1	NBK201366	
vocal cord involvement	1	NBK201366	
respiratory therapy/support (e	1	NBK201366	
, bipap)	1	NBK201366	
physical therapy/exercise to maintain as much function as possible	1	NBK201366	
orthopedic evaluation with consideration of surgical intervention (i	1	NBK201366	
patients undergoing surgical fusion typically do well	1	NBK201366	
appropriate treatment includes:	1	NBK1242	
prosthetic and adaptive devices for weak hands	1	NBK1242	
ankle/foot orthoses to correct foot drop and aid walking	1	NBK1468	
fewer than 5% of affected individuals need wheelchairs	1	NBK1468	
treatment of spinal deformities	1	NBK1340	
physiotherapy helps to preserve flexibility	1	NBK1340	
treatment of foot deformities	1	NBK1340	
physiotherapy to preserve flexibility	1	NBK1340	
treatment of pain and cramps	1	NBK1340	
, pregabalin, gabapentin)	1	NBK1340	
cramps can be controlled with quinine	1	NBK1340	
some need wheelchairs	1	NBK1340	
surgery to correct spine deformities	1	NBK153601	
wheelchairs as needed because of gait instability	1	NBK153601	
no specific treatment reverses the manifestations of cmt4j	1	NBK169431	
severely affected individuals need wheelchairs	1	NBK169431	
bipap for those with respiratory muscle weakness	1	NBK169431	
peripheral neuropathy	1	NBK1876	
see charcot-marie-tooth hereditary neuropathy overview, management	1	NBK1876	
individualized educational program for developmental delay	1	NBK1342	
feeding gastrostomy tube placement for failure to thrive	1	NBK1342	
management of hearing loss	1	NBK1342	
management of cataracts and other ophthalmologic complications	1	NBK1342	
use of sunscreens for cutaneous photosensitivity	1	NBK1342	
use of sunglasses for lens and retina protection	1	NBK1342	
spectacle correction of refractive errors	1	NBK1482	
psychosocial support for affected individuals and their families	1	NBK1482	
recurrent infections should be treated per standard therapy	1	NBK1482	
no specific support exists for individuals with col4a1-related disorders	1	NBK7046	
seizures are managed using standard protocols	1	NBK7046	
glaucoma is initially treated with topical anti-glaucoma medication	1	NBK7046	
coenzyme q10 supplementation	1	NBK410087	
coq4-related coenzyme q10 deficiency	1	NBK410087	
coq6-related coenzyme q10 deficiency	1	NBK410087	
homozygotes for the pathogenic variants p	1	NBK410087	
gly255arg or p	1	NBK410087	
ala353asp responded [heeringa et al 2011]	1	NBK410087	
coq8b-related coenzyme q10 deficiency	1	NBK410087	
pdss2-related coenzyme q10 deficiency	1	NBK410087	
coq8a-related coenzyme q10 deficiency	1	NBK410087	
coq9-related coenzyme q10 deficiency	1	NBK410087	
most infants require nasogastric or gastrostomy feeding	1	NBK1507	
pyloric stenosis is treated surgically	1	NBK1507	
anecdotally, affected children have very high caloric needs	1	NBK1507	
kyphoscoliosis may require surgical correction	1	NBK1507	
dental abnormalities should be addressed by a pediatric dentist	1	NBK1507	
papillomata	1	NBK1507	
thus, cortisol deficiency may also be considered	1	NBK1507	
malignant tumors	1	NBK1507	
treatment of malignant tumors follows standard protocols	1	NBK1507	
info and ghr	1	NBK1527	
nlm	1	NBK1527	
nih	1	NBK1527	
gov	1	NBK1527	
current treatment for long-chain fatty-acid oxidation disorders:	1	NBK1253	
avoid known triggers	1	NBK1253	
treatment consists primarily of surgical intervention	1	NBK1461	
cytokine administration may shorten the consolidation period	1	NBK1455	
timing of subsequent craniofacial surgeries influences their success	1	NBK1455	
limbs	1	NBK1455	
behavior therapy for behavior problems by developmental pediatrician	1	NBK3794	
seizure management with antiepileptic drugs by epilepsy specialist	1	NBK3794	
treatment of movement disorder by movement disorder specialist	1	NBK3794	
gamt deficiency	1	NBK3794	
treatment is as follows:	1	NBK3794	
4-0	1	NBK3794	
8g/kg/day)	1	NBK3794	
available databases (e	1	NBK3794	
treatment outcome of symptomatic individuals with gamt deficiency	1	NBK3794	
in 18% of individuals seizures were eliminated	1	NBK3794	
in 49% seizure frequency decreased	1	NBK3794	
improvement was seen in 60% of individuals	1	NBK3794	
treatment outcome of asymptomatic individuals with gamt deficiency	1	NBK3794	
agat deficiency	1	NBK3794	
treatment outcome of symptomatic individuals with agat deficiency	1	NBK3794	
treatment outcome of asymptomatic individuals with agat deficiency	1	NBK3794	
crtr deficiency	1	NBK3794	
the goal of treatment is to replenish cerebral creatine levels	1	NBK3794	
treatment has included:	1	NBK3794	
glycine 150 mg/kg bw/day in 3 doses	1	NBK3794	
treatment outcome of individuals with crtr deficiency	1	NBK3794	
spectacles or contact lenses for correction of refractive errors	1	NBK2690	
management of strabismus	1	NBK2690	
penetrating keratoplasty	1	NBK2690	
most grafts remain clear after penetrating keratoplasty	1	NBK2690	
see acmg-act sheet, acmg algorithm	1	NBK1458	
acute management of hyperammonemia	1	NBK1458	
rapidly decreasing plasma ammonia concentration	1	NBK1458	
scavenger therapy should be continued while dialysis is being performed	1	NBK1458	
note: exchange transfusions have no place in hyperammonemic treatment	1	NBK1458	
0-1	1	NBK1458	
control of intracranial pressure	1	NBK1458	
cerebral edema and ischemia may be documented by mri	1	NBK1458	
chronic management	1	NBK1458	
protein restriction	1	NBK1458	
nitrogen scavenger therapy	1	NBK1458	
as children grow, doses change to 9	1	NBK1458	
9-13 g/m2/day of sodium phenylbutyrate and 8	1	NBK1458	
8-15	1	NBK1458	
4 g/m2/day of arginine	1	NBK1458	
the initial dosage for phenylbutyrate-naïve patients is 4	1	NBK1458	
5-11	1	NBK1458	
2 ml/m2/day (5-12	1	NBK1458	
4 g/m2/day)	1	NBK1458	
living related-donor liver transplantation	1	NBK1458	
renal fanconi syndrome	1	NBK1400	
phosphate replacement to prevent and treat rickets	1	NBK1400	
renal glomerular disease	1	NBK1400	
renal transplantation	1	NBK1400	
73 m2 and azotemia and hypertension rapidly progress	1	NBK1400	
symptoms often determine the exact time of transplantation	1	NBK1400	
retinal involvement is irreversible	1	NBK1400	
nutrition must be adequate for growth	1	NBK1400	
oral l-thyroxine replacement for hypothyroidism	1	NBK1400	
insulin for diabetes mellitus	1	NBK1400	
speech therapy and physical therapy	1	NBK1400	
standard treatment for benign intracranial hypertension	1	NBK1400	
other central nervous system complications are irreversible	1	NBK1400	
chenodeoxycholic acid (cdca)	1	NBK1409	
normalization of nerve conduction velocities and subsequent stabilization	1	NBK1409	
cdca treatment may be more useful when started early	1	NBK1409	
luyckx et al 2014]	1	NBK1409	
coenzyme q10 (coq10) treatment may improve muscle weakness	1	NBK1409	
repair of inguinal hernia(s)	1	NBK5200	
routine management of hip dislocation	1	NBK5200	
routine management of refractive errors	1	NBK5200	
antiepileptic drugs (aeds): valproate	1	NBK5200	
or a combination of aeds can be used	1	NBK5200	
psychological help as needed for self-image issues	1	NBK5200	
recommended drugs are nadolol (1-2	1	NBK1289	
flecainide	1	NBK1289	
however, urinary ne excretion exceeds normal levels	1	NBK1474	
fludrocortisone, at dosages of 0	1	NBK1474	
ptosis can be corrected by surgery	1	NBK1474	
sinus problems should be treated as needed	1	NBK1474	
dilated cardiomyopathy	1	NBK1119	
mean lvef increased from 36% to 53%	1	NBK1119	
measurement of reduced sphericity indicated improved ventricular geometry	1	NBK1119	
scoliosis treatment as needed is appropriate	1	NBK1119	
corticosteroid therapy	1	NBK1119	
prednisone	1	NBK1119	
75 mg/kg/day or 1	1	NBK1119	
5 and 0	1	NBK1119	
6 mg/kg/day [fenichel et al 1991]	1	NBK1119	
follow-up studies showed that a dose of 0	1	NBK1119	
3 mg/kg/day [fenichel et al 1991]	1	NBK1119	
35 mg/kg/day) in both dmd and bmd	1	NBK1119	
4 mg/kg/day	1	NBK1119	
at lower doses of 0	1	NBK1119	
alternate-day dosing and intermittent dosing (e	1	NBK1119	
side effects did not negatively affect quality of life	1	NBK1119	
initiation and length of treatment	1	NBK1119	
75 mg/kg/day, prednisone 0	1	NBK1119	
published guidelines	1	NBK1119	
the optimal maintenance dose of prednisone (0	1	NBK1119	
3 mg/kg/day	1	NBK1119	
5 mg/kg/day	1	NBK1119	
3 mg/kg/day after three to four months	1	NBK1119	
deflazacort (0	1	NBK1119	
bmd	1	NBK1119	
elements of the guidelines include the following:	1	NBK1674	
consider therapy based on cardiac phenotype (i	1	NBK1674	
, dcm or arrhythmia)	1	NBK1674	
cardiac conduction system disease and arrhythmias	1	NBK1674	
, atrial or atrioventricular node ablations)	1	NBK1674	
lmna-related dcm	1	NBK1674	
symptomatic dcm represents late disease	1	NBK1309	
individuals with idiopathic or familial dilated cardiomyopathy should:	1	NBK1309	
epileptic seizures require antiepileptic drugs (aeds)	1	NBK1185	
special adaptive chairs or positioners may be required	1	NBK1185	
educational	1	NBK1216	
spectacle correction is appropriate where indicated	1	NBK1216	
manifestations of the 16p11	1	NBK11167	
early diagnosis and provision of therapies facilitate the best outcome	1	NBK11167	
referral to other appropriate medical specialists (sue	1	NBK11167	
neurodevelopmental disabilities including asd	1	NBK11167	
obesity and overweight	1	NBK11167	
maintain an active lifestyle	1	NBK11167	
chiari i malformation or syringomyelia	1	NBK11167	
the spasms are responsive to acth	1	NBK1191	
special feeding techniques or devices, e	1	NBK1191	
structural anomalies (e	1	NBK1191	
hypothyroidism is treated in a standard manner	1	NBK1191	
no guidelines have been established for treatment of dent disease	1	NBK99494	
thiazide diuretics in doses greater than 0	1	NBK99494	
however, their effectiveness has not been clear	1	NBK99494	
the response to antiepileptic drugs (aeds) is variable	1	NBK385626	
routine ophthalmologic management of strabismus, if present	1	NBK100664	
routine correction of refractive error	1	NBK269029	
see hereditary deafness and hearing loss overview for details	1	NBK1251	
hearing habilitation	1	NBK1251	
for those with nonsyndromic bilateral congenital hearing loss	1	NBK1251	
hearing aids should be fitted as soon as possible	1	NBK1251	
educational programs designed for individuals with hearing impairment are appropriate	1	NBK1251	
see deafness and hereditary hearing loss overview	1	NBK57098	
management of neurologic manifestations in neonatal multisystem disease	1	NBK7040	
hypotonia may be significant	1	NBK7040	
the one-year survival rate was 64%	1	NBK7040	
five of the 14 survived longer than five years	1	NBK7040	
corticosteroid administration	1	NBK7047	
corticosteroids may be slowly tapered to the minimal effective dose	1	NBK7047	
the recommended maximum maintenance dose is ≤0	1	NBK7047	
red blood cell transfusion	1	NBK7047	
7% ±10	1	NBK7047	
1% ±11	1	NBK7047	
survival was the best (92	1	NBK7047	
cancer treatment	1	NBK7047	
treatment of malignancies should be coordinated by an oncologist	1	NBK7047	
, for clubfeet)	1	NBK1350	
comprehensive coordinated care among specialties is required	1	NBK22301	
bone marrow failure (bmf)	1	NBK22301	
, aggression, mood swings)	1	NBK22301	
the suggested starting dose of oxymetholone is 0	1	NBK22301	
hematopoietic growth factors may be useful in bmf	1	NBK22301	
this risk has not been quantitated	1	NBK22301	
studies are ongoing	1	NBK22301	
dld pathogenic variants cause variable deficiency in three enzymatic pathways	1	NBK220444	
branched chain alpha-ketoacid dehydrogenase (bckdh) complex	1	NBK220444	
α-ketoglutarate dehydrogenase (αkgdh) complex	1	NBK220444	
pyruvate dehydrogenase (pdh) complex	1	NBK220444	
early-onset neurologic presentation	1	NBK220444	
review of treatment strategies	1	NBK220444	
protein/bcaa-restriction	1	NBK220444	
ketogenic/high-fat diet	1	NBK220444	
five had no clinical or biochemical benefit	1	NBK220444	
two improved clinically	1	NBK220444	
carbohydrate tolerance	1	NBK220444	
dichloroacetate (dca)	1	NBK220444	
additional therapies used with limited success include:	1	NBK220444	
coenzyme q10	1	NBK220444	
lipoic acid	1	NBK220444	
biotin	1	NBK220444	
empiric recommendations	1	NBK220444	
for acute management (based on the above review)	1	NBK220444	
this is typically achieved by the following:	1	NBK220444	
promotion of an anabolic state:	1	NBK220444	
maintain serum glucose concentration in the normal range	1	NBK220444	
protein should then be reintroduced gradually	1	NBK220444	
hepatic presentation	1	NBK220444	
correction of metabolic acidosis with sodium bicarbonate	1	NBK220444	
correction of any coagulopathy with fresh frozen plasma	1	NBK220444	
avoidance of liver-toxic medications	1	NBK220444	
episodes of catabolic stress (e	1	NBK220444	
caution:	1	NBK1447	
high doses are usually required (0	1	NBK1447	
4-1	1	NBK1447	
0 mg/kg/day of glibenclamide)	1	NBK1447	
transfer protocols are available at www	1	NBK1447	
diabetesgenes	1	NBK1447	
org	1	NBK1447	
high caloric intake should be maintained to achieve weight gain	1	NBK1447	
insulin can be discontinued when blood glucose concentrations stabilize	1	NBK1534	
, some residual endogenous insulin remains)	1	NBK1534	
note: macroglossia could potentially cause airway obstruction	1	NBK1534	
currently no effective treatment exists for any type of hsan	1	NBK84112	
provision of corrective lenses for myopia	1	NBK1878	
treatment of retinal detachments or glaucoma	1	NBK1878	
antiepileptic drugs for seizures	1	NBK1878	
children	1	NBK1508	
adults	1	NBK1508	
gradual increase to higher doses is recommended	1	NBK1508	
for affected children, adaptation of educational programming to abilities	1	NBK1491	
duane anomaly	1	NBK1373	
severe strabismus may require eye surgery	1	NBK1373	
radial ray malformations	1	NBK1373	
hearing deficits	1	NBK1373	
hearing aids may be required	1	NBK1373	
nonsurgical treatment of ophthalmologic findings	1	NBK1190	
surgical treatment of ophthalmologic findings (extraocular muscle surgery)	1	NBK1190	
to correct or improve compensatory head posture	1	NBK1190	
to improve upshoot or downshoot	1	NBK1190	
principles of surgical approach as reviewed in	1	NBK1190	
kekunnaya et al [2015]	1	NBK1190	
type 1 and type 3	1	NBK1190	
type 2	1	NBK1190	
approach for non-treatment	1	NBK258640	
approach for treatment	1	NBK258640	
the galactose challenge	1	NBK258640	
for example:	1	NBK258640	
, after the introduction of solid foods)	1	NBK258640	
supportive care may include the following:	1	NBK367946	
occupational and physical therapy	1	NBK367946	
alternative and augmentative communication	1	NBK367946	
behavioral therapy (e	1	NBK367946	
, applied behavioral analysis therapy)	1	NBK367946	
psychotropic medications for behavioral manifestations	1	NBK367946	
many of these are preventable	1	NBK367946	
seizures should be managed by a neurologist using standard practice	1	NBK344340	
childhood apraxia of speech	1	NBK327268	
anxiety/selective mutism	1	NBK327268	
autism spectrum disorder (asd)	1	NBK327268	
attention deficit hyperactivity disorder (adhd)	1	NBK327268	
aggression	1	NBK327268	
applied behavior analysis intervention is recommended	1	NBK327268	
oppositionality	1	NBK327268	
specific medical problems are treated in the following ways:	1	NBK327268	
hydrocephalus as needed with ventriculo-peritoneal shunting	1	NBK327268	
aortic dilation with beta blocker therapy in some affected individuals	1	NBK327268	
strabismus in the usual manner	1	NBK327268	
recurrent otitis media in the usual manner	1	NBK327268	
poor feeding in infants	1	NBK327268	
human growth hormone replacement therapy	1	NBK327268	
club feet	1	NBK327268	
casting	1	NBK327268	
educational program should be tailored to individual needs	1	NBK3823	
educational programs to address the specific needs identified	1	NBK333438	
speech therapy directed at improving communication skills	1	NBK333438	
therapeutic management of sleep disturbances if necessary	1	NBK333438	
early intervention with occupational therapy for feeding problems	1	NBK333438	
consideration of tube feeding for severe persisting feeding problems	1	NBK333438	
anticholinergics (e	1	NBK1492	
, trihexyphenidyl)	1	NBK1492	
if medications fail	1	NBK1492	
, prior to sufficient medication trials)	1	NBK1492	
acetazolamide	1	NBK25442	
sulthiame 50-200 mg daily may reduce the attack rate	1	NBK25442	
this medication is generally well tolerated	1	NBK1501	
surgical intervention is required to correct pyloric atresia	1	NBK1157	
many children need medical treatment for gastroesophageal reflux disease	1	NBK1157	
primary layers may include any the following:	1	NBK1304	
ordinary band-aids®	1	NBK1304	
non-stick products (e	1	NBK1304	
, telfa® or n-terface®)	1	NBK1304	
, mepitel® or mepilex®)	1	NBK1304	
other nutritional deficiencies must also be addressed:	1	NBK1304	
calcium and vitamin d supplementation for osteopenia and osteoporosis	1	NBK1304	
selenium and carnitine replacement to help prevent dilated cardiomyopathy	1	NBK1304	
zinc replacement to enhance wound healing	1	NBK1304	
occupational therapy may be helpful in preventing progressive hand contractures	1	NBK1304	
psychosocial support including social services and psychological counseling is essential	1	NBK1304	
ordinaryband-aids®	1	NBK1125	
the most common secondary complication is infection	1	NBK1125	
both antibiotics and antiseptics need to be employed	1	NBK1125	
dressings usually involve three layers:	1	NBK1369	
some individuals with ebs can use ordinary bandages	1	NBK1369	
foam dressings and/or rolls of gauze (e	1	NBK1369	
, one-layer) dressing	1	NBK1369	
dystrophic nails	1	NBK1200	
in many cases, wigs are helpful	1	NBK1200	
palmoplantar hyperkeratosis	1	NBK1200	
skin emollients may help relieve palmoplantar hyperkeratosis	1	NBK1200	
however, pain can be difficult to control	1	NBK1123	
career counseling is recommended	1	NBK1306	
deep stitches should be applied generously	1	NBK1244	
anti-inflammatory drugs may help with joint pain	1	NBK1244	
cardiovascular problems should be treated in a standard manner	1	NBK1244	
modalities must be tailored to the individual	1	NBK1279	
assistive devices	1	NBK1279	
braces are useful to improve joint stability	1	NBK1279	
pain medication	1	NBK1279	
adjustments may be necessary for other populations	1	NBK1279	
nsaids (nonsteroidal anti-inflammatory drugs) (e	1	NBK1279	
cox-2 inhibitors (e	1	NBK1279	
they are also sometimes helpful in treating neuropathic pain	1	NBK1279	
all require gradual titration before reaching therapeutic levels	1	NBK1279	
topiramate and lamotrigine have also been used successfully	1	NBK1279	
nausea is the most common side effect	1	NBK1279	
routine use of benzodiazepines is not recommended	1	NBK1279	
medication precautions	1	NBK1279	
abrupt cessation of anti-seizure medications can precipitate a seizure	1	NBK1279	
when discontinuing, they should be tapered gradually	1	NBK1279	
severity can range from mild to life threatening	1	NBK1279	
surgery and other procedures	1	NBK1279	
anesthetic nerve blocks can provide temporary relief of neuropathic pain	1	NBK1279	
bone density	1	NBK1279	
for severe bleeding (e	1	NBK1279	
other treatable causes, such as h	1	NBK1279	
pylori infection, should be investigated	1	NBK1279	
rarely, severe enlargement (>4	1	NBK1279	
5-5	1	NBK1279	
0 cm) requires surgical evaluation	1	NBK1279	
periodontal disease should be identified and treated	1	NBK1279	
temporomandibular joint laxity and dysfunction are difficult to treat	1	NBK1279	
there are no specific interventions of proven benefit	1	NBK1279	
intra-oral devices are sometimes helpful	1	NBK1279	
psychiatric	1	NBK1279	
antidepressants are also of great benefit	1	NBK1279	
consumer support groups are available and can be very beneficial	1	NBK1279	
, the uterus in pregnancy)	1	NBK1494	
bracing may be required to support unstable joints	1	NBK1462	
swimming is recommended	1	NBK1462	
vascular surgery is fraught with danger	1	NBK1462	
antispastic medications	1	NBK453432	
muscle relaxants	1	NBK453432	
contractures	1	NBK453432	
severe diarrhea	1	NBK453432	
maintain hydration & caloric intake	1	NBK453432	
tube feeding often necessary	1	NBK453432	
poor energy metabolism & oxidative stress	1	NBK453432	
, contractures)	1	NBK453432	
, feeding, grooming, dressing, writing)	1	NBK453432	
routine repair is appropriate	1	NBK54467	
pulmonary emphysema is treated symptomatically	1	NBK54467	
no definitive treatment is available	1	NBK54467	
based on experience in other related disorders (e	1	NBK54467	
aortic aneurysm replacement has been performed successfully	1	NBK54467	
joint hypermobility can be supported by muscle reinforcing physical therapy	1	NBK54467	
standard management of gastroesophageal reflux	1	NBK1263	
standard interventions for:	1	NBK1263	
cardiac defects	1	NBK1263	
hip dysplasia and other skeletal complications	1	NBK1263	
cryptorchidism and/or micropenis	1	NBK1263	
refractive errors, strabismus, or other ophthalmologic issues	1	NBK1263	
seizures, if present	1	NBK1263	
then 1 mg 1x daily thereafter)	1	NBK190102	
prevnar-13® and h	1	NBK190102	
the incidence of post-splenectomy sepsis varies among studies	1	NBK190102	
cholecystectomy	1	NBK190102	
valproic acid is the first drug of choice	1	NBK1142	
it diminishes myoclonus and the frequency of generalized seizures	1	NBK1142	
the phototoxic pain is not responsive to narcotic analgesics	1	NBK100826	
tanning products	1	NBK100826	
β-carotene	1	NBK100826	
hepatic complications may be accompanied by motor neuropathy	1	NBK100826	
the pain is not responsive to narcotic analgesics	1	NBK121284	
sun creams containing a physical reflecting agent (e	1	NBK121284	
reports on treatments in a series involve heterogeneous populations	1	NBK1163	
cooling the extremities reduces pain in a symptomatic person	1	NBK1163	
01) [mork et al 2004]	1	NBK1163	
experts have reported typically mild to moderate pain relief	1	NBK1163	
remissions (i	1	NBK1163	
carbamazepine	1	NBK1163	
oxcarbazepine use in treating em has not been reported	1	NBK1163	
topical application of 1	1	NBK1163	
0% amitriptyline hydrochloride and 0	1	NBK1163	
calcium antagonists	1	NBK1163	
magnesium	1	NBK1163	
cyclosporine was successful in one person with erythromelalgia	1	NBK1163	
sympathetic block, surgical sympathectomy, and epidural infusion	1	NBK1163	
the main problems to manage are:	1	NBK236968	
adaptation of education to the level of cognitive handicap	1	NBK236968	
epilepsy, which is amendable to standard treatments	1	NBK236968	
osteochondromas require no therapy in the absence of clinical problems	1	NBK1235	
leg-length inequalities greater than 2	1	NBK1235	
surgical resection is the treatment for sarcomatous degeneration	1	NBK1235	
3% (±5	1	NBK1401	
9%) [mehta et al 2017]	1	NBK1401	
mds/aml treatment remains challenging	1	NBK1401	
solid tumors	1	NBK1401	
acroparesthesia	1	NBK1292	
diphenylhydantoin	1	NBK1292	
a potential side effect of diphenylhydantoin is gingival hypertrophy	1	NBK1292	
carbamazepine has similar effects	1	NBK1292	
chronic hemodialysis and/or renal transplantation have become lifesaving procedures	1	NBK1292	
therefore, successful renal transplantation corrects renal function	1	NBK1292	
thrombosis	1	NBK1368	
5 (therapeutic range 2	1	NBK1368	
colonic polyps	1	NBK1345	
types of colectomy include the following:	1	NBK1345	
total colectomy with ileorectal anastomosis (ira)	1	NBK1345	
this is a single-stage procedure	1	NBK1345	
total proctocolectomy with permanent ileostomy	1	NBK1345	
the choice of procedure depends on the clinical circumstances	1	NBK1345	
small-bowel polyps	1	NBK1345	
osteomas may be removed for cosmetic reasons	1	NBK1345	
desmoid tumors	1	NBK1345	
adrenal tumors	1	NBK1345	
chemoprevention	1	NBK1345	
nsaids	1	NBK1345	
appropriate treatment for:	1	NBK5201	
inguinal hernias	1	NBK5201	
routine repair	1	NBK5201	
cutis laxa	1	NBK5201	
pulmonary emphysema	1	NBK5201	
no treatment available	1	NBK5201	
no definite treatment is available to date	1	NBK425540	
inadequate nutrition	1	NBK425540	
standard treatment w/antiepileptic drugs	1	NBK425540	
immobility/wheelchair dependence	1	NBK425540	
, wheelchair	1	NBK425540	
cardiomyopathy and arrhythmia	1	NBK425540	
standard treatment per cardiology recommendations	1	NBK425540	
consider granulocyte colony stimulating factor 2	1	NBK425540	
significant acidosis	1	NBK425540	
consider bicarbonate therapy	1	NBK425540	
cataract and/or strabismus	1	NBK425540	
surgical treatment if indicated	1	NBK425540	
hearing aids	1	NBK425540	
there is no definite treatment for fcmd	1	NBK1206	
monitoring for orthopedic complications such as foot deformity and scoliosis	1	NBK1206	
prompt treatment of acute respiratory tract infections	1	NBK1206	
antiepileptic drugs (aeds) when indicated	1	NBK1206	
surgical treatment for gastroesophageal reflux when indicated	1	NBK1206	
gastrostomy when indicated to assure adequate caloric intake	1	NBK1206	
routine therapy of cardiomyopathy	1	NBK1206	
feeding problems	1	NBK1180	
maintain adequate nutrition and avoid aspiration	1	NBK1180	
gastroesophageal reflux	1	NBK1180	
orthostatic hypotension	1	NBK1180	
counter-maneuvers (e	1	NBK1180	
squatting had the greatest effect	1	NBK1180	
kidney and bladder	1	NBK1180	
bradyarrhythmia	1	NBK1180	
soft contact lenses can promote corneal healing	1	NBK1180	
corneal transplantation has had limited success	1	NBK1180	
spinal fusion may be necessary	1	NBK1180	
many adults use walkers or wheelchairs when outside the home	1	NBK1180	
sialorrhea is a common	1	NBK1180	
surgical treatment of gastrointestinal atresia when present	1	NBK7050	
follow up and treatment of possible cardiac and renal anomalies	1	NBK7050	
treatment for significant hearing loss	1	NBK7050	
developmental or educational intervention for children with learning difficulties	1	NBK7050	
retinal avascularity per se often requires no treatment	1	NBK1147	
individualized management of behavior problems	1	NBK1676	
neurologic management of seizures	1	NBK1676	
standard management of chronic constipation for individuals with fgs1	1	NBK1676	
communication rehabilitation with sign languages or alternative means of communication	1	NBK114458	
standard treatment for any of the following if identified:	1	NBK114458	
refractive errors and strabismus	1	NBK114458	
orthopedic complications	1	NBK114458	
investigation for celiac disease if indicated by clinical features	1	NBK114458	
cervical spine instability	1	NBK2534	
large joint dislocations	1	NBK2534	
scoliosis is treated medically	1	NBK2534	
no effective surgical intervention has been described	1	NBK2534	
club feet are managed in a routine manner	1	NBK2534	
febrile and inflammatory episodes are usually treated with nsaids	1	NBK1227	
papillomatosis	1	NBK1543	
camptodactyly often improves with physical and occupational therapy	1	NBK1543	
consultation with:	1	NBK1543	
folate formulations	1	NBK1673	
leucovorin is available in oral and parenteral formulations	1	NBK1673	
neither drug is available for parenteral administration	1	NBK1673	
deplin® is available as a 15-mg tablet	1	NBK1673	
folate dosing	1	NBK1673	
with intramuscular injections of approximately 1	1	NBK1673	
speech and language deficits	1	NBK368474	
no single recommended treatment exists	1	NBK368474	
dysarthria [pennington et al 2009]	1	NBK368474	
language deficits [law et al 2003]	1	NBK368474	
literacy impairments [snowling & hulme 2012]	1	NBK368474	
cognitive deficits	1	NBK368474	
fine and gross motor deficits	1	NBK368474	
fragile x syndrome	1	NBK1384	
therapy must be individualized and closely monitored	1	NBK1384	
fxtas	1	NBK1384	
poi	1	NBK1384	
there is little objective evidence regarding management of frda	1	NBK1281	
speech therapy to maximize communication skills	1	NBK1281	
treatment of sleep apnea by continuous positive airway pressure	1	NBK1281	
measures include the following:	1	NBK1281	
in fryns syndrome, additional anomalies may dictate further consultations	1	NBK1459	
see also congenital diaphragmatic hernia overview	1	NBK1459	
physical therapy and rehabilitation	1	NBK1443	
consultation with a physical therapist is indicated	1	NBK1443	
exercise in fshd	1	NBK1443	
ophthalmologic disease	1	NBK1443	
orthopedic intervention	1	NBK1443	
there is no consensus treatment guideline for ftd3	1	NBK1199	
individuals with seizures are treated with antiepileptic drugs	1	NBK1505	
nutritional intervention (e	1	NBK1506	
wheelchairs can be useful for some individuals	1	NBK1506	
5x109/l can vary greatly among patients	1	NBK285321	
fevers and infections require prompt treatment with antibiotics	1	NBK285321	
treatment of arterial calcification	1	NBK253403	
bisphosphonate therapy	1	NBK253403	
026, log-rank test)	1	NBK253403	
the dose of pamidronate has varied from 0	1	NBK253403	
cardiovascular treatment	1	NBK253403	
anti-hypertensive therapy	1	NBK253403	
017-0	1	NBK253403	
068 μg/kg/min [ciana et al 1997]	1	NBK253403	
prevention of coronary thrombosis	1	NBK253403	
treatment of hearing loss	1	NBK253403	
generalized epimerase deficiency galactosemia	1	NBK51671	
, some fruits and vegetables, organ meats)	1	NBK51671	
, hepatic cirrhosis or mature cataracts)	1	NBK51671	
peripheral epimerase deficiency galactosemia	1	NBK51671	
intermediate epimerase deficiency galactosemia	1	NBK51671	
however, insufficient data exist to make firm recommendations	1	NBK51671	
appropriate ophthalmologic treatment (e	1	NBK1136	
individuals with gata1-related cytopenia are treated supportively	1	NBK1364	
transfusion of blood products for severe anemia and bleeding	1	NBK1269	
analgesics for bone pain	1	NBK1269	
, improved joint range of motion)	1	NBK1269	
supplemental treatment	1	NBK1269	
care is best provided by a physician (e	1	NBK1318	
clobazam (0	1	NBK1318	
topiramate [coppola et al 2002]	1	NBK1318	
ethosuximide	1	NBK1318	
can be effective for absence seizures	1	NBK1318	
levetiracetam (20-80 mg/kg/day)	1	NBK1318	
potassium bromide	1	NBK1318	
phenobarbital	1	NBK1318	
sleep deprivation and illness can exacerbate scn1a-related seizures	1	NBK1318	
routine seizure and personal safety counseling is indicated	1	NBK1318	
seizures are not always responsive to conventional aeds	1	NBK1318	
ethosuximide and high-dose piracetam for myoclonic seizures	1	NBK1318	
placement of an indwelling venous access device	1	NBK1318	
creating a portable microenvironment	1	NBK1318	
having a written emergency department protocol	1	NBK1318	
establishing emergency routines for the family	1	NBK1318	
creating personal time to decrease parent stress	1	NBK1318	
finding respite care	1	NBK1318	
contacting an internet support group	1	NBK1318	
joint manifestations: regular physiotherapy to prevent joint limitation	1	NBK11168	
heart: valve replacement	1	NBK11168	
tracheal stenosis: tracheostomy when severe	1	NBK11168	
surgical treatment	1	NBK1135	
pcg is almost always managed surgically	1	NBK1135	
beta-blockers (e	1	NBK1135	
, timolol), parasympathomimetics (e	1	NBK1135	
, pilocarpine), sympathomimetics (e	1	NBK1135	
treatment of refractive errors	1	NBK1135	
affected individuals develop a mild compensated metabolic acidosis when ketotic	1	NBK1430	
phenobarbital and valproic acid can inhibit glut1 transport	1	NBK1430	
valproic acid may partially inhibit beta-oxidation of fatty acids	1	NBK1430	
these agents also can cause kidney stones	1	NBK1430	
response has been modest at best	1	NBK1430	
gm1 gangliosidosis	1	NBK164500	
maintenance of adequate hydration and adequate calories for growth	1	NBK164500	
aggressive seizure control	1	NBK164500	
medical management of cardiac involvement	1	NBK164500	
mps ivb	1	NBK164500	
the general concepts of care include the following	1	NBK1547	
sex assignment	1	NBK1547	
all individuals should receive a sex of rearing	1	NBK1547	
surgical intervention should focus on functionality	1	NBK1547	
removal of müllerian remnants may be considered	1	NBK1547	
management of gonads	1	NBK1547	
hormone therapy	1	NBK1547	
if an individual is given a male sex assignment:	1	NBK1547	
5 standard deviations below the mean for age)	1	NBK1547	
testosterone therapy is typically required to initiate and sustain puberty	1	NBK1547	
if an individual is given a female sex assignment:	1	NBK1547	
estrogen therapy is used to initiate breast development and puberty	1	NBK1547	
psychosocial aspects of care	1	NBK1547	
” [lee et al 2006]	1	NBK1547	
later, educational and behavioral therapy are often warranted	1	NBK1523	
oral-motor therapy to alleviate chewing and swallowing problems	1	NBK1198	
routine protocols to alleviate sleep apnea	1	NBK1198	
tympanostomy tube placement for recurrent ear infections	1	NBK1198	
surgical removal of ingrown toenails to prevent infection	1	NBK1198	
walkers or other assistive walking devices	1	NBK1198	
intravenous fluids to prevent dehydration in individuals with recurrent vomiting	1	NBK1198	
surgical bone lengthening may be an option for some	1	NBK1481	
adaptive aids for people with short stature are appropriate	1	NBK1481	
speech/language deficits	1	NBK385627	
metabolic specialist familiar with the multisystem nature of gsdi	1	NBK1312	
medical nutrition therapy goals	1	NBK1312	
maintain	1	NBK1312	
normal glucose levels and prevent hypoglycemia:	1	NBK1312	
frequent daytime feedings	1	NBK1312	
note: recommendations for uncooked cornstarch dosing are: 1	1	NBK1312	
provide	1	NBK1312	
optimal nutrition for growth and development:	1	NBK1312	
, protein low in fat)	1	NBK1312	
treatment of other manifestations	1	NBK1312	
sodium levels should also be monitored	1	NBK1312	
kidney transplantation can be performed for esrd	1	NBK1312	
liver transplantation can be considered when other interventions have failed	1	NBK1312	
g-csf should be administered subcutaneously starting at 1	1	NBK1312	
0 μg/kg given daily or every other day	1	NBK1312	
0 x 109/l is reached	1	NBK1312	
arteriopathy	1	NBK1261	
conduction disturbances	1	NBK1261	
muscle weakness	1	NBK1261	
nutrition/feeding	1	NBK1261	
respiratory insufficiency	1	NBK1261	
respiratory support including cpap and bipap may be required	1	NBK1261	
special formulas are not required	1	NBK26372	
3 mmol/l)	1	NBK26372	
emergency protocol	1	NBK26372	
5 normal saline administered at 1	1	NBK26372	
hepatic manifestations	1	NBK115333	
selecting appropriate candidates for liver transplantation can be complex	1	NBK115333	
aerobic training (on a regular diet)	1	NBK1344	
95% confidence intervals 20	1	NBK1344	
3 to 2496	1	NBK1344	
7) after controlling for age	1	NBK1344	
7 metabolic equivalents (mets, with 1met equaling 3	1	NBK1344	
5 ml o2/kg/min) necessary for independent living	1	NBK1344	
5mets higher than in those who were not active	1	NBK1344	
avoid a totally sedentary life, which induces deconditioning	1	NBK1344	
pharmacologic and nutritional treatments	1	NBK1344	
the authors' conclusions:	1	NBK1344	
this treatment does not influence sustained or unexpected exercise	1	NBK1344	
a carbohydrate-rich diet was of benefit	1	NBK1344	
pharmacologic treatments	1	NBK1344	
nutritional treatments	1	NBK1344	
liver phk deficiency	1	NBK55061	
hypoglycemia	1	NBK55061	
the dose of cornstarch can range from 0	1	NBK55061	
6 to 2	1	NBK55061	
5 g/kg every six hours based on clinical symptoms	1	NBK55061	
for signs of	1	NBK55061	
muscle phk deficiency	1	NBK55061	
surgery may be required	1	NBK349073	
hypothalamic involvement	1	NBK349073	
central diabetes insipidus may require treatment with desmopressin	1	NBK349073	
temperature dysregulation can be managed by modifying the environment	1	NBK349073	
surgery of hand and foot defects can improve dexterity	1	NBK349073	
tethered cord may require surgical intervention	1	NBK349073	
some children may require a gastrostomy and/or tracheostomy	1	NBK349073	
acute attacks	1	NBK114807	
in an individual presenting with acute abdominal symptoms:	1	NBK114807	
discontinue all nonessential medications	1	NBK114807	
provide glucose-containing iv solution to reverse the fasting state	1	NBK114807	
treat seizures with a short-acting benzodiazepine (e	1	NBK114807	
not yet approved in the us)	1	NBK114807	
some individuals recover with a glucose infusion only	1	NBK114807	
200 mg once daily is appropriate for most individuals	1	NBK114807	
the following responses to hematin infusion can be expected:	1	NBK114807	
chronic (cutaneous) manifestations	1	NBK114807	
grey or smoke colored filters provide only partial protection	1	NBK114807	
pharmacologic agents may suppress abnormal movements	1	NBK1529	
tremor in one individual was suppressed with clonazepam	1	NBK1529	
no specific therapy is currently available for alsp	1	NBK100239	
other:	1	NBK100239	
treatment should be coordinated through a hemophilia treatment center	1	NBK1404	
(individuals in the usa see national hemophilia foundation	1	NBK1404	
immunizations should be administered preferably subcutaneously	1	NBK1404	
ddavp®	1	NBK1404	
(desmopressin acetate)	1	NBK1404	
immune tolerance therapy	1	NBK1404	
elsewhere worldwide: see world federation of hæmophilia)	1	NBK1495	
immunizations should be administered subcutaneously	1	NBK1495	
inhibitors	1	NBK1495	
clinical	1	NBK1440	
biochemical	1	NBK1440	
non-expressing p	1	NBK1440	
cys282tyr homozygotes	1	NBK1440	
variceal bleeding	1	NBK2701	
transjugular intrahepatic portosystemic shunts (tips) are widely available	1	NBK2701	
hypersplenism	1	NBK2701	
hypersplenism usually does not result in clinically significant sequelae	1	NBK2701	
abnormalities of the biliary tree	1	NBK2701	
cholangitis is best treated with rapid institution of appropriate antibiotics	1	NBK2701	
biliary stones	1	NBK2701	
cholangiocarcinoma and hepatocellular carcinoma	1	NBK2701	
these should be managed by a multidisciplinary team	1	NBK2701	
patient education	1	NBK2701	
urologic referral is indicated	1	NBK1423	
gynecologic referral is indicated	1	NBK1423	
hymenectomy may be necessary for tight constriction ring	1	NBK1423	
however, no data on its use are available	1	NBK390610	
lymphedema management (manual lymphatic drainage, compression)	1	NBK390610	
muscle	1	NBK390610	
physical therapy and exercise to promote mobility and prevent contractures	1	NBK390610	
lung	1	NBK390610	
noninvasive ventilation if needed	1	NBK390610	
pancreas	1	NBK390610	
treatment of pancreatic exocrine insufficiency with pancreatic enzyme supplementation	1	NBK390610	
treatment of cholestasis with ursodeoxycholic acid	1	NBK390610	
enteral feeding as needed	1	NBK390610	
surgical removal of visually significant cataracts	1	NBK390610	
the primary curative treatment of gastric cancer is surgical resection	1	NBK1139	
frequent small meals tend to maximize caloric intake	1	NBK1121	
stiffened peripheral vasculature may be less tolerant to dehydration	1	NBK1121	
therefore maintaining optimal hydration orally is recommended	1	NBK1121	
infections are generally handled as for unaffected children	1	NBK1121	
anesthetics should be used with particular caution	1	NBK1121	
nitroglycerin is frequently of benefit if angina develops	1	NBK1121	
statins are recommended for their putative effect on farnesylation inhibition	1	NBK1121	
injuries	1	NBK1121	
wound healing is normal	1	NBK1121	
fracture rate is equivalent to the general pediatric population	1	NBK1121	
hips	1	NBK1121	
teeth	1	NBK1121	
, finger) joints	1	NBK1121	
eye care	1	NBK1121	
hearing aids can be used, when clinically necessary	1	NBK1121	
treatment of acute hyperammonemic episodes	1	NBK97260	
, as part of nitrogen scavenging therapy)	1	NBK97260	
this approach also stops all protein intake	1	NBK97260	
infusion 1	1	NBK97260	
infants and children	1	NBK97260	
adolescents and adults	1	NBK97260	
10% arginine hcl	1	NBK97260	
210 mg/kg/day	1	NBK97260	
drug	1	NBK97260	
action	1	NBK97260	
glucose	1	NBK97260	
arginine 1	1	NBK97260	
sodium benzoate 3	1	NBK97260	
sodium phenylacetate 3	1	NBK97260	
hemodialysis	1	NBK97260	
dialysis may be prolonged if the catabolic state persists	1	NBK97260	
note: non-essential amino acids (i	1	NBK97260	
nosebleeds	1	NBK1351	
oral drug therapy	1	NBK1351	
topical drug therapy	1	NBK1351	
, timolol 0	1	NBK1351	
gastrointestinal bleeding	1	NBK1351	
pulmonary avms	1	NBK1351	
hepatic avms	1	NBK1351	
cerebral avms	1	NBK1351	
cerebral avms greater than 1	1	NBK1351	
intestinal polyps	1	NBK1351	
most investigators recommend maintaining all glucose levels above 3	1	NBK1375	
somatostatin analogs (e	1	NBK1375	
glucagon, which increases hepatic gluconeogenesis, helps prevents hypoglycemia	1	NBK1375	
however, therapeutic success has not been confirmed	1	NBK1375	
dietary intervention:	1	NBK1375	
night-time continuous gastric drip containing glucose or glucose polymer	1	NBK1375	
in such individuals, surgery must be considered	1	NBK1375	
if structural damage to the lungs (e	1	NBK25507	
, pseudomonas) or fungi (e	1	NBK25507	
, aspergillus)	1	NBK25507	
adequate skin lubrication is needed with frequent bleach baths	1	NBK25507	
hlh-1994	1	NBK1444	
hlh-2004	1	NBK1444	
in general, treatment involves the following:	1	NBK1444	
after achievement of clinical remission in simplex cases (i	1	NBK1444	
, a single occurrence in a family)	1	NBK1444	
cutaneous lesions	1	NBK1252	
cutaneous leiomyomas should be examined by a dermatologist	1	NBK1252	
treatment of cutaneous leiomyomas is difficult:	1	NBK1252	
surgical excision may be performed for a solitary painful lesion	1	NBK1252	
lesions can be treated by cryoablation and/or lasers	1	NBK1252	
uterine fibroids should be evaluated by a gynecologist	1	NBK1252	
hysterectomy should be performed only when necessary	1	NBK1252	
renal tumors	1	NBK1252	
early detection of kidney tumor in hlrcc is important	1	NBK1252	
chelation therapy with disodium calcium edetate	1	NBK100241	
short term	1	NBK100241	
, >3 hours)	1	NBK100241	
long term	1	NBK100241	
chelation therapy should be continued lifelong	1	NBK100241	
iron therapy	1	NBK100241	
iron is a competitive inhibitor of intestinal manganese uptake	1	NBK100241	
dystonia can result in physical deformities and pain	1	NBK100241	
at present no disease-modifying therapy exists	1	NBK185330	
pain management is the primary goal of therapy:	1	NBK1395	
cleft palate is best managed by a local craniofacial team	1	NBK1395	
management of colon cancer in a person with lynch syndrome	1	NBK1211	
complications should be managed appropriately (e	1	NBK1524	
multidisciplinary management at various ages may include:	1	NBK1150	
endocrinology to optimize bone homeostasis and avoid exacerbating treatments	1	NBK1150	
nephrology to monitor calcium homeostasis and examine for nephrocalcinosis	1	NBK1150	
neurology to prophylactically or prospectively treat seizures and manage myopathy	1	NBK1150	
neurosurgery or craniofacial team to manage pseudocraniosynostosis	1	NBK1150	
orthopedics to manage primary and secondary skeletal manifestations	1	NBK1150	
pain management	1	NBK1150	
pediatric and adult dentistry to manage tooth loss	1	NBK1150	
enzyme replacement therapy	1	NBK1150	
perinatal/infantile hpp study outcomes	1	NBK1150	
survival	1	NBK1150	
bone findings	1	NBK1150	
juvenile-onset hpp study outcomes	1	NBK1150	
age at treatment onset was six to 12 years	1	NBK1150	
perinatal types	1	NBK1150	
infantile type	1	NBK1150	
in the absence of ert, supportive management remains	1	NBK1150	
calcium homeostasis	1	NBK1150	
craniosynostosis in those with the infantile phenotype is variable	1	NBK1150	
childhood (juvenile) and adult hypophosphatasia	1	NBK1150	
osteoarthritis may respond to nsaids	1	NBK1150	
pseudofractures and stress fractures are difficult to manage	1	NBK1150	
early surgical repair may improve feeding	1	NBK1530	
the principles of treatment are summarized in table 7	1	NBK1338	
goal	1	NBK1338	
means	1	NBK1338	
practical details	1	NBK1338	
to avoid triggering or aggravating factors for paralytic attacks	1	NBK1338	
avoid:	1	NBK1338	
strenuous effortprolonged immobilitycarbohydrate-rich diet	1	NBK1338	
treatment of paralytic attack:	1	NBK1338	
shorten/prevent aggravation of the weakness episodenormalize kalemia	1	NBK1338	
preventive treatment for paralytic attacks	1	NBK1338	
daily k+ supplementation	1	NBK1338	
slow-release forms of potassium may be used	1	NBK1338	
diamox (acetazolamide)	1	NBK1338	
k+-sparing diuretics	1	NBK1338	
preventive treatment for late-onset myopathy	1	NBK1338	
diamox (acetazolamide)?	1	NBK1338	
medical precautions	1	NBK1338	
other elements of management	1	NBK1338	
strenuous effort	1	NBK1338	
prolonged immobility	1	NBK1338	
carbohydrate-rich diet	1	NBK1338	
provide dietary review/counseling	1	NBK1338	
shorten/prevent aggravation of the weakness episode	1	NBK1338	
normalize kalemia	1	NBK1338	
avoid glucose intake	1	NBK1338	
do not use slow-release forms of potassium	1	NBK1338	
oral potassium: initially, 1 meq/kg	1	NBK1338	
3 meq/kg after 30 minutes if no improvement	1	NBK1338	
iv potassium: 0	1	NBK1338	
avoid corticosteroids if possible	1	NBK1338	
kinesitherapy in case of permanent pelvic deficit	1	NBK1338	
paralytic crisis	1	NBK1338	
mild to moderate paralytic episodes	1	NBK1338	
aqueous potassium contained in vials may act more rapidly	1	NBK1338	
, 4	1	NBK1338	
3 meq/kg can be administered (20 meq	1	NBK1338	
, 1	1	NBK1338	
severe paralytic episodes	1	NBK1338	
note the following critical points:	1	NBK1338	
3 meq/kg/h of potassium (i	1	NBK1338	
some individuals exhibit serious arrhythmias with only mild hypokalemia	1	NBK1338	
they are associated with a risk for cardiac arrest	1	NBK1338	
attempting to abort paralytic attacks when they begin	1	NBK1338	
correction of these refractive errors can improve visual acuity	1	NBK1287	
the surgery is not always successful	1	NBK1287	
humidifiers may reduce the frequency of nosebleeds	1	NBK1287	
oral contraceptives can limit the duration of menstrual periods	1	NBK1287	
the authors know of several additional successful lung transplantations	1	NBK1287	
primary hyperparathyroidism	1	NBK3789	
minimally invasive parathyroidectomy requires the use of:	1	NBK3789	
preoperative imaging (e	1	NBK3789	
jaw tumors	1	NBK3789	
uterine tumors	1	NBK3789	
a diabetic clinic is a good source of advice	1	NBK49247	
appropriate shoes and socks are recommended	1	NBK49247	
it is best to prevent callous formation in neuropathic skin	1	NBK49247	
hyperthermia or hypothermia	1	NBK1769	
hypothermia responds to warming by a blanket as necessary	1	NBK1769	
of note, longstanding infections require wide surgical debridement	1	NBK1769	
bone and joint deformities can be managed by corrective osteotomy	1	NBK1769	
joint dislocations are best treated conservatively	1	NBK1769	
the oral self-mutilation (i	1	NBK1769	
6-0	1	NBK1769	
see warren & nade [1999]	1	NBK1390	
charcot joints may require arthrodesis	1	NBK1390	
opiates are contraindicated as hsn1a is a chronic disorder	1	NBK1390	
current recommendations:	1	NBK1509	
commonly required interventions include the following:	1	NBK1274	
shunting for hydrocephalus	1	NBK1274	
tonsillectomy and adenoidectomy	1	NBK1274	
positive pressure ventilation (cpap or tracheostomy)	1	NBK1274	
carpal tunnel release	1	NBK1274	
cardiac valve replacement	1	NBK1274	
inguinal hernia repair	1	NBK1274	
hip replacement	1	NBK1274	
developmental, occupational, and physical therapy are often necessary	1	NBK1274	
for further information about eculizumab, click here	1	NBK1367	
typically, plasma exchange is undertaken daily initially	1	NBK1367	
cfb	1	NBK1367	
cfh autoantibodies	1	NBK1367	
cfi	1	NBK1367	
, persistent severe thrombocytopenia and hemolytic anemia)	1	NBK1367	
molecular genetic testing can help to define graft prognosis	1	NBK1367	
c3, cfb, and cfi	1	NBK1367	
four individuals with isolated	1	NBK1367	
importantly, there were no ahus recurrences after transplantation	1	NBK1367	
beta blockers	1	NBK1768	
l-type calcium channel blockers	1	NBK1768	
note: direct vasodilators (e	1	NBK1768	
dose is based on response to therapy	1	NBK53700	
gout typically responds well to prednisone or colchicine	1	NBK53700	
prednisone is the preferable alternative	1	NBK53700	
fludrocortisone treatment (0	1	NBK53700	
mineralocorticoid replacement	1	NBK53700	
kidney transplantation cures adtkd-ren	1	NBK53700	
treatment for hyperpp is symptomatic and not curative	1	NBK1496	
, 2 g glucose per kg body weight)	1	NBK1496	
1 mg salbutamol	1	NBK1496	
calcium gluconate (0	1	NBK1496	
adults with fh	1	NBK174884	
risk factors (e	1	NBK174884	
4 mmol/l])	1	NBK174884	
risk factors:	1	NBK174884	
clinically evident cad or other atherosclerotic cardiovascular disease	1	NBK174884	
8 mmol/l)	1	NBK174884	
diabetes mellitus or metabolic syndrome	1	NBK174884	
women age <55 years)	1	NBK174884	
current smoking	1	NBK174884	
3 mmol/l] using an isoform insensitive assay)	1	NBK174884	
class	1	NBK174884	
ldl-lowering response	1	NBK174884	
statins	1	NBK174884	
↑ ldlr activity (1o)	1	NBK174884	
>35% 1, 2	1	NBK174884	
cholesterol absorption inhibitors (ezetimibe)	1	NBK174884	
mipomersen (apob antisense) 4	1	NBK174884	
blocks apob production in the liver	1	NBK174884	
mtp inhibitor(lomitapide) 4	1	NBK174884	
pcsk9 inhibitors(alirocumab, evolocumab)	1	NBK174884	
↓ ldl-receptor degradation	1	NBK174884	
50% 6	1	NBK174884	
bile acid sequestrants(cholestyramine, colesevelam)	1	NBK174884	
stanol esters	1	NBK174884	
10% 1, 3	1	NBK174884	
children with fh	1	NBK174884	
9 mmol/l)	1	NBK174884	
consultation or referral to a lipid specialist is recommended	1	NBK174884	
statins are the preferred initial pharmacologic treatment in children	1	NBK174884	
4 mmol/l)	1	NBK174884	
children and adults with homozygous fh (hofh)	1	NBK174884	
nla guidelines for homozygous fh (full text):	1	NBK174884	
referral to a lipid specialist is indicated	1	NBK174884	
early initiation of therapy and monitoring are recommended	1	NBK174884	
multiple drug therapy is usually needed	1	NBK174884	
many states do not have an apheresis center	1	NBK174884	
in adults the initial dose is 0	1	NBK1260	
5 mg twice a day	1	NBK1260	
the dose can be increased up to 2	1	NBK1260	
0 mg three times a day	1	NBK1260	
antiepileptic drugs if epileptic seizures are present	1	NBK2587	
the usual neurosurgical approach to spinal stenosis is laminectomy	1	NBK1477	
the l2-3 level most commonly required decompression	1	NBK1477	
seizure disorders should be treated in the standard manner	1	NBK1477	
management of blisters in a standard manner (i	1	NBK1472	
, not opening them, avoiding trauma)	1	NBK1472	
topical treatment (e	1	NBK1472	
, medications, oatmeal baths) to relieve discomfort	1	NBK1472	
significant skin involvement may benefit from dermatology management	1	NBK1472	
treatment of infections as for any other cellulitis	1	NBK1472	
standard treatment for retinal detachment	1	NBK1472	
physical and occupational therapy to promote mobility and independence	1	NBK1243	
aids for mobility and limb function	1	NBK1243	
treatment is symptomatic only:	1	NBK1262	
management should be tailored to the individual	1	NBK1476	
paget disease of bone	1	NBK1476	
actonel®/risedronate	1	NBK1476	
fosamax®/alendronate	1	NBK1476	
aredia®/pamidronate	1	NBK1476	
tnfα antagonists have also been used	1	NBK258641	
growth hormone (gh) therapy	1	NBK190103	
treatment by a psychiatrist for neuropsychiatric symptoms is indicated	1	NBK1675	
dopamine agonist therapy has been tried in some cases	1	NBK97965	
monitor fluid intake to assure adequate intravascular volume	1	NBK1118	
appropriate medications for management of seizures and spasticity	1	NBK453433	
chest physiotherapy to prevent respiratory complications	1	NBK453433	
sleep studies to assess nocturnal hypoventilation and institute appropriate interventions	1	NBK453433	
assessment for scoliosis	1	NBK453433	
dietary	1	NBK453433	
medical	1	NBK453433	
management focuses on rehabilitation to optimize mobility and communication	1	NBK1470	
treatment of seizures follows standard management principles	1	NBK1470	
treatment of iron overload	1	NBK1170	
it is simple, safe, and effective	1	NBK1170	
the hematocrit should be monitored prior to phlebotomy	1	NBK1170	
usually four to six phlebotomies annually are sufficient	1	NBK1170	
treatment of secondary complications	1	NBK1170	
transdermal preparations (i	1	NBK1170	
arthropathy is not modified by treatment	1	NBK1170	
cirrhosis is thought to be irreversible despite iron removal	1	NBK1170	
diabetes mellitus may require insulin administration	1	NBK1170	
cardiac issues	1	NBK1405	
even with additional therapies (e	1	NBK1405	
qtc interval >550 msec	1	NBK1405	
syncope before age five years	1	NBK1405	
left cardiac sympathetic denervation has been effective for some individuals	1	NBK1405	
iron deficiency anemia	1	NBK1405	
hypotonia and therapeutic interventions	1	NBK1325	
periodic neuropsychologic and developmental testing at appropriate ages	1	NBK1325	
other cns malformations	1	NBK1325	
posterior fossa cysts and fluid collections rarely require intervention	1	NBK1325	
encephalocele may require primary surgical closure	1	NBK1325	
corrective lenses for refractive errors	1	NBK1325	
consultation with a nephrologist is indicated	1	NBK1325	
hepatic fibrosis	1	NBK1325	
consultation with a gastroenterologist is indicated	1	NBK1325	
some individuals have needed orthotopic liver transplantation	1	NBK1325	
surgical treatment for polydactyly	1	NBK1325	
appropriate medical management by an orthopedic specialist for scoliosis	1	NBK1325	
orofacial clefting is treated by standard surgical interventions	1	NBK1325	
no specific guidelines are currently available	1	NBK1478	
jps	1	NBK1469	
jps/hht	1	NBK1469	
treat manifestations of hht as needed	1	NBK1469	
see hereditary hemorrhagic telangiectasia	1	NBK1469	
monitoring for nocturnal lagophthalmos by parents or caregivers is recommended	1	NBK62111	
if present, evaluation by an ophthalmologist is indicated	1	NBK62111	
skeletal features	1	NBK114806	
early referral to physical therapy to help increase joint mobility	1	NBK114806	
orchiopexy in males with undescended testes	1	NBK114806	
anal anomalies	1	NBK114806	
referral to an urologist or nephrologist as indicated	1	NBK114806	
facial features	1	NBK114806	
hearing aids as needed for hearing loss	1	NBK114806	
no specific management guidelines have been developed	1	NBK425128	
management is mostly supportive	1	NBK425128	
lacrimal duct obstruction	1	NBK425128	
tear duct massage	1	NBK425128	
consider lacrimal duct stent placement	1	NBK425128	
cleft palate, bifid uvula, or velopharyngeal insufficiency	1	NBK425128	
management by a cleft/craniofacial team	1	NBK425128	
cpap or bipap	1	NBK425128	
ent evaluation for tonsillectomy/adenoidectomy	1	NBK425128	
pulmonary consultation	1	NBK425128	
feeding difficulties or signs of aspiration	1	NBK425128	
use of a special nipple or bottle with cleft palate	1	NBK425128	
short-term nasogastric feeding tube	1	NBK425128	
consideration of gastrostomy tube	1	NBK425128	
gastroesophageal reflux disease	1	NBK425128	
standard positioning & pharmacologic treatment	1	NBK425128	
musculoskeletal findings (i	1	NBK425128	
, contractures, scoliosis)	1	NBK425128	
ankle-foot orthoses or other assistive devices	1	NBK425128	
physical therapy and/or occupational therapy evaluation	1	NBK425128	
consultation w/an orthopedist	1	NBK425128	
seizure disorder	1	NBK425128	
evaluation of blood sugar & electrolytes	1	NBK425128	
standard treatment for seizures	1	NBK425128	
consider eeg and referral to a neurologist	1	NBK425128	
unexplained hypoglycemia or suspected hyperinsulinism	1	NBK425128	
consideration of diazoxide therapy	1	NBK425128	
consider referral to an endocrinologist	1	NBK425128	
consider referral to a neurodevelopmental specialist and/or neuropsychiatric testing	1	NBK425128	
benign familial neonatal epilepsy (bfne)	1	NBK201978	
all but three had family histories of neonatal seizures	1	NBK201978	
pathogenic variants in kcnq3 were present in two	1	NBK201978	
earlier initiation of cbz was associated with shorter hospitalization	1	NBK201978	
no side effects of cbz were reported	1	NBK201978	
8 years)	1	NBK201978	
benign familial infantile epilepsy (bfie)	1	NBK201978	
no established treatment for kindler syndrome exists	1	NBK349072	
standard blister care in childhood	1	NBK349072	
antibiotics may be used to treat an infected blister	1	NBK349072	
use of moisturizers for dry, pruritic skin	1	NBK349072	
mucosal involvement	1	NBK349072	
mouth and periodontium	1	NBK349072	
gastrointestinal tract	1	NBK349072	
esophageal dilatation may be indicated for those with dysphagia	1	NBK349072	
anal stenosis and bleeding requires regular laxatives	1	NBK349072	
severe colitis may require surgical bowel resection in some cases	1	NBK349072	
urethra	1	NBK349072	
meatal stenosis may require dilatation	1	NBK349072	
strictures may require stenting and/ or surgical intervention	1	NBK349072	
phimosis	1	NBK349072	
no well-controlled treatment trials have been reported	1	NBK47079	
specialized neurologic care for individuals with epilepsy	1	NBK47079	
males with igd age ≥18 years	1	NBK1334	
hormone replacement therapy for males not desiring fertility	1	NBK1334	
doses do vary with newer testosterone preparations	1	NBK1334	
if testosterone levels fall, therapy should be reinitiated	1	NBK1334	
human chorionic gonadotropin (hcg)	1	NBK1334	
male infants/adolescents with suspicion of igd	1	NBK1334	
if igd is clinically suspected (e	1	NBK1334	
fsh is added at doses ranging from 37	1	NBK1334	
5 to 75 iu as either hmg or recombinant formulation	1	NBK1334	
pulsatile gnrh stimulation vs	1	NBK1334	
females with igd	1	NBK1334	
hormone replacement therapy for females not desiring fertility	1	NBK1334	
many formulations of estrogens are available	1	NBK1334	
a suggested oral regimen is using premarin 0	1	NBK1334	
25 mg daily	1	NBK1334	
in vitro fertilization	1	NBK1334	
the following treatment recommendations are appropriate:	1	NBK390670	
educational intervention and speech therapy beginning in infancy	1	NBK390670	
cataract and ptosis surgery if indicated	1	NBK390670	
hearing aids or cochlear implant if needed	1	NBK390670	
cardiac function assessment and treatment if needed	1	NBK390670	
orchidopexy in males with undescended testes	1	NBK390670	
treatment of vesicoureteral reflux if indicated	1	NBK390670	
other facial	1	NBK390670	
cleft palate repair if present	1	NBK390670	
placement of eyelid slings for severe ptosis	1	NBK1203	
cochlear implants and hearing aids for neurosensory hearing loss	1	NBK1203	
hormone replacement for endocrinopathies	1	NBK1203	
dilation of the upper esophageal sphincter to alleviate cricopharyngeal achalasia	1	NBK1203	
replacement of pancreatic enzymes in pearson syndrome	1	NBK1203	
treatment of depression	1	NBK1203	
ventilatory support for respiratory abnormalities in leigh syndrome	1	NBK1203	
surgical treatment should be performed as needed	1	NBK1484	
developmental progress should be monitored and stimulated	1	NBK1484	
adducted thumbs	1	NBK1484	
surgical intervention is not generally indicated	1	NBK1484	
a splint may help reduce the degree of adduction	1	NBK1484	
neurologic features should be monitored	1	NBK1484	
follow up and treatment is nonspecific	1	NBK1484	
autonomic dysfunction	1	NBK338165	
neurogenic bladder:	1	NBK338165	
urinary urgency may require spasmolytics (e	1	NBK338165	
, solifenacine succinate)	1	NBK338165	
, docusate) or a laxative is needed	1	NBK338165	
sexual dysfunction can be alleviated with sildenafil	1	NBK338165	
anhidrosis is managed by avoiding overheating	1	NBK338165	
cognitive dysfunction can affect social interactions and financial management	1	NBK338165	
valproic acid is the traditional antiepileptic treatment for ld	1	NBK1389	
wolman disease	1	NBK305870	
malabsorption and malnutrition	1	NBK305870	
hepatomegaly and liver disease	1	NBK305870	
adrenal cortical insufficiency	1	NBK305870	
consider discussion of comfort care options	1	NBK305870	
cesd	1	NBK305870	
lipophilic vitamin supplementation may also be beneficial	1	NBK305870	
the following as needed:	1	NBK43417	
recurrence is possible even with more definitive treatment	1	NBK1457	
surgery for ptosis if clinically indicated (e	1	NBK1457	
, obscured vision, cosmetic appearance)	1	NBK1457	
individualized education plans for learning disorders and school performance issues	1	NBK47312	
biotin-thiamine-responsive basal ganglia disease	1	NBK320989	
biotinidase deficiency	1	NBK320989	
(btd)	1	NBK320989	
coenzyme q10 biosynthesis deficiency	1	NBK320989	
(pdss2)	1	NBK320989	
early intervention with special education maximizes cognitive development	1	NBK1521	
referral to services for the visually impaired is recommended	1	NBK1521	
treatment of hearing loss may include the following:	1	NBK1383	
extrapyramidal manifestations	1	NBK184570	
dystonia and dyskinesias may cause significant disability	1	NBK184570	
pharmacologic treatment may result in significant functional improvement	1	NBK184570	
cognitive developmental delay/encephalopathy	1	NBK184570	
augmentative communication may be used to address speech deficits	1	NBK184570	
referral to a cardiologist for standard supportive treatment of cardiomyopathy	1	NBK1408	
clinical genetics consultation	1	NBK1408	
avoidance of prolonged immobility is recommended	1	NBK1313	
there is no curative therapy for lp	1	NBK338540	
treatments of unproven efficacy	1	NBK338540	
click here (pdf) for further details	1	NBK338540	
specific treatment for lms does not currently exist	1	NBK368476	
lateral spinal meningoceles	1	NBK368476	
symptomatic treatment of neurologic sequelae (e	1	NBK368476	
physiotherapy to reduce risk for joint subluxation and dislocation	1	NBK368476	
routine management of the following:	1	NBK368476	
congenital cardiac defects	1	NBK368476	
hyperuricemia	1	NBK1149	
allopurinol therapy results in the accumulation of hypoxanthine and xanthine	1	NBK1149	
xanthine may also form stones	1	NBK1149	
hypoxanthine is soluble	1	NBK1149	
neurologic dysfunction	1	NBK1149	
two important considerations when managing cardiovascular features of lds:	1	NBK1133	
vascular disease is not limited to the aortic root	1	NBK1133	
0 cm	1	NBK1133	
0 cm and the excellent response to prophylactic surgery	1	NBK1133	
clubfeet require surgical correction by an orthopedic surgeon	1	NBK1133	
surgical intervention for protusio acetabulae is rarely indicated	1	NBK1133	
treatment focuses on pain control	1	NBK1133	
orthotics are only indicated for severe pes planus	1	NBK1133	
some individuals prefer use of arch supports	1	NBK1133	
others find them irritating	1	NBK1133	
surgical intervention is rarely indicated or successful	1	NBK1133	
cataract surgeons and glaucoma specialists may also be needed	1	NBK1480	
others require surgery	1	NBK1480	
most seizure disorders can be controlled with anticonvulsant therapy	1	NBK1480	
early childhood and preschool intervention programs, e	1	NBK1480	
kidney	1	NBK1480	
, with surgical procedures	1	NBK1480	
most undescended testes descend with time into the scrotum	1	NBK1480	
some require hormone therapy and/or surgical correction	1	NBK1480	
treatment of acute hyperammonemic crises	1	NBK1361	
pharmacologic management	1	NBK1361	
therapy with ondansetron can be started to decrease vomiting	1	NBK1361	
dietary protein restriction and citrulline supplementation	1	NBK1361	
current treatment consists of dietary protein restriction (0	1	NBK1361	
8-1	1	NBK1361	
5 g/kg/day in children and 0	1	NBK1361	
lysine supplementation	1	NBK1361	
carnitine supplemetation	1	NBK1361	
additional therapies	1	NBK1361	
treatment of late complications	1	NBK1361	
however, relapses may require serial lavage	1	NBK1361	
medical nutrition therapy	1	NBK1308	
recurrent or persistent eruptive xanthomas indicate inadequate therapy	1	NBK1308	
treatment is largely symptomatic	1	NBK343782	
oxygen supplementation if necessary	1	NBK343782	
education on complete bladder emptying when voiding	1	NBK343782	
medical treatment of pulmonary hypertension (e	1	NBK343782	
, by sildenafil)	1	NBK343782	
surgical treatment of congenital diaphragmatic hernia or severe hiatal hernia	1	NBK343782	
physical therapy for muscle strength and joint stability	1	NBK343782	
psychosocial support	1	NBK343782	
painful bilateral madelung deformity (uncommon)	1	NBK1215	
audiologist	1	NBK5199	
dietitian	1	NBK5199	
clinical geneticist and genetic counselor	1	NBK5199	
nurse coordinator	1	NBK5199	
ophthalmologist	1	NBK5199	
oral and maxillofacial surgeon	1	NBK5199	
orthodontist	1	NBK5199	
orthopedist	1	NBK5199	
otolaryngologist	1	NBK5199	
pediatric dentist	1	NBK5199	
pediatrician	1	NBK5199	
plastic and reconstructive surgeon	1	NBK5199	
psychosocial professionals (psychologist, social worker)	1	NBK5199	
speech pathologist	1	NBK5199	
referral to a craniofacial center or otolaryngologist is recommended	1	NBK5199	
face	1	NBK5199	
jaw and teeth	1	NBK5199	
good oral hygiene is especially important for children with cfm	1	NBK5199	
children should have consistent primary preventative dental care	1	NBK5199	
early referral to an otolaryngologist is recommended	1	NBK5199	
this surgery typically occurs after age five years	1	NBK5199	
speech	1	NBK5199	
ears	1	NBK5199	
options for management of microtia include the following:	1	NBK5199	
no action	1	NBK5199	
prosthetic management, either adhesive or implant-retained	1	NBK5199	
family and social support	1	NBK5199	
crmo is treated as follows:	1	NBK1974	
thus, their efficacy in this disorder is unknown	1	NBK1974	
physical therapy to avoid disuse atrophy of muscles or contractures	1	NBK1974	
colon polyps and colon cancer	1	NBK107219	
colonoscopy is effective surveillance for colon cancer	1	NBK107219	
duodenal polyps	1	NBK107219	
management of polyps is similar to individuals with fap	1	NBK107219	
protusio acetabulae can be associated with pain or functional limitations	1	NBK1335	
surgical intervention is rarely indicated	1	NBK1335	
orthotics are indicated only in severe cases	1	NBK1335	
surgical intervention is rarely indicated or fully successful	1	NBK1335	
pneumothorax can be a recurrent problem	1	NBK1335	
school-age children benefit from an individualized educational program	1	NBK390803	
no information is available on response to specific aeds	1	NBK390803	
fibrous dysplasia	1	NBK274564	
the primary elements of management include the following	1	NBK274564	
see fibrous dysplasia management (pdf):	1	NBK274564	
see precocious puberty management in girls (pdf)	1	NBK274564	
see gonadal involvement management in boys (pdf)	1	NBK274564	
, letrozole) [boyce et al 2012]	1	NBK274564	
thyroid disease	1	NBK274564	
see hyperthyroidism management (pdf)	1	NBK274564	
methimazole is effective for management of hyperthyroidism	1	NBK274564	
the risk may potentially be enhanced by radiation exposure	1	NBK274564	
growth hormone (gh) excess	1	NBK274564	
see gh excess: management (pdf)	1	NBK274564	
medical therapy is the preferred first-line treatment	1	NBK274564	
fgf23-mediated phosphate wasting	1	NBK274564	
hypercortisolism	1	NBK274564	
see hypercortisolism management (pdf)	1	NBK274564	
definitive treatment includes surgical removal of the diseased adrenal glands	1	NBK274564	
care by a nephrologist is recommended	1	NBK153723	
gout prevention with allopurinol or probenecid should be considered	1	NBK1356	
kidney disease	1	NBK1356	
kidney transplantation cures adtkd-umod	1	NBK1356	
treatment of psychiatric problems according to the clinical presentation	1	NBK1354	
antiepileptic drugs (aeds) for treatment of seizures	1	NBK1354	
early-onset	1	NBK97333	
nutrition/weight	1	NBK97333	
weight needs to increase annually by small increments	1	NBK97333	
gastroesophageal reflux is treated as needed	1	NBK97333	
respiratory function testing	1	NBK97333	
assistance with coughing	1	NBK97333	
noninvasive ventilation support is indicated in the setting of:	1	NBK97333	
daytime hypercapnea and/or nocturnal hypoventilation	1	NBK97333	
toddlers often fight the masks	1	NBK97333	
non-ambulant children require standing frames for postural support	1	NBK97333	
late-onset	1	NBK97333	
antiepileptic drugs should be used to treat seizures	1	NBK97333	
additional management in healthy adults who have the 15q13	1	NBK50780	
, schizophrenia)	1	NBK50780	
routine treatment of ophthalmologic, cardiac, neurologic findings	1	NBK84258	
speech, occupational, and physical therapies	1	NBK84258	
because manifestations of 16p12	1	NBK274565	
early diagnosis and treatment facilitate the best outcome	1	NBK274565	
developmental and cognitive delays	1	NBK274565	
initiate developmental therapies promptly when indicated	1	NBK274565	
individuals with 16p12	1	NBK274565	
psychiatric and/or behavior problems	1	NBK274565	
standard treatment should be provided for hearing loss	1	NBK274565	
other malformations	1	NBK274565	
mody5	1	NBK401562	
neurodevelopmental/neuropsychiatric disorders	1	NBK401562	
routine medical care by a pediatrician or other primary physician	1	NBK24676	
speech therapy directed at improving verbal and nonverbal communication skills	1	NBK24676	
the seizures usually are easy to control with medication	1	NBK24676	
treatment for cryptorchidism if indicated	1	NBK24676	
routine treatment of ophthalmologic, cardiac, and neurologic findings	1	NBK52787	
speech, occupational, and physical therapies, as appropriate	1	NBK52787	
early speech and language therapy to address speech delays	1	NBK385289	
individualized education program (iep) for school-age children	1	NBK385289	
applied behavioral analysis or other treatment for manifestations of asd	1	NBK385289	
ataxia may require assistive devices or eventually wheelchair	1	NBK9674	
consultation with a speech pathologist may be helpful	1	NBK9674	
cognitive impairment	1	NBK1284	
developmental stimulation including speech therapy is appropriate	1	NBK1284	
treatment is nonspecific	1	NBK1284	
predisposition to infections	1	NBK1284	
all vaccines should be given	1	NBK1284	
gastrointestinal dysfunction	1	NBK1284	
for (progressive) spasticity	1	NBK195853	
for excessive drooling	1	NBK195853	
patients experienced great improvement (e	1	NBK195853	
for failure to thrive	1	NBK195853	
no therapy is available for peo or retinopathy	1	NBK1233	
physical therapy should be implemented in individuals after strokes	1	NBK1233	
seizures respond to traditional anticonvulsant therapy	1	NBK1233	
standard analgesics can be used for migraine headaches	1	NBK1233	
cardiac manifestations can benefit from standard pharmacologic therapy	1	NBK1233	
phpt	1	NBK1538	
subtotal parathyroidectomy (i	1	NBK1538	
removal of ≤3	1	NBK1538	
pituitary tumors	1	NBK1538	
prl-secreting tumors (prolactinomas)	1	NBK1538	
growth hormone-secreting tumors	1	NBK1538	
acth-secreting tumors	1	NBK1538	
non-secreting pituitary adenomas	1	NBK1538	
gastrinoma	1	NBK1538	
pancreatic tumors	1	NBK1538	
the optimal therapy of gastrinoma is controversial	1	NBK1538	
occult metastatic disease (i	1	NBK1538	
carcinoid tumors	1	NBK1538	
adrenocortical tumors	1	NBK1538	
medullary thyroid carcinoma (mtc)	1	NBK1257	
menkes disease	1	NBK1413	
surgery for bladder diverticula that occur in classic menkes disease	1	NBK1413	
developmental intervention	1	NBK1413	
atp7a-related dmn	1	NBK1413	
physical therapy (strength and stretching exercises)	1	NBK1413	
occupational therapy	1	NBK1413	
ankle foot orthotics	1	NBK1413	
the seizure disorder can be treated with conventional anticonvulsant therapy	1	NBK1520	
clonazepam can also reduce myoclonus	1	NBK1520	
physical therapy is helpful for any impaired motor abilities	1	NBK1520	
standard pharmacologic therapy is used to treat cardiac symptoms	1	NBK1520	
mandibulofacial dysostosis	1	NBK214367	
see esophageal atresia/tracheoesophageal fistula overview	1	NBK214367	
thumb anomalies	1	NBK214367	
other thumb anomalies are not generally functionally significant	1	NBK214367	
short stature is managed expectantly	1	NBK214367	
treatment of scoliosis by spinal fusion is appropriate	1	NBK1499	
orthoses are indicated for treatment of foot drop	1	NBK1499	
discontinue use of potent inhalation agents and succinylcholine	1	NBK1146	
increase minute ventilation to lower end-tidal co2	1	NBK1146	
get help	1	NBK1146	
prepare and administer dantrolene: 2	1	NBK1146	
5 mg/kg initial dose	1	NBK1146	
tachycardia, hypercarbia, and muscle rigidity respond rapidly	1	NBK1146	
multiple doses of dantrolene may be needed	1	NBK1146	
the suggested upper limit is 10 mg/kg	1	NBK1146	
however, more may be given as needed	1	NBK1146	
continue dantrolene at 1	1	NBK1146	
dantrolene may aggravate previously existing muscle weakness	1	NBK1146	
begin cooling measures	1	NBK1146	
stop cooling measures at core body temperature of 38	1	NBK1146	
5° c	1	NBK1146	
treat cardiac arrhythmias as needed	1	NBK1146	
do not use calcium channel blockers	1	NBK1146	
check values every six to 12 hours	1	NBK1146	
the earliest sign of rhabdomyolysis is myoglobinuria/myoglobinemia	1	NBK1146	
serum ck levels may not rise for several hours	1	NBK1146	
ensure urine output of 2	1	NBK1146	
evaluate need for invasive monitoring and continued mechanical ventilation	1	NBK1146	
myoglobinuria	1	NBK1146	
physical habilitation	1	NBK174452	
standard care for other medical issues (e	1	NBK174452	
therapy is supportive and involves the following:	1	NBK9587	
special education programs tailored to the needs of the individual	1	NBK9587	
speech and language therapy	1	NBK9587	
behavioral therapy as needed	1	NBK9587	
occupational therapy as needed	1	NBK9587	
community services that provide support for families	1	NBK9587	
ritalin® may be helpful to treat marked hyperkinesia	1	NBK9587	
objective efficiency of gh therapy has not been evaluated	1	NBK9587	
use of a prosthesis in severe microphthalmia and anophthalmia	1	NBK7041	
, fitting stockings, massage) is important	1	NBK1239	
adaptation of the school environment (e	1	NBK279760	
no definitive treatments exist for the limb-girdle muscular dystrophies	1	NBK1303	
standard treatment is indicated for the following:	1	NBK1502	
polydactyly and syndactyly	1	NBK1502	
anal anomalies and hirschsprung disease (surgical treatment)	1	NBK1502	
joint	1	NBK1828	
intellectual impairment in ml ii is rarely severe	1	NBK1828	
severe gingival thickening can compromise routine dental cleaning	1	NBK1828	
otic	1	NBK1828	
the recommended dose is 1 mg/kg monthly	1	NBK1875	
bone density needs to be monitored closely	1	NBK1875	
the long-term effect(s) are unknown	1	NBK1875	
sillence, personal communication]	1	NBK1875	
not all affected individuals benefit from bisphosphonate treatment	1	NBK1875	
the prevalence decreases with age	1	NBK1875	
psychosocial support of patients and families is recommended	1	NBK24701	
management of pain in the hips is required	1	NBK24701	
surgical correction of strabismus	1	NBK1214	
speech therapy as needed	1	NBK1535	
pulmonary function and vision may also need attention	1	NBK1130	
stabilization of critically ill individuals	1	NBK1231	
volume replacement with isotonic solutions	1	NBK1231	
adequate kcals must be delivered	1	NBK1231	
once symptoms appear, treatment is primarily supportive	1	NBK1179	
management of gi dysfunction can include the following:	1	NBK1179	
trial of dromperidone for nausea and vomiting	1	NBK1179	
celiac plexus block with bupivicaine	1	NBK1179	
physical therapy and occupational therapy to help preserve mobility	1	NBK1179	
activity as tolerated should be encouraged	1	NBK1179	
osteopenia and osteolysis	1	NBK373578	
at present no specific therapy can alleviate the progressive osteopenia	1	NBK373578	
nonsteroidal anti-inflammatory drugs may not provide sufficient relief	1	NBK373578	
provide medical or surgical interventions as appropriate	1	NBK373578	
monosomy 7 in children with de	1	NBK45015	
novo aml (i	1	NBK45015	
eye anomalies	1	NBK1728	
notched or bifid nose	1	NBK1728	
rhinoplasty may be performed for cosmetic purposes	1	NBK1728	
anal stenosis is generally managed by serial dilatations	1	NBK1728	
the cardiomyopathy may respond to ace inhibitors or other medication	1	NBK1433	
cardiac consultation is recommended	1	NBK1433	
kyphoscoliosis may be treated with surgical stabilization of the spine	1	NBK1433	
there is no treatment for spinal rigidity	1	NBK1433	
these agents are not widely used in children	1	NBK1425	
renal allografts	1	NBK1425	
001)	1	NBK1425	
005)	1	NBK1425	
allograft survival appears to be age-dependent in ddd	1	NBK1425	
neurosurgical complications (hydrocephalus and cerebellar tonsillar ectopia)	1	NBK396098	
epilepsy may require long-term antiepileptic treatment	1	NBK396098	
developmental delays	1	NBK396098	
joint replacement and atlanto-occipital stabilization may be necessary	1	NBK1162	
repeated surgery may be required	1	NBK1162	
cardiac valve replacement should be considered early	1	NBK1162	
hearing aids should also be considered	1	NBK1162	
ent (otolaryngologic)	1	NBK1162	
gastrointestinal system	1	NBK1162	
hydrocephaly	1	NBK1162	
early surgical intervention may prevent severe complications	1	NBK1162	
physical therapist to optimize mobility	1	NBK148668	
occupational therapist to optimize autonomy	1	NBK148668	
psychological support to optimize coping skills and quality of life	1	NBK148668	
educational professions to optimize learning in a medically fragile individual	1	NBK148668	
home care for affected individuals with multiple medical equipment needs	1	NBK148668	
hospice for end-of-life care	1	NBK148668	
enzyme replacement therapy (ert)	1	NBK148668	
the recommendation dose is 2 mg/kg/week intravenous	1	NBK148668	
upper extremities	1	NBK148668	
knee and ankle valgus	1	NBK148668	
however, no absolute indications for intervention exist	1	NBK148668	
hip dysplasia	1	NBK148668	
affected individuals undergoing surgical fusion typically do well	1	NBK148668	
lumbar spine malalignment	1	NBK148668	
when kyphosis exceeds 45 degrees, progression is likely	1	NBK148668	
progressive thoracolumbar kyphosis greater than 70 degrees	1	NBK148668	
uncontrolled back pain	1	NBK148668	
neurologic changes related to spinal stenosis	1	NBK148668	
thus tachycardia treatment with beta blockers should be avoided	1	NBK148668	
restrictive lung disease is managed by supportive treatment	1	NBK148668	
learning environment	1	NBK148668	
cataract surgery may benefit those with cataracts	1	NBK148668	
orthodontic management to correct malocclusion may be necessary	1	NBK148668	
prevention of hypoglycemia requires frequent feeds and avoidance of fasting	1	NBK92947	
hepatocellular carcinoma	1	NBK92947	
treatment of muscular manifestations is symptomatic	1	NBK1192	
cataracts are removed surgically during the first decade of life	1	NBK1192	
hypergonadotropic hypogonadism (i	1	NBK1192	
home therapy	1	NBK1319	
acute decompensation	1	NBK1319	
indication for hospitalization	1	NBK1319	
number	1	NBK1319	
vomiting and viral gastroenteritis	1	NBK1319	
viral bronchiolitis	1	NBK1319	
sinusitis	1	NBK1319	
neonatal encephalopathy	1	NBK1319	
urinary tract infection	1	NBK1319	
cellulitis	1	NBK1319	
influenza	1	NBK1319	
viral meningitis	1	NBK1319	
bacterial pharyngitis	1	NBK1319	
esophageal candidiasis	1	NBK1319	
appendicitis	1	NBK1319	
the primary goals of in-hospital therapy	1	NBK1319	
25 mosm/l per hour	1	NBK1319	
minimize exposure to hypotonic fluid sources	1	NBK1319	
the most commonly encountered are hypokalemia and hypophosphatemia	1	NBK1319	
methods of achieving these goals	1	NBK1319	
identify and treat precipitating conditions (e	1	NBK1319	
, infection, inflammation, and fever)	1	NBK1319	
administer antiemetics (e	1	NBK1319	
, odansetron 0	1	NBK1319	
15 mg/kg/dose) to control nausea and vomiting	1	NBK1319	
provide at least 1	1	NBK1319	
10 units/kg/hour and titrated to maintain euglycemia	1	NBK1319	
5 g/kg/day	1	NBK1319	
provide specific amino acid supplements during metabolic crisis:	1	NBK1319	
isoleucine and valine	1	NBK1319	
20-120 mg/kg/day each	1	NBK1319	
glutamine and alanine	1	NBK1319	
tyrosine	1	NBK1319	
strauss & morton, unpublished observation]	1	NBK1319	
nutrient	1	NBK1319	
age in months (# of persons)	1	NBK1319	
0-2 (31)	1	NBK1319	
3-5 (18)	1	NBK1319	
6-8 (21)	1	NBK1319	
9-12 (18)	1	NBK1319	
13-18 (21)	1	NBK1319	
19-24 (18)	1	NBK1319	
25-36 (32)	1	NBK1319	
leucine (mg)	1	NBK1319	
72(64-84)	1	NBK1319	
58(47-68)	1	NBK1319	
44(37-51)	1	NBK1319	
35(30-41)	1	NBK1319	
33(26-39)	1	NBK1319	
27(22-28)	1	NBK1319	
21(20-25)	1	NBK1319	
energy (kcal)	1	NBK1319	
111(103-119)	1	NBK1319	
99(94-107)	1	NBK1319	
89(82-99)	1	NBK1319	
78(71-87)	1	NBK1319	
67(55-77)	1	NBK1319	
57(49-71)	1	NBK1319	
38(39-51)	1	NBK1319	
total protein (g)	1	NBK1319	
1-2	1	NBK1319	
5(1	1	NBK1319	
isoleucine supplement (mg)	1	NBK1319	
4(0-7)	1	NBK1319	
3(0-3	1	NBK1319	
7(0-3	1	NBK1319	
6(0-3	1	NBK1319	
8(2	1	NBK1319	
1-5	1	NBK1319	
7(1	1	NBK1319	
5(3	1	NBK1319	
valine supplement (mg)	1	NBK1319	
5(9	1	NBK1319	
8-14	1	NBK1319	
4(9	1	NBK1319	
0-13	1	NBK1319	
0(9	1	NBK1319	
5-12	1	NBK1319	
1(6	1	NBK1319	
8(5	1	NBK1319	
4-10	1	NBK1319	
2(2	1	NBK1319	
8(4	1	NBK1319	
9-8	1	NBK1319	
alanine intake (mg)	1	NBK1319	
233(200-262)	1	NBK1319	
209(197-234)	1	NBK1319	
206(193-225)	1	NBK1319	
189(168-218)	1	NBK1319	
178(159-199)	1	NBK1319	
159(140-192)	1	NBK1319	
117(114-149)	1	NBK1319	
glutamine intake (mg)	1	NBK1319	
416(361-471)	1	NBK1319	
363(337-405)	1	NBK1319	
358(332-400)	1	NBK1319	
320(288-371)	1	NBK1319	
294(252-337)	1	NBK1319	
256(221-318)	1	NBK1319	
184(181-235)	1	NBK1319	
iron (mg)	1	NBK1319	
1(2	1	NBK1319	
6-2	1	NBK1319	
8(1	1	NBK1319	
zinc (mg)	1	NBK1319	
6(3	1	NBK1319	
1-4	1	NBK1319	
4-4	1	NBK1319	
9-4	1	NBK1319	
6(2	1	NBK1319	
6-3	1	NBK1319	
selenium (µg)	1	NBK1319	
0(5	1	NBK1319	
7-6	1	NBK1319	
7(4	1	NBK1319	
8-6	1	NBK1319	
7(5	1	NBK1319	
3-6	1	NBK1319	
3(4	1	NBK1319	
4-6	1	NBK1319	
0(4	1	NBK1319	
0-4	1	NBK1319	
378(307-401)	1	NBK1319	
330(307-378)	1	NBK1319	
330(307-354)	1	NBK1319	
307(260-354)	1	NBK1319	
307(283-330)	1	NBK1319	
283(236-330)	1	NBK1319	
212(212-260)	1	NBK1319	
leucine / energy ratio (mg/kcal)	1	NBK1319	
65(0	1	NBK1319	
57-0	1	NBK1319	
72)	1	NBK1319	
58(0	1	NBK1319	
48-0	1	NBK1319	
66)	1	NBK1319	
56)	1	NBK1319	
46(0	1	NBK1319	
37-0	1	NBK1319	
53)	1	NBK1319	
48(0	1	NBK1319	
38-0	1	NBK1319	
54(0	1	NBK1319	
44-0	1	NBK1319	
55)	1	NBK1319	
control of brain edema	1	NBK1319	
measure head circumference and fontanel size in neonates	1	NBK1319	
papilledema	1	NBK1319	
disorientation, combativeness	1	NBK1319	
depressed level of consciousness	1	NBK1319	
refractory vomiting	1	NBK1319	
extremity hyperreflexia	1	NBK1319	
bradycardic hypertension	1	NBK1319	
hyperactive gag	1	NBK1319	
pupillary asymmetry	1	NBK1319	
ophthalmoplegia	1	NBK1319	
decorticate posturing	1	NBK1319	
methods to minimize the possibility of brain swelling:	1	NBK1319	
elevate the individual's head	1	NBK1319	
note: give furosemide (0	1	NBK1319	
methods to manage brain swelling:	1	NBK1319	
furosemide: 0	1	NBK1319	
0 mg/kg, followed by	1	NBK1319	
mannitol: 0	1	NBK1319	
0 g/kg over 60 minutes, followed by	1	NBK1319	
hypertonic (3%-5%) saline: 2	1	NBK1319	
5 meq/kg over 60 minutes	1	NBK1319	
neuroimaging	1	NBK1319	
hemodialysis/hemofiltration	1	NBK1319	
other potential complications in hospitalized persons with msud:	1	NBK1319	
monitor for and promptly treat hospital-acquired infections	1	NBK1319	
superficial and invasive candida infections are common	1	NBK1319	
the management of enlarged parietal foramina is generally conservative	1	NBK1128	
associated headaches or seizures should be treated symptomatically	1	NBK1128	
appropriate rehabilitation, e	1	NBK1422	
enrollment in educational programs appropriate for the hearing impaired	1	NBK1422	
for mild keratoderma, use of lotions and emollients	1	NBK1422	
for severe keratoderma, dermatologic evaluation	1	NBK1422	
treatment by a psychiatrist for those with significant neuropsychiatric symptoms	1	NBK185329	
tracheostomy as indicated for difficulty managing secretions	1	NBK185329	
prevention strategies under investigation	1	NBK1224	
other disciplines are involved as needed	1	NBK1415	
this procedure is usually transcranial (i	1	NBK1415	
severe initial clinical presentation requiring a staged repair	1	NBK1415	
postoperative increased icp	1	NBK1415	
recurrent deformity requiring a second transcranial repair:	1	NBK1415	
seven (24	1	NBK1415	
1%) of 29 individuals with the p	1	NBK1415	
3%) of 47 without the pathogenic variant	1	NBK1415	
048) [thomas et al 2005]	1	NBK1415	
15 were expected to undergo extracranial contouring	1	NBK1415	
note that none had increased icp	1	NBK1415	
hearing loss is often sensorineural	1	NBK1415	
strabismus surgery/correction is indicated to prevent amblyopia	1	NBK1415	
evaluation for hscr and ultrashort hscr	1	NBK1412	
referral to a urologist or nephrologist as indicated	1	NBK1412	
bleeding tendency	1	NBK2689	
suturing for treatment of accidental or surgical wounds	1	NBK2689	
mouthwash with tranexamic acid may control gingival bleeding	1	NBK2689	
eltrombopag	1	NBK2689	
antifibrinolytic agents	1	NBK2689	
ten of them benefited from cochlear implants	1	NBK2689	
glomerular nephropathy	1	NBK2689	
dialysis or kidney transplantation is required in individuals with esrd	1	NBK2689	
cataract surgery remedies clouding of the lens	1	NBK2689	
elevation of liver enzymes does not require any specific treatment	1	NBK2689	
treatment is largely symptomatic and may include the following	1	NBK425723	
elective tracheal surgery/intubation should be avoided	1	NBK425723	
symptomatic treatment of restrictive lung disease	1	NBK425723	
oxygen supplementation as necessary	1	NBK425723	
noninvasive 3d imaging may be preferred	1	NBK425723	
neuropsychiatric	1	NBK425723	
global developmental disability/intellectual disability educational issues	1	NBK425723	
persistent middle ear effusions	1	NBK425723	
myringotomy tubes as needed	1	NBK425723	
ophthalmology	1	NBK425723	
routine treatment of strabismus and refractive errors	1	NBK425723	
all experienced substantial improvement of both myoclonus (61	1	NBK1414	
5%) and dystonia (48	1	NBK1414	
2%)	1	NBK1414	
no adverse effects on cognition or affect were noted	1	NBK1414	
the results of case studies are summarized below:	1	NBK1414	
no specific therapy currently exists for this disorder	1	NBK5299	
special education evaluation is indicated for children with dm1	1	NBK1165	
statins)	1	NBK1165	
pain management can be an important part of dm1 treatment	1	NBK1165	
treatment guidelines for dm2 have been published	1	NBK1466	
no one medication has been consistently effective	1	NBK1466	
treatment as in the general population for:	1	NBK1132	
glaucoma	1	NBK1132	
supportive management includes treatment of the following:	1	NBK1173	
treatments for nbia are palliative	1	NBK121988	
botulinum toxin for those with focal dystonia	1	NBK121988	
l-dopa treatment, which is beneficial in rare cases	1	NBK121988	
some will develop prominent dyskinesias early in the treatment	1	NBK121988	
spectacles as needed to correct refractive errors	1	NBK321516	
orchiopexy as needed	1	NBK321516	
trihexyphenydil improves dystonia and sialorrhea	1	NBK1428	
general management	1	NBK1177	
thiazide diuretics (i	1	NBK1177	
emergency treatment for dehydration	1	NBK1177	
5% dextrose in water is the preferred solution	1	NBK1177	
if administration of iv fluids is required, 2	1	NBK1177	
special situations	1	NBK1177	
hydronephrosis, hydroureter, and megacystis	1	NBK1177	
aggressive treatment of lower respiratory tract infections	1	NBK1288	
standard treatment of gastroesophageal reflux, if present	1	NBK1288	
physical therapy for maintenance/improvement of function and joint mobility	1	NBK1288	
speech therapy if dysarthria and/or hypernasal speech is present	1	NBK1288	
currently no cure for nephronophthisis exists	1	NBK368475	
treatment of anemia, hypertension, and proteinuria if present	1	NBK368475	
dialysis or renal transplantation when patients reach esrd	1	NBK368475	
botulinum toxin is helpful for painful focal dystonia	1	NBK1141	
further studies are in progress	1	NBK1109	
vestibular schwannoma	1	NBK1201	
therapy remains primarily surgical	1	NBK1201	
small vestibular tumors (<1	1	NBK1201	
lip-reading skills may be enhanced by instruction	1	NBK1201	
ocular involvement	1	NBK1201	
infections	1	NBK1176	
the spectrum of recurrent infections in nbs is not opportunistic	1	NBK1176	
puberty and fertility	1	NBK1176	
females are infertile	1	NBK1176	
similarly, no male paternity has been reported	1	NBK1176	
no effective treatment for severe glycine encephalopathy exists	1	NBK1357	
flusser et al 2005	1	NBK1357	
van hove et al, unpublished]	1	NBK1357	
it increases alertness	1	NBK1357	
nmda receptor site antagonists	1	NBK1357	
use of each has resulted in improved seizure control	1	NBK1357	
this may be different in mildly affected children	1	NBK1357	
blood concentration can be monitored	1	NBK1357	
seizure control is important for symptomatic benefit	1	NBK1357	
various antiepileptic drugs have been used with variable success	1	NBK1357	
most affected individuals need physical therapy	1	NBK1357	
scoliosis is managed with standard techniques	1	NBK1357	
chorea	1	NBK185066	
children: 0	1	NBK185066	
adults: 37	1	NBK185066	
5 mg/day starting dose divided in 2-3 doses	1	NBK185066	
of note:	1	NBK185066	
other neurologic manifestations	1	NBK185066	
pulmonary dysfunction	1	NBK185066	
treat asthma and interstitial lung disease as needed	1	NBK185066	
thyroid hormone replacement therapy is recommended	1	NBK185066	
there is substantial early mortality associated with hypertrophic cardiomyopathy	1	NBK1124	
significant short stature compared with normal peers	1	NBK1124	
documented response to gh treatment in studies	1	NBK1124	
no standard dose has been established	1	NBK1124	
the increase in height sd varies from 0	1	NBK1124	
6 to 1	1	NBK1124	
ophthalmologic evaluation is warranted	1	NBK1331	
at 23 months of life	1	NBK1331	
5 months) [walsh et al 2010]	1	NBK1331	
severe neurodegenerative form (npd-a)	1	NBK1370	
progressive neurologic disease	1	NBK1370	
regular consultation with a dietician should be provided	1	NBK1370	
sleep disorder	1	NBK1370	
npd-b	1	NBK1370	
most affected individuals have thrombocytopenia	1	NBK1370	
individuals with symptomatic pulmonary disease may require supplemental oxygen	1	NBK1370	
no curative therapy for npc exists	1	NBK1296	
child syndrome	1	NBK51754	
oral aromatic retinoids (etretinate) to ameliorate cutaneous symptoms	1	NBK51754	
topical statins	1	NBK51754	
dermatologic surgery	1	NBK51754	
orthopedic abnormalities	1	NBK51754	
other medical care as appropriate based on clinical findings	1	NBK51754	
ck syndrome	1	NBK51754	
antiepileptic drugs (aed) to control seizures	1	NBK51754	
ophthalmologic management of ocular abnormalities	1	NBK51754	
ophthalmologic care	1	NBK1166	
surgery may improve peripheral binocularity or appearance	1	NBK1166	
nystagmus surgery remains highly controversial	1	NBK1166	
additional classroom aids may include:	1	NBK1166	
high contrast reading materials (black on white)	1	NBK1166	
large font texts or xerographically enlarged worksheets	1	NBK1166	
computers and tablets with zoom-magnification text software	1	NBK1166	
skin cancer is treated as for the general population	1	NBK1232	
a hat with a brim (e	1	NBK1510	
removal of accessory teeth	1	NBK1188	
orthodontia for malocclusion	1	NBK1188	
surgery to repair syndactyly, if present	1	NBK1188	
routine management of seizures	1	NBK1188	
physical medicine treatment	1	NBK1295	
avoid sudden acceleration/deceleration movements	1	NBK1295	
and avoid throwing a child in the air	1	NBK1295	
older children should not ride on amusement park rides	1	NBK1295	
physical activity serves a number of purposes	1	NBK1295	
analgesics can be used to control pain from fractures	1	NBK1295	
casts should be small and lightweight	1	NBK1295	
these studies are still ongoing	1	NBK1295	
a study comparing pamidronate to zoledronic acid was completed	1	NBK1295	
to date, the results have not been published	1	NBK1295	
basilar impression	1	NBK1295	
criteria for surgical intervention are not well defined	1	NBK1295	
plastic polymers are sometimes used to coat teeth	1	NBK1295	
outcome data are limited	1	NBK1295	
management of lethal oi	1	NBK1295	
other therapies	1	NBK1295	
, pulse oximeter) and ventilation (i	1	NBK1427	
ongoing studies have not confirmed this report	1	NBK1427	
hirschsprung disease	1	NBK1427	
tumors of neural crest origin	1	NBK1427	
no treatment for opa1 is of proven efficacy	1	NBK1248	
for treatment of ataxia, see ataxia overview	1	NBK1248	
hand and foot malformations may also require surgery	1	NBK1393	
surgical correction of limb bowing has not been reported	1	NBK1393	
apnea prevention	1	NBK1393	
treatment as needed by an ophthalmologist	1	NBK1327	
surgical intervention as needed for hypospadias	1	NBK1327	
surgical treatment of medically significant laryngotracheoesophageal (lte) abnormalities	1	NBK1327	
surgical management for cleft lip/palate and other craniofacial anomalies	1	NBK1327	
neuropsychological support	1	NBK1327	
surgical intervention for imperforate anus	1	NBK1327	
surgical repair as needed for heart defects	1	NBK1327	
ptosis	1	NBK1126	
however, the procedure requires general anesthesia	1	NBK1126	
food should be cut into small pieces	1	NBK1126	
care of hyperammonemic coma	1	NBK154378	
rapid lowering of the plasma ammonia	1	NBK154378	
ammonia scavenger therapy	1	NBK154378	
citrulline is supplemented at 170 mg/kg/day or 3	1	NBK154378	
8g/m2/day (enterally)	1	NBK154378	
table 2	1	NBK154378	
patient weight	1	NBK154378	
components of infusion solution	1	NBK154378	
loading 1 and maintenance dose 2, 3	1	NBK154378	
sodium phenylacetate & sodium benzoate 4	1	NBK154378	
arginine hcl injection, 10%	1	NBK154378	
arginine hcl 5	1	NBK154378	
<25 kg	1	NBK154378	
undiluted: 2	1	NBK154378	
0 ml at 100 mg/ml	1	NBK154378	
200 mg/kg	1	NBK154378	
≥25 kg	1	NBK154378	
40 ml at 100 mg/ml	1	NBK154378	
4,000 mg/m2	1	NBK154378	
protein intake	1	NBK154378	
recommendations for ammonia scavenger therapy:	1	NBK154378	
9-13	1	NBK154378	
0 g/m2/day of sodium phenylbutyrate and 3	1	NBK154378	
it is typically performed by age six months	1	NBK154378	
attention deficit/hyperactivity disorder (adhd)	1	NBK154378	
seizure disorders	1	NBK154378	
learning disability/intellectual disability	1	NBK154378	
also see urea cycle disorders overview	1	NBK154378	
bleeding disorder	1	NBK447152	
cardiac fibrosis	1	NBK447152	
pancreatectomy	1	NBK190101	
issues to consider prior to referral for tpiat:	1	NBK190101	
the operation is irreversible	1	NBK190101	
pain relief is not universal	1	NBK190101	
chronic pancreatitis	1	NBK190101	
cholecystokinin (cck) and its analogs (e	1	NBK190101	
, mineral oil, olestra), or	1	NBK190101	
, orlistat), or	1	NBK190101	
routine screening of patients with chronic pancreatitis for glucose intolerance	1	NBK190101	
esrd is treated with renal replacement therapy (i	1	NBK1451	
, dialysis and/or renal transplantation)	1	NBK1451	
registration or institutional access required)	1	NBK1548	
most are benign and can be completely excised	1	NBK1548	
preoperative	1	NBK1548	
a liberal sodium diet	1	NBK1548	
, 3 days prior to surgery)	1	NBK1548	
postoperative	1	NBK1548	
occupational, physical, and speech therapy are often helpful	1	NBK1223	
treatment focuses on symptomatic therapy	1	NBK1448	
feeding and nutrition	1	NBK1448	
no specific metabolic diet is recommended	1	NBK1448	
neurologic function	1	NBK1448	
early intervention services should be provided	1	NBK1448	
seizures are present in approximately one third of affected individuals	1	NBK1448	
standard antiepileptic drugs (aeds) may be used	1	NBK1448	
no type of aed is contraindicated	1	NBK1448	
pch2	1	NBK9673	
919g>t (p	1	NBK9673	
ala307ser)	1	NBK9673	
all other subtypes are very rare	1	NBK9673	
the main problems to manage:	1	NBK9673	
central visual impairment	1	NBK9673	
epilepsy, which is amenable to standard treatments	1	NBK9673	
physiotherapy can be helpful	1	NBK9673	
pch4 and pch5	1	NBK9673	
respiratory support is usually given for a limited time	1	NBK9673	
palmoplantar keratoderma	1	NBK1280	
however, trimming too aggressively can greatly increase pain	1	NBK1280	
topical therapies to remove the hyperkeratosis:	1	NBK1280	
occlusive ointments are often poorly tolerated	1	NBK1280	
nail dystrophy	1	NBK1280	
particularly troublesome nails can be successfully removed surgically	1	NBK1280	
oral leukokeratosis	1	NBK1280	
follicular hyperkeratosis	1	NBK1280	
leukokeratosis with laryngeal involvement	1	NBK1280	
cysts	1	NBK1280	
intralesional injection of steroid (e	1	NBK1280	
if necessary, cysts can be excised	1	NBK1280	
at present, no specific therapies can correct ciliary dysfunction	1	NBK1122	
, vigorous exercise)	1	NBK1122	
routine immunizations to protect against respiratory pathogens:	1	NBK1122	
pertussis	1	NBK1122	
haemophilus influenzae type b	1	NBK1122	
pneumococcal vaccine	1	NBK1122	
annual influenza virus vaccine	1	NBK1122	
this approach, however, is controversial	1	NBK1122	
nasal congestion and sinus infections	1	NBK1122	
chronic/recurrent ear infection	1	NBK1122	
male infertility	1	NBK1122	
situs abnormalities	1	NBK1122	
special education programs should be offered	1	NBK1486	
, carbamazepine, phenytoin, valproate)	1	NBK1537	
hearing habilitation (hearing aids as early as possible)	1	NBK1467	
educational programs designed for individuals with hearing impairment	1	NBK1467	
provision should be made for any special educational needs	1	NBK242617	
estrogen can be administered orally or topically	1	NBK242617	
before considering pregnancy, uterine size should be assessed	1	NBK242617	
depression	1	NBK47027	
weight loss	1	NBK47027	
additional management is symptomatic and expectant	1	NBK1464	
thoracic society 2000, american thoracic	1	NBK1230	
society & european respiratory society 2002]	1	NBK1230	
transplantation are good candidates	1	NBK1230	
five-year survival rates post transplant in	1	NBK1230	
non-pharmologic treatments:	1	NBK1230	
oxygen therapy may improve exercise tolerance in patients with	1	NBK1230	
hypoxemia	1	NBK1230	
pulmonary rehabilitation is a recommended option for patients who would	1	NBK1230	
benefit	1	NBK1230	
ipf	1	NBK1230	
immunosuppressive/cytotoxic agents, and antifibrotic agents	1	NBK1230	
however, at least	1	NBK1230	
two antifibrotic pharmacologic interventions recently approved may be an option	1	NBK1230	
see therapies under	1	NBK1230	
investigation	1	NBK1230	
no management guidelines have been published	1	NBK395975	
the majority of individuals with pfcp require no regular treatment	1	NBK395975	
when symptoms of the hyperviscosity syndrome are evident	1	NBK395975	
hyperviscosity symptoms (see	1	NBK395975	
evaluations following initial diagnosis)	1	NBK395975	
grade 1	1	NBK395975	
grade 2	1	NBK395975	
in the presence of persistent symptoms perform phlebotomy	1	NBK395975	
grade 3	1	NBK395975	
consider additional aspirin treatment	1	NBK395975	
thromboembolic events	1	NBK395975	
provide acute treatment according to established practice for the event	1	NBK395975	
evaluate for other thrombophilic risk factors	1	NBK395975	
consider additional aspirin treatment in all patients	1	NBK395975	
consider life-long anticoagulation (e	1	NBK395975	
pharmacologic therapy	1	NBK1297	
nutritional therapy and supplementation	1	NBK1297	
nasogastric tube feeding has been useful in some infants	1	NBK1297	
other approaches	1	NBK1297	
interruption of the enterohepatic circulation of bile acids	1	NBK1297	
the internal biliary bypass approach of cholecystojejunocolic anastomosis	1	NBK1297	
liver transplantation (ltx)	1	NBK1297	
steatohepatitis can be progressive and lead to cirrhosis	1	NBK1297	
extrahepatic manifestations	1	NBK1297	
the general therapies for nephrolithiasis benefit all individuals with ph1	1	NBK1283	
patients should be advised to seek early medical attention	1	NBK1283	
alkalinzation of urine (ph 6	1	NBK1283	
2-6	1	NBK1283	
15 mg/kg or 0	1	NBK1283	
3-0	1	NBK1283	
treatment of kidney stones	1	NBK1283	
swl	1	NBK1283	
ureteroscopy	1	NBK1283	
percutaneous nephrolithotomy and ureteroscopy	1	NBK1283	
reduction of oxalate biosynthesis	1	NBK1283	
agt is a pyridoxal phosphate (plp)-dependent enzyme	1	NBK1283	
7 mmol/1	1	NBK1283	
phe152ile pathogenic allele	1	NBK1283	
73 m2/day)	1	NBK1283	
transplantation (tx) options:	1	NBK1283	
simultaneous liver - kidney	1	NBK1283	
sequential liver - kidney	1	NBK1283	
isolated kidney	1	NBK1283	
isolated liver	1	NBK1283	
hemodialysis (hd) strategy:	1	NBK1283	
perioperative ± postoperative based on pox & gfr	1	NBK1283	
preoperative & perioperative	1	NBK1283	
sometimes perioperative	1	NBK1283	
ckd category / residual gfr	1	NBK1283	
ckd category 3 (30<gfr<59)	1	NBK1283	
option in carefully selected patients	1	NBK1283	
ckd category 4 (15<gfr<29)	1	NBK1283	
option	1	NBK1283	
ckd category 5 (gfr <15)	1	NBK1283	
infantile form (esrd <2 yrs)	1	NBK1283	
use of deceased vs	1	NBK1283	
living donors for either or both organs	1	NBK1283	
, gfr >60 ml/min/1	1	NBK1283	
adequate fluid intake (>2	1	NBK2692	
5 l/m2 surface area/day)	1	NBK2692	
urinary inhibitors of calcium oxalate crystallization:	1	NBK2692	
potassium citrate (0	1	NBK2692	
maintainance of high oral fluid intake (>2	1	NBK316514	
5 l/m2 bsa)	1	NBK316514	
oral administration of an inhibitor of calcium oxalate crystallization	1	NBK316514	
avoidance of supersaturation of calcium oxalate in the blood	1	NBK316514	
avoidance of marked dietary oxalate excess	1	NBK316514	
simple avoidance of marked dietary oxalate excess is recommended	1	NBK316514	
metabolic abnormalities and hypertension generally improve within one week	1	NBK65707	
different thiazide diuretics exist, with different dosing regimens	1	NBK65707	
anal atresia or stenosis should be treated in standard fashion	1	NBK1465	
seizures are treated symptomatically	1	NBK1465	
repair of polydactyly should be undertaken on an elective basis	1	NBK1465	
if asymptomatic, observation alone is prudent	1	NBK1488	
when symptomatic, topical agents (e	1	NBK1488	
leg-length discrepancy secondary to segmental somatic overgrowth	1	NBK153722	
cardiac abnormalities (i	1	NBK153722	
, structural cardiovascular disease and arrhythmias)	1	NBK153722	
renal abnormalities	1	NBK153722	
speech, swallowing, and feeding difficulties	1	NBK153722	
neurologic and neurosurgical manifestations	1	NBK153722	
mcap syndrome	1	NBK153722	
hmeg	1	NBK153722	
somatic overgrowth, vascular, lymphatic and musculoskeletal manifestations	1	NBK153722	
infant feeding assessment to address early hypotonia as needed	1	NBK100240	
behavioral modification for self-injurious behavior or anxiety	1	NBK100240	
eyeglasses or surgery as needed for amblyopia	1	NBK100240	
orthopedic treatment of scoliosis as indicated	1	NBK100240	
standard care for other medical issues	1	NBK100240	
polyps	1	NBK1266	
this strategy has two goals:	1	NBK1266	
from st	1	NBK1266	
intussusception should be treated in a standard manner	1	NBK1266	
malignancies should be treated in a standard manner	1	NBK1266	
intramuscular botulinum toxin	1	NBK1490	
intrathecal and intraventricular baclofen	1	NBK1490	
ablative pallidotomy or thalmotomy	1	NBK1490	
referral for adaptive aids as needed (e	1	NBK1490	
, a walker or wheelchair for gait abnormalities)	1	NBK1490	
other manifestations	1	NBK1490	
treatment and interventions for retinopathy as per ophthalmology	1	NBK1490	
flank pain	1	NBK1246	
cyst hemorrhage and gross hematuria	1	NBK1246	
nephrolithiasis	1	NBK1246	
5), and administration of allopurinol	1	NBK1246	
cyst infection	1	NBK1246	
cyst infection is often difficult to treat	1	NBK1246	
therapeutic agents of choice include trimethoprim-sulfamethoxazole and fluoroquinolones	1	NBK1246	
chloramphenicol has shown therapeutic efficacy in otherwise refractory disease	1	NBK1246	
end-stage renal disease (esrd)	1	NBK1246	
females appear to do better than males	1	NBK1246	
complications directly related to adpkd are rare	1	NBK1246	
polycystic liver disease	1	NBK1246	
and the results are often short-lived	1	NBK1246	
ruptured or symptomatic intracranial aneurysm	1	NBK1246	
asymptomatic aneurysms	1	NBK1246	
those aneurysms measuring 5	1	NBK1246	
if the size increases, surgery is indicated	1	NBK1246	
the management of aneurysms 6	1	NBK1246	
0-9	1	NBK1246	
0 mm in size remains controversial	1	NBK1246	
surgical intervention is usually indicated for aneurysms larger than 10	1	NBK1246	
aortic dissection	1	NBK1246	
early recognition and treatment of dehydration is critical	1	NBK1326	
and (2) the risk for ascending cholangitis	1	NBK1326	
administration of synthetic bile acids	1	NBK1326	
portosystemic shunting may be necessary to treat progressive portal hypertension	1	NBK1326	
dual-organ transplantation	1	NBK1326	
see table 2 (pdf) and figure 1	1	NBK1326	
feeding and growth	1	NBK1326	
see acmg management guidelines for pku	1	NBK1504	
treatment of classic pku	1	NBK1504	
restriction of dietary phenylalanine	1	NBK1504	
maintain blood tyr in the normal range	1	NBK1504	
sapropterin (kuvan®)	1	NBK1504	
reviewed in ho & christodoulou [2014]	1	NBK1504	
large neutral amino acids (lnaa) transporters	1	NBK1504	
treatment for non-classic hyperphenylalaninemia	1	NBK1504	
neuropsychiatric testing may be considered to identify learning differences	1	NBK1504	
bone health assessment	1	NBK1504	
only symptomatic treatment is available	1	NBK1197	
epileptic seizures may worsen the individual's condition	1	NBK1197	
those with severe dysphagia may require feeding by gastrostomy	1	NBK1182	
response to pharmacologic treatment is poor	1	NBK1221	
however, clonazepam or diazepam can be effective	1	NBK1221	
no disease-modifying drug treatment exists for pnpla6-related disorders	1	NBK247161	
speech therapy [sapir et al 2003]	1	NBK247161	
swallowing therapy	1	NBK247161	
assistive walking devices and ankle-foot orthotics	1	NBK247161	
, baclofen [oral or intrathecal], tolperison	1	NBK247161	
botox® injections) and urinary urgency (e	1	NBK247161	
hypothyroidism is treated with thyroid hormone replacement (e	1	NBK247161	
, levothyroxine) at the time of diagnosis	1	NBK247161	
dysphagia management is therefore important	1	NBK99167	
hypersalivation is managed with the multidisciplinary team and an otolaryngologist	1	NBK99167	
treatment must be individualized	1	NBK99167	
therapies to consider include rehabilitation (e	1	NBK99167	
, oromotor therapy, behavioral therapy)	1	NBK99167	
medical therapy (e	1	NBK99167	
, anticholinergic medications, botulinum toxin injections)	1	NBK99167	
and, in severe cases, surgery (e	1	NBK99167	
learning difficulties are likely to progress slowly	1	NBK99167	
patients should be followed regularly by an endocrinologist	1	NBK99167	
patients need to be followed regularly by an ophthalmologist	1	NBK99167	
the following treatment is recommended:	1	NBK1329	
speech therapy for those with language impairment	1	NBK1329	
occupational therapy for those with language impairment	1	NBK1329	
severe obesity	1	NBK174451	
therefore, lifestyle measures should be instigated	1	NBK174451	
fair skin	1	NBK174451	
growth hormone (gh) deficiency	1	NBK174451	
treatment is highly effective	1	NBK143129	
iron reduction	1	NBK143129	
iron chelation therapy (e	1	NBK143129	
serum ferritin concentration should be measured before starting phlebotomy treatment	1	NBK143129	
for persons with the hfe genotypes p	1	NBK143129	
cys282tyr or p	1	NBK143129	
low-dose anti-malarial agents	1	NBK143129	
combining both treatment modalities (i	1	NBK143129	
pct may also improve after treatment of coexisting hepatitis c	1	NBK143129	
pct should be treated first in most individuals:	1	NBK143129	
neurovisceral symptoms	1	NBK121283	
most acute neurovisceral attacks require hospital admission	1	NBK121283	
harmful medications should be discontinued	1	NBK121283	
cutaneous symptoms	1	NBK121283	
patients should wear protective clothing and avoid exposure to sunlight	1	NBK121283	
topical steroids are of little or no benefit	1	NBK121283	
strabismus and/or refractive errors	1	NBK447920	
standard treatment as recommended by ophthalmologist	1	NBK447920	
dental crowding / malocclusion	1	NBK447920	
evidence of sleep apnea	1	NBK447920	
standard treatment as indicated	1	NBK447920	
diet diary & calorie counts may be requested	1	NBK447920	
hypoglycemia, short stature, evidence of growth hormone deficiency	1	NBK447920	
standard treatment(s) as recommended by endocrinologist	1	NBK447920	
standard treatment as recommended by cardiologist	1	NBK447920	
renal anomaly and/or vesicoureteral reflux	1	NBK447920	
standard treatment as recommended by nephrologist/urologist	1	NBK447920	
enrollment in dda (developmental disabilities administration) is recommended	1	NBK447920	
, scoliosis)	1	NBK447920	
consider:	1	NBK447920	
evaluation for alternative means of communication (e	1	NBK447920	
pleuropulmonary blastoma (ppb)	1	NBK196157	
individuals receiving neoadjuvant chemotherapy may have marked tumor reduction	1	NBK196157	
chemotherapy alone is insufficient to eradicate solid ppb	1	NBK196157	
pleural effusions	1	NBK196157	
drainage of pleural effusions should be approached with caution	1	NBK196157	
surgery for metastases	1	NBK196157	
therapeutic resection of bone and liver metastases is rarely indicated	1	NBK196157	
type i ppb	1	NBK196157	
types ii and iii ppb	1	NBK196157	
aggressive chemotherapy is necessary	1	NBK196157	
ppbregistry	1	NBK196157	
radiation therapy	1	NBK196157	
treatment failure	1	NBK196157	
ovarian sex cord-stromal tumors	1	NBK196157	
sertoli-leydig cell tumor	1	NBK196157	
juvenile granulosa cell tumor (jgct)	1	NBK196157	
hyperthermic chemotherapy has been used by some investigators	1	NBK196157	
gynandroblastoma	1	NBK196157	
the malignant potential of gynandroblastoma is not yet clear	1	NBK196157	
cystic nephroma	1	NBK196157	
multinodular goiter (mng) and thyroid cancer	1	NBK196157	
observation with or without biopsy	1	NBK196157	
ciliary body medulloepithelioma (cbme)	1	NBK196157	
the four management options include:	1	NBK196157	
observation	1	NBK196157	
local resection	1	NBK196157	
however, many of these tumors will progress	1	NBK196157	
enucleation	1	NBK196157	
long-term survival is common after this definitive therapy	1	NBK196157	
orbital exenteration	1	NBK196157	
nasal chondromesenchymal hamartoma (ncmh)	1	NBK196157	
however, complete extirpation is preferred	1	NBK196157	
pituitary blastoma	1	NBK196157	
pineoblastoma	1	NBK196157	
immediate management issues may include interventions for obstructive hydrocephalus	1	NBK196157	
an aggressive surgical approach is associated with prolonged survival	1	NBK196157	
medications in use for pah include the following:	1	NBK1485	
endothelin blockers (oral)bosentanambrisenanmacitentan	1	NBK1485	
phosphodiesterase inhibitors (oral)sildenafiltadalafil	1	NBK1485	
guanylate cyclase stimulator (oral)riociguat	1	NBK1485	
calcium channel blockers	1	NBK1485	
adjunctive agents	1	NBK1485	
mean survival after lung transplantation is about five years	1	NBK1485	
no specific therapy for ppd is available	1	NBK327267	
pain due to secondary osteoarthritis may respond to nsaids	1	NBK327267	
physical therapy may help preserve joint mobility	1	NBK327267	
immobilization (e	1	NBK327267	
, casting) should be avoided	1	NBK327267	
angular deformities of lower limbs	1	NBK327267	
progressive joint stiffness	1	NBK327267	
, hip and knee replacement)	1	NBK327267	
progressive stiffness and deformities of the spine	1	NBK327267	
scoliosis and mild kyphosis can be managed with bracing	1	NBK327267	
therapy is aimed at controlling symptoms that may cause discomfort	1	NBK1229	
myoclonus can sometimes be mitigated by clonazepam	1	NBK1229	
issues related to dysphagia are often difficult to resolve	1	NBK1229	
no curative treatment is available	1	NBK299584	
care is preferably provided by a multidisciplinary team	1	NBK299584	
growth hormone	1	NBK1347	
, recombinant) gh	1	NBK1347	
tsh	1	NBK1347	
lh and fsh	1	NBK1347	
usually sex steroids are used to maintain secondary sex characteristics	1	NBK1347	
acth	1	NBK1347	
neonatal/acute decompensation	1	NBK92946	
in-patient management	1	NBK92946	
assess and manage ventilation and circulation as necessary	1	NBK92946	
determine the need for sepsis workup and antibiotics	1	NBK92946	
reverse catabolism by giving intravenous glucose and lipids	1	NBK92946	
dextrose solutions exceeding the concentration of 12	1	NBK92946	
5% require a central line placement	1	NBK92946	
additional calories can be provided using parenteral lipid emulsion	1	NBK92946	
manage protein intake to reduce propiogenic precursors	1	NBK92946	
remove toxic compounds	1	NBK92946	
pharmacologic detoxification:	1	NBK92946	
oral n-carbamoylglutamate (carglumic acid	1	NBK92946	
manage pancreatitis using standard practices	1	NBK92946	
home management of metabolic status	1	NBK92946	
at-home detection and monitoring of urine ketones	1	NBK92946	
diet modification under the direction of the metabolic team	1	NBK92946	
management of arrhythmias is similar to that from other causes	1	NBK92946	
dermatologic manifestations (e	1	NBK92946	
evaluation for dvts	1	NBK99495	
evaluation of pe	1	NBK99495	
bullous pulmonary disease	1	NBK99495	
psychosocial issues	1	NBK99495	
0 mg/dl (360 μmol/l)	1	NBK1973	
febuxostat, a newer urate-lowering xanthine oxidase inhibitor	1	NBK1973	
note: excretion of >1	1	NBK1973	
high daily fluid intake (i	1	NBK1973	
, ≥2 l/day in the adult)	1	NBK1973	
xanthinuria does not respond to urinary alkalinization	1	NBK1973	
several expert groups (e	1	NBK84399	
giessen, germany)	1	NBK84399	
burtonsville, md)	1	NBK84399	
cholecystokinin (cck) and its analogues (e	1	NBK84399	
13c-mixed triglyceride breath test	1	NBK84399	
72-hour fecal fat	1	NBK84399	
sudan stain	1	NBK84399	
, mineral oil, olestra)	1	NBK84399	
, orlistat)	1	NBK84399	
chronic pancreatitis is associated with a gradual loss of function	1	NBK84399	
surgical methods are standard	1	NBK1487	
a target inr of 2	1	NBK1148	
5 (therapeutic range: 2	1	NBK1148	
anticoagulation is recommended:	1	NBK1148	
indefinitely for those with recurrent idiopathic vte	1	NBK1148	
cognitive/developmental delay	1	NBK426063	
see global developmental disability/ intellectual disability educational issues	1	NBK426063	
management by a neurologist	1	NBK426063	
, dystonia, dyskinesia, dysconjugate eye movements)	1	NBK426063	
vision deficits	1	NBK426063	
correction of refractive errors	1	NBK426063	
vision support	1	NBK426063	
standard treatment for strabismus & exophoria	1	NBK426063	
supplementary oxygen (at night) & rarely tracheostomy	1	NBK426063	
ambulatory peripheral saturation monitoring may be required	1	NBK426063	
congenital heart defect	1	NBK426063	
frequent aspiration (or high risk of aspiration)	1	NBK426063	
a percutaneous endoscopic gastrostomy tube may be considered	1	NBK426063	
medical management	1	NBK426063	
referral to a gastroenterologist may be required in severe cases	1	NBK426063	
congenital urogenital defect	1	NBK426063	
management as per current practice for the specific urogenital defect	1	NBK426063	
progressive neuropathic scoliosis may require spinal fusion	1	NBK426063	
osteoporosis/osteopenia	1	NBK426063	
instability in standing position	1	NBK426063	
neuropathic hip dysplasia, progressive subluxation, & dislocation	1	NBK426063	
consideration of hip reconstructions w/varus derotational proximal femoral osteotomies	1	NBK426063	
vitamin d deficiency	1	NBK426063	
vitamin d supplementation	1	NBK426063	
anterior pituitary hormone deficiencies	1	NBK426063	
standard treatment as directed by an endocrinologist	1	NBK426063	
global developmental disability/ intellectual disability educational issues	1	NBK426063	
, scoliosis, hip dislocation)	1	NBK426063	
, feeding, grooming, dressing)	1	NBK426063	
feeding, hyperphagia, and obesity	1	NBK1330	
therapies, education and behavior management	1	NBK1330	
initiate appropriate educational programming in children:	1	NBK1330	
social skills training groups have been beneficial	1	NBK1330	
however, preservation of fertility is not an issue	1	NBK1330	
standard treatment is appropriate	1	NBK1330	
angulo & miller, unpublished data]	1	NBK1330	
schulze et al 2001	1	NBK1330	
vats & cassidy, unpublished data]	1	NBK1330	
sleep issues	1	NBK1330	
skin picking	1	NBK1330	
management of strabismus is as for any infant	1	NBK1330	
adulthood	1	NBK1330	
affected individuals generally require a sheltered employment environment	1	NBK1330	
no specific treatment for pxe exists	1	NBK1113	
for all phenotypes	1	NBK1115	
occupational therapy to maximize motor function	1	NBK1115	
speech therapy for dysarthria	1	NBK1115	
rdp	1	NBK1115	
standard therapies for the following are appropriate:	1	NBK1115	
ahc	1	NBK1115	
episode prophylaxis (avoiding triggers	1	NBK1115	
prophylactic medications	1	NBK1115	
flunarizine	1	NBK1115	
chloral hydrate	1	NBK1115	
other sleep inducers	1	NBK1115	
epilepsy management utilizes existing anticonvulsants	1	NBK1115	
capos syndrome	1	NBK1115	
symptomatic treatment includes hearing and visual aids	1	NBK1115	
capillary malformations (cms)	1	NBK52764	
avms/avfs	1	NBK52764	
, embolization vs	1	NBK52764	
surgery)	1	NBK52764	
cardiac overload	1	NBK52764	
hemihyperplasia and/or leg length discrepancy	1	NBK52764	
lymphangiography to evaluate for lymphatic malformations may be considered	1	NBK52764	
prostheses	1	NBK1153	
intervention and/or special education if developmental delays are detected	1	NBK1153	
cataract extraction may preserve some vision	1	NBK1270	
orthopedic procedures have improved function in some individuals	1	NBK1270	
dietary restriction of phytanic acid intake	1	NBK1353	
avoidance of sudden weight loss	1	NBK1353	
lifelong treatment with hydrating creams	1	NBK1353	
treatment of acute presentation	1	NBK1353	
treatment options for the eye include enucleation	1	NBK1452	
cryotherapy	1	NBK1452	
radiation therapy using episcleral plaques	1	NBK1452	
legal use of telescopic lenses may vary by locale	1	NBK1222	
retinoschisis affects primarily the inner retinal layers	1	NBK1222	
psychosocial support for families is an integral part of management	1	NBK1497	
they are tolerated better than milk of magnesia	1	NBK1497	
high dose supplementation	1	NBK299312	
supportive care	1	NBK299312	
respiratory support	1	NBK299312	
physiotherapy to avoid contractures	1	NBK299312	
occupational therapy for support in activities of daily living	1	NBK299312	
orthotics for limb and trunk bracing	1	NBK299312	
speech and language therapy to avoid choking and respiratory problems	1	NBK299312	
wheel chair as needed	1	NBK299312	
low vision aids for those with decreased visual acuity	1	NBK299312	
routine management of scoliosis to avoid long term respiratory problems	1	NBK299312	
routine management of depression	1	NBK299312	
pharmacologic treatment focuses on improving pain and correcting bone deformation	1	NBK83985	
low dose	1	NBK83985	
high dose	1	NBK83985	
50 to 0	1	NBK83985	
75 µg daily	1	NBK83985	
in these individuals, surgical treatment is frequently pursued	1	NBK83985	
the literature consists of case series	1	NBK83985	
craniofacial treatment	1	NBK83985	
sensorineural hearing loss has been reported in persons with xlh	1	NBK83985	
see hereditary hearing loss and deafness overview, management	1	NBK83985	
corrective surgeries may be required for repair of:	1	NBK268648	
abnormal penile insertion/penoscrotal position	1	NBK268648	
hormone therapy may be helpful for males with micropenis	1	NBK268648	
orthodontic treatment is typically required	1	NBK268648	
corrective surgeries may be required for the following:	1	NBK1240	
syndactyly repair	1	NBK1240	
severe scoliosis secondary to hemivertebrae and rib abnormalities	1	NBK1240	
cleft lip and cleft palate repair	1	NBK1240	
hormone therapy should be monitored by a pediatric endocrinologist	1	NBK1240	
orthodontic treatment is usually required	1	NBK1240	
no treatment is required	1	NBK114805	
cystoid macular edema (cme)	1	NBK1417	
optical aids	1	NBK1417	
however, its current cost limits widespread use	1	NBK1417	
retinal prostheses	1	NBK1417	
agencies for the visually impaired	1	NBK1417	
general management guidelines for those with systemic involvement:	1	NBK195854	
nutritional support (e	1	NBK195854	
management may include consideration of tracheostomy and artificial ventilation	1	NBK195854	
referral to a pediatric neurologist for seizure management	1	NBK195854	
of note, seizures may be refractory to treatment	1	NBK195854	
aggressive management of fever and infection	1	NBK195854	
5 epimutations possibly because children with 11p15	1	NBK1324	
initial treatment is use of a shoe lift	1	NBK1324	
neurodevelopment	1	NBK1324	
gastrointestinal disorders should be aggressively managed	1	NBK1324	
craniofacial anomalies	1	NBK1324	
orthognathic surgery is rarely required	1	NBK1324	
referral of males with cryptorchidism to a urologist	1	NBK1324	
referral of males with micropenis to an endocrinologist	1	NBK1324	
androgenic hormone therapy as indicated	1	NBK1324	
neoplasia	1	NBK1324	
standard treatment for hearing loss if identified	1	NBK1526	
standard treatment for cardiac defects if identified	1	NBK1526	
aggressive management of gastroesophageal reflux and constipation	1	NBK1526	
standard treatment for cryptorchidism if identified	1	NBK1526	
surgical repair of significantly angulated thumbs or duplicated halluces	1	NBK1526	
appropriate treatment for sleep apnea if identified	1	NBK1526	
visually significant cataracts require surgical removal	1	NBK1237	
complete cessation of symptoms is the goal	1	NBK1129	
it is therefore important that:	1	NBK1129	
adequate posture should be maintained when lying prone and sitting	1	NBK83297	
hematologic manifestations	1	NBK435692	
treatment is symptomatic:	1	NBK3795	
sensory axonal neuropathy	1	NBK3795	
physiotherapy and orthoses to prevent foot and spine deformity	1	NBK3795	
supportive shoes, splints, and braces	1	NBK3795	
foot care to treat calluses and ulcerations	1	NBK3795	
a walker, wheelchair, physiotherapy, occupational therapy	1	NBK3795	
some patients have benefited from lamotrigine or levetiracetam	1	NBK3795	
psychiatric symptoms	1	NBK3795	
canes and walkers help prevent falling	1	NBK1175	
occupational therapy, including home adaptations	1	NBK1757	
physiotherapy and assessment for cane and wheelchair	1	NBK1757	
ankle-foot orthotics (afos) for those with neuropathy	1	NBK1757	
modest success has been observed in some affected individuals	1	NBK1202	
supplements of antioxidants, which may have some beneficial effects	1	NBK1202	
treatment of psychiatric syndromes as needed	1	NBK1202	
technical assistance with writing and other fine-motor tasks	1	NBK1202	
epileptic seizures can be improved by treatment with anticonvulsive medications	1	NBK1225	
treatment of seizures with antiepileptic drugs (aeds)	1	NBK1438	
treatment of dystonia with local injections of botulinum toxin	1	NBK1438	
at present, only symptomatic treatments are available	1	NBK54582	
these include the following:	1	NBK54582	
crutches (less often canes) and walkers	1	NBK54582	
speech/language therapy for dysarthria and swallowing difficulties	1	NBK54582	
surgical intervention as needed for severe ptosis	1	NBK54582	
symptoms of restless legs syndrome may respond to these agents	1	NBK1196	
non-pharmacologic therapy is important in sca3:	1	NBK1196	
specific treatment for sca36 is currently not available	1	NBK231880	
walking aids to facilitate ambulation and mobility	1	NBK231880	
the use of a wheelchair is rare	1	NBK231880	
speech therapy and communication devices for those with dysarthria	1	NBK231880	
the utility of cochlear implants in sca36 is unknown	1	NBK231880	
vestibular suppressants may reduce vertigo and/or osscilopsia	1	NBK1140	
canes, walking sticks, and walkers help prevent falling	1	NBK1140	
note: rbd is rare in individuals with sca6	1	NBK1140	
continuous positive airway pressure may be used for sleep apnea	1	NBK1140	
cerebellar ataxia	1	NBK1256	
retinal degeneration	1	NBK1256	
use of canes and walkers helps prevent falls	1	NBK1268	
compound heterozygous for pathogenic variant and a susceptibility variant	1	NBK63582	
free carnitine levels were normal in all individuals	1	NBK63582	
no published treatment guidelines exist	1	NBK379665	
, dravet syndrome	1	NBK379665	
see scn1a-related seizure disorders and differential diagnosis)	1	NBK379665	
sodium channel blockers	1	NBK379665	
other aeds	1	NBK379665	
vagus nerve stimulator	1	NBK379665	
cannabinoids	1	NBK379665	
sleep hygiene	1	NBK379665	
it prevents the following:	1	NBK1189	
in most cases, cranioplasty precedes palatal repair	1	NBK1189	
ophthalmologic abnormalities are treated in a standard fashion	1	NBK1189	
routine monitoring (see surveillance) is recommended	1	NBK1756	
hematologic abnormalities	1	NBK1756	
prompt treatment of hypoglycemia if present	1	NBK1219	
ophthalmologist for management of vision problems	1	NBK1219	
neurologist if seizures are present	1	NBK1219	
oncologist if a tumor is identified	1	NBK1219	
surgical intervention for aneurysms may be indicated	1	NBK1277	
surgical repair of abdominal hernias may be indicated	1	NBK1277	
cleft palate and craniosynostosis require management by a craniofacial team	1	NBK1277	
surgical fixation of cervical spine instability may be necessary	1	NBK1277	
clubfoot deformity may require surgical correction	1	NBK1277	
pectus excavatum may be severe	1	NBK1277	
rarely, surgical correction is indicated for medical reasons	1	NBK1277	
physiotherapy	1	NBK1277	
physiotherapy may help increase mobility in individuals with joint contractures	1	NBK1277	
axenfeld-rieger anomaly or related anterior chamber ocular anomalies	1	NBK201365	
dental anomalies	1	NBK201365	
insulin resistance/diabetes mellitus	1	NBK201365	
a systematic approach to pain management should be reviewed regularly	1	NBK1377	
vaso-occlusive pain episodes (including dactylitis)	1	NBK1377	
, cold, dehydration)	1	NBK1377	
nsaids (e	1	NBK1377	
fever/suspected infection	1	NBK1377	
individuals with temperature greater than 38	1	NBK1377	
rapid triage and physical assessment	1	NBK1377	
urgent cbc and reticulocyte count	1	NBK1377	
acute chest syndrome (acs)	1	NBK1377	
perform chest x-ray examination	1	NBK1377	
incentive spirometry should be encouraged	1	NBK1377	
aplastic crisis	1	NBK1377	
blood transfusion may be necessary	1	NBK1377	
splenic sequestration	1	NBK1377	
pulmonary hypertension	1	NBK1377	
the following general approach is reasonable:	1	NBK1377	
, thrombotic disease, obstructive sleep apnea)	1	NBK1377	
optimization of scd-related therapy to stop progression (e	1	NBK1377	
stroke	1	NBK1377	
cerebral hemorrhage requires immediate neurosurgical consultation	1	NBK1377	
chronic transfusion has been shown to reduce silent infarcts	1	NBK1377	
priapism	1	NBK1377	
there is no effective treatment for xlsa/a	1	NBK1321	
weighted eating utensils may help promote independent skills in childhood	1	NBK1321	
speech therapy may improve intelligibility problems resulting from dysarthria	1	NBK1321	
hepatic and systemic iron overload does not occur	1	NBK1321	
orthopedic manifestations	1	NBK1376	
treatment of scoliosis and/or kyphosis is standard	1	NBK1376	
immunologic manifestations	1	NBK1376	
individuals with autoimmune problems have had variable responses to treatment	1	NBK1376	
infectious disease manifestations	1	NBK1376	
hypothyroidism can be treated with levothyroxine supplementation	1	NBK1376	
chelation therapy	1	NBK431123	
monitoring includes the following:	1	NBK431123	
complete blood count	1	NBK431123	
assessment of liver function	1	NBK431123	
assessment of iron status	1	NBK431123	
treatment may need to be discontinued if:	1	NBK431123	
white blood count is <3	1	NBK431123	
5x109/l	1	NBK431123	
neutrophil count is <2	1	NBK431123	
0x109/l	1	NBK431123	
platelet count is <150x109/l	1	NBK431123	
although the role of atypical tranquilizers (e	1	NBK442323	
treatment of status dystonicus	1	NBK442323	
standard protocols are used in an intensive care setting	1	NBK442323	
cholesterol supplementation	1	NBK1143	
dental management can be challenging	1	NBK1143	
recurrent otitis media may require tympanostomy tube placement	1	NBK1143	
see spinal muscular atrophy	1	NBK2594	
feeding/growth	1	NBK2594	
manage gastroesophageal reflux disorder in the standard manner	1	NBK2594	
use oral suctioning as needed	1	NBK2594	
in some cases artificial ventilation and tracheostomy may be employed	1	NBK2594	
manage accordingly	1	NBK2594	
health issues specific to sma	1	NBK1352	
scoliosis occurs frequently in individuals with sma ii	1	NBK1352	
no surgical complications were identified	1	NBK1352	
hip dislocation is another orthopedic concern in sma	1	NBK1352	
ongoing pediatric care with regular immunizations	1	NBK1310	
[hildenbrand & smith 2012]	1	NBK1310	
no well-controlled treatment trials have been reported:	1	NBK1310	
thus, dosages may not be exact	1	NBK1310	
enclosed bed system for containment during sleep	1	NBK1310	
treatment with diet or medication as indicated	1	NBK1310	
treatment with corrective lenses as indicated for ophthalmologic abnormalities	1	NBK1310	
treatment of recurrent otitis media with tympanostomy tubes as needed	1	NBK1310	
the bones in sclerosteosis are thick and dense	1	NBK1228	
surgical intervention may be difficult and prolonged	1	NBK1228	
standard neurosurgical instruments may not be sufficient (i	1	NBK1228	
tooth extraction may be difficult	1	NBK1228	
management by an orthodontic or craniofacial team is recommended	1	NBK1228	
when clinical problems (e	1	NBK1479	
care includes:	1	NBK1300	
early referral to an experienced multidisciplinary team	1	NBK1300	
referral to special educational services for visually impaired infants	1	NBK1300	
referral to endocrinologist for growth or hypogonadism concerns	1	NBK1300	
referral to physiotherapist if any evidence of motor impairment exists	1	NBK1300	
referral to special educational services for neurodevelopmental problems as needed	1	NBK1300	
parent/caregiver training in seizure management	1	NBK1300	
no specific drug treatment or cures exist for spg11	1	NBK1210	
physiotherapy for stretching of the spastic muscles to prevent contractures	1	NBK1210	
anti-spastic drugs such as baclofen and tizanidine	1	NBK1210	
anticholinergic drugs are indicated for urinary urgency	1	NBK1210	
psychiatric manifestations should be treated in accordance with standard practice	1	NBK1210	
physiotherapy is appropriate	1	NBK1307	
foot deformities are corrected by surgical treatment	1	NBK1307	
improve muscle strength (through resistance exercise)	1	NBK1382	
improve cardiovascular fitness	1	NBK1382	
oxybutynin is helpful in reducing urinary urgency	1	NBK1382	
see also hereditary spastic paraplegia overview	1	NBK1382	
spasticity can be treated with:	1	NBK45978	
oral baclofen or tizanidine	1	NBK45978	
chemodenervation with botulinum a or b toxins	1	NBK45978	
intrathecal baclofen pump	1	NBK45978	
see also prevention of secondary complications	1	NBK45978	
referral to orthotic services may be helpful	1	NBK45978	
urinary urgency can be treated with anticholinergic antispasmodic drugs	1	NBK45978	
symptomatic treatment includes use of the following:	1	NBK1160	
antispastic drugs for leg spasticity	1	NBK1160	
anticholinergic antispasmodic drugs for urinary urgency	1	NBK1160	
regular physiotherapy for stretching of spastic muscles	1	NBK1160	
no specific drug treatments or cures exist for spg7	1	NBK1107	
antispasmodic drugs (e	1	NBK1827	
no significant toxicity limits their use	1	NBK1827	
routine treatment of inguinal herniae	1	NBK8828	
surgical intervention as needed if scoliosis is significant	1	NBK8828	
l-dopa (0	1	NBK304122	
optimal therapeutic level is determined by clinical response	1	NBK304122	
tetrahydrobiopterin (bh4	1	NBK304122	
monoamine oxidase inhibitors (selegeline)	1	NBK304122	
serotonin reuptake inhibitors (sertraline)	1	NBK304122	
melatonin	1	NBK304122	
dopamine agonists (bromocriptine, pramipexole)	1	NBK304122	
anticholinergics	1	NBK304122	
methylphenidate	1	NBK304122	
5 years [escalera et al 2010]	1	NBK1195	
and speech therapy [gropman 2003]	1	NBK1195	
refractive errors should be corrected with spectacles	1	NBK1302	
myringotomy tubes are often required	1	NBK1302	
some of these treatments have only been partially effective	1	NBK131810	
current treatment therapies focus on the following:	1	NBK131810	
treatments should begin at the time of diagnosis	1	NBK131810	
often existing xanthomas regress	1	NBK131810	
partial ileal bypass surgery (i	1	NBK131810	
sitosterolemia does not respond to standard statin treatment	1	NBK131810	
global developmental delay, cognitive dysfunction and intellectual disability	1	NBK396561	
seizure management is symptomatic	1	NBK396561	
other neurologic findings	1	NBK396561	
bracing for scoliosis and kyphosis	1	NBK6803	
blepharoplasty for significant ptosis	1	NBK6803	
hearing aids and/or cochlear implantation for sensorineural hearing loss	1	NBK6803	
agents such as gabapentin should be considered	1	NBK1525	
gentle handling may reduce pain that is worsened with movement	1	NBK1525	
splinting of affected joints may provide comfort	1	NBK1525	
consultation with a pain management specialist may be helpful	1	NBK1525	
palliative care may be an option in severe cases	1	NBK1525	
a nutritionist should follow affected individuals	1	NBK1525	
protein-losing enteropathy	1	NBK1525	
an effective long-term treatment is lacking	1	NBK1525	
dermatitis	1	NBK1525	
perianal masses may be excised, but may recur	1	NBK1525	
contractures are typically progressive	1	NBK1525	
immune system/infections	1	NBK1525	
the treatment for thrombocytopenia is platelet transfusion as needed	1	NBK23758	
but the clinical response is unpredictable and generally poor	1	NBK1218	
the management of epilepsy in many genetic epilepsies is complex	1	NBK274566	
refer to an urologist or nephrologist as indicated	1	NBK274566	
manage according to the anomalies detected	1	NBK274566	
imperforate anus	1	NBK1445	
immediate surgical intervention is required	1	NBK1445	
thumb malformations	1	NBK1445	
, removal of additional thumbs)	1	NBK1445	
birth to 2 years: airway and feeding difficulties	1	NBK1532	
13 years to 18 years: orthognathic surgery	1	NBK1532	
generally, bone reconstruction precedes soft tissue corrections	1	NBK1532	
reconstruction can prevent the progression of facial asymmetry	1	NBK1532	
maxillomandibular reconstruction	1	NBK1532	
orthognathic procedures are typically indicated before age 16 years	1	NBK1532	
misaligned teeth often require orthodonture	1	NBK1532	
nasal reconstruction, if needed, should follow orthognathic surgeries	1	NBK1532	
other measures:	1	NBK1366	
medication to control seizures, as in the general population	1	NBK1366	
shunt placement, when hydrocephaly is identified	1	NBK1366	
suboccipital decompression for relief of craniocervical junction constriction	1	NBK1366	
hearing aids, when hearing loss is identified	1	NBK1366	
supplemental oxygen should be administered as needed	1	NBK5192	
other individualized ambulatory devices may be indicated	1	NBK1276	
carpal tunnel release surgery for carpal tunnel syndrome	1	NBK1194	
vitrectomy for vitreous involvement	1	NBK1194	
therapeutic phlebotomy	1	NBK1349	
periodic phlebotomy (i	1	NBK1349	
the usual therapy is weekly phlebotomy	1	NBK1349	
camaschella & roetto, unpublished observation]	1	NBK1349	
treatment of clinical complications	1	NBK1349	
in some cases, joint replacement has been performed	1	NBK1349	
diabetes mellitus may require lifelong insulin treatment	1	NBK1349	
glycopyrolate or scopolamine to improve drooling	1	NBK26373	
standard anticonvulsant medication to control seizures, if present	1	NBK26373	
placement of permanent feeding tube to avert malnutrition	1	NBK26373	
see also therapies under investigation	1	NBK26373	
, 0	1	NBK1437	
mild form (th-deficient drd)	1	NBK1437	
individuals demonstrate complete responsiveness of symptoms to levodopa treatment	1	NBK1437	
individuals show a marked response to levodopa	1	NBK1437	
very severe form (th-deficient progressive infantile encephalopathy)	1	NBK1437	
individuals are extremely sensitive to levodopa	1	NBK1437	
2 to 1	1	NBK1437	
long qt interval	1	NBK1403	
beta-blockers	1	NBK1403	
pacemaker	1	NBK1403	
implants	1	NBK1403	
respiratory infections	1	NBK1403	
the possibility of reduced immune response should be considered	1	NBK1403	
surgical release of syndactyly	1	NBK1403	
currently there is no definitive treatment	1	NBK114628	
management should involve a multidisciplinary team	1	NBK114628	
management of trps is principally supportive	1	NBK425926	
ectodermal features	1	NBK425926	
hair	1	NBK425926	
however, reported results vary	1	NBK425926	
hands	1	NBK425926	
regular simple analgesia (e	1	NBK425926	
physiotherapy may aid mobility	1	NBK425926	
for trps ii only	1	NBK425926	
exostoses	1	NBK425926	
restriction of dietary trimethylamine and its precursors	1	NBK1103	
choline	1	NBK1103	
dietary choline is absorbed through the small intestine	1	NBK1103	
trimethylamine n-oxide	1	NBK1103	
intake of such vegetables should be restricted	1	NBK1103	
use of acid soaps and body lotions	1	NBK1103	
trimethylamine is a strong base (pka 9	1	NBK1103	
thus, at ph 6	1	NBK1103	
0, less than 0	1	NBK1103	
02% of trimethylamine exists as the volatile free base	1	NBK1103	
sequestering of trimethylamine produced in the gut	1	NBK1103	
suppression of intestinal production of trimethylamine	1	NBK1103	
enhancement of residual fmo3 enzyme activity	1	NBK1103	
counseling	1	NBK1103	
affected individuals and their families benefit from counseling	1	NBK1103	
see table 3	1	NBK447257	
dental crowding /	1	NBK447257	
malocclusion	1	NBK447257	
dietary diary & calorie counts may be requested	1	NBK447257	
gerd and/or constipation	1	NBK447257	
standard treatment(s)	1	NBK447257	
standard treatment(s) as recommended by neurologist	1	NBK447257	
scoliosis / kyphosis	1	NBK447257	
standard treatment as recommended by orthopedist	1	NBK447257	
effectiveness should be evaluated on an individual basis	1	NBK447257	
high-dose thiamine supplementation:	1	NBK1282	
invariably improves the hematologic picture	1	NBK1282	
additional treatment	1	NBK1282	
red blood cell transfusion for severe anemia is indicated	1	NBK1282	
treatment has included cochlear implant [hagr 2014]	1	NBK1282	
in some instances intrathecal baclofen pumps can be considered	1	NBK395611	
dystonia can be managed with:	1	NBK395611	
baclofen or intramuscular botulinum toxin when associated with spasticity	1	NBK395611	
trihexyphenidyl or tetrabenazine	1	NBK395611	
dysarthria may warrant augmentative communication tools	1	NBK395611	
anticonvulsant medications should be used when seizures are present	1	NBK395611	
subependymal giant cell astrocytomas (segas)	1	NBK1220	
additional trials are underway to confirm these preliminary findings	1	NBK1220	
renal angiomyolipoma	1	NBK1220	
facial angiofibromas	1	NBK1220	
cardiac rhabdomyomas	1	NBK1220	
, outflow tract obstruction) was surgery	1	NBK1220	
however, response to treatment is highly individual	1	NBK1220	
oxygen therapy is necessary with impaired lung function	1	NBK1220	
persons with severe disease require lung transplantation	1	NBK1220	
management guidelines have been published	1	NBK1515	
acute management of liver failure	1	NBK1515	
nitisinone (orfadin®)	1	NBK1515	
nitisinone is generally prescribed at 1	1	NBK1515	
0 mg/kg/day	1	NBK1515	
individual requirements may vary	1	NBK1515	
nitisinone is typically given in two divided doses	1	NBK1515	
low-tyrosine diet	1	NBK1515	
3 mg/dl)	1	NBK1515	
transplant recipients require long-term immunosuppression	1	NBK1515	
transplant recipients may also benefit from low-dose (0	1	NBK1515	
ocular abnormalities (nystagmus/strabismus)	1	NBK453434	
ophthalmologic management	1	NBK453434	
oral feeding difficulties	1	NBK453434	
g-tube feeding	1	NBK453434	
braces and/or corrective surgery	1	NBK453434	
self-injurious behavior	1	NBK453434	
behavior modification therapy	1	NBK453434	
hypo/hypertonia, gross motor delays, sensory processing difficulties	1	NBK453434	
physical therapy, occupational therapy	1	NBK453434	
absent speech	1	NBK453434	
sign language instruction	1	NBK453434	
consider alternate forms of communication	1	NBK453434	
urinary tract	1	NBK154138	
urinary tract infections warrant rapid and complete treatment	1	NBK154138	
antibiotic prophylaxis may also be considered	1	NBK154138	
bowel	1	NBK154138	
constipation is managed as for the general population	1	NBK154138	
balance	1	NBK1265	
hearing aids are helpful	1	NBK1341	
environmental trauma (e	1	NBK1341	
, noise) or a genetic susceptibility (e	1	NBK1341	
in such individuals, cochlear implantation may be warranted	1	NBK1341	
no guidelines exist for the management of vhl lesions	1	NBK1463	
cns hemangioblastoma	1	NBK1463	
two patients required additional surgery	1	NBK1463	
retinal hemangioblastoma	1	NBK1463	
renal cell carcinoma	1	NBK1463	
3% and 4	1	NBK1463	
3%, respectively [young et al 2012]	1	NBK1463	
pheochromocytomas	1	NBK1463	
pheochromocytomas should be surgically removed	1	NBK1463	
laparoscopic approaches have been shown to be effective	1	NBK1463	
partial adrenalectomy could be considered	1	NBK1463	
one long-term follow-up study (9	1	NBK1463	
partial adrenalectomy is also therapy of choice in children	1	NBK1463	
in 10 vhl patients 18 successful operations were performed	1	NBK1463	
after follow up (median 7	1	NBK1463	
pancreatic cysts and neuroendocrine tumors	1	NBK1463	
a tumor of ≥3 cm	1	NBK1463	
a pathogenic variant in exon 3	1	NBK1463	
a tumor with a doubling rate <500 days	1	NBK1463	
endolymphatic sac tumors (elst)	1	NBK1463	
twenty-nine patients were symptomatic	1	NBK1463	
epididymal or broad ligament papillary cyst adenomas	1	NBK1463	
physical therapy to promote ambulation	1	NBK1874	
treatment is required for any symptomatic vmcm lesion	1	NBK1967	
an appropriate dose is 0	1	NBK1271	
625 ml/kg) or 150 mg/m2 (3	1	NBK1271	
75 ml/m2)	1	NBK1271	
desmopressin	1	NBK7014	
intranasal preparations are also available	1	NBK7014	
intravenous infusion of vwf/fviii clotting factor concentrates	1	NBK7014	
in those who are non-responsive to desmopressin (i	1	NBK7014	
virus inactivation procedures eliminate potential pathogens	1	NBK7014	
indirect treatments	1	NBK7014	
fibrinolytic inhibitors (i	1	NBK7014	
hormonal treatments (i	1	NBK7014	
treatment by vwd type	1	NBK7014	
type 1 vwd	1	NBK7014	
treatments that directly increase vwf levels (e	1	NBK7014	
indirect treatment with fibrinolytic inhibitors or hormones is often effective	1	NBK7014	
type 2a vwd	1	NBK7014	
indirect treatments can be beneficial	1	NBK7014	
type 2b vwd	1	NBK7014	
[federici et al 2009]	1	NBK7014	
indirect treatments (i	1	NBK7014	
, fibrinolytic inhibitors) can be useful	1	NBK7014	
type 2m vwd	1	NBK7014	
type 2n vwd	1	NBK7014	
type 3 vwd	1	NBK7014	
desmopressin is not effective in type 3 vwd	1	NBK7014	
indirect treatments may also be beneficial	1	NBK7014	
vwf levels are higher in the neonatal period	1	NBK7014	
pharmacotherapy	1	NBK447258	
to reduce or delay side effects (e	1	NBK447258	
patients treated with ergot-derived dopamine agonists require periodic echocardiograms	1	NBK447258	
droxidopa may be used to treat orthostasis	1	NBK447258	
click here for full text	1	NBK1407	
management is supportive/symptomatic	1	NBK1407	
cleft lip	1	NBK1407	
management is surgical, dental, and orthodontic	1	NBK1407	
lip pits	1	NBK1407	
popliteal pterygium	1	NBK1407	
syndactyly may require surgery	1	NBK1407	
the genital anomalies may result in infertility	1	NBK1407	
refractive error is corrected by spectacles or contact lenses	1	NBK3821	
visually disabling cataract is treated by cataract surgery	1	NBK3821	
wiskott-aldrich syndrome	1	NBK1178	
[buchbinder et al 2014]	1	NBK1178	
hematopoietic cell transplantation (hct)	1	NBK1178	
eczema	1	NBK1178	
topical steroids are the mainstay of therapy	1	NBK1178	
autoimmune disease	1	NBK1178	
x-linked thrombocytopenia (xlt)	1	NBK1178	
, risk of secondary malignancy, infertility)	1	NBK1178	
x-linked neutropenia (xln)	1	NBK1178	
camptodactyly	1	NBK148820	
occasionally toe camptodactyly may require surgical intervention	1	NBK148820	
physiotherapy may also be beneficial	1	NBK148820	
ligamentous laxity	1	NBK148820	
control of type 2 diabetes mellitus	1	NBK1514	
use of cholesterol-lowering drugs if lipid profile is abnormal	1	NBK1514	
muscle atrophy is a potential complication	1	NBK1514	
surgical treatment of ocular cataracts	1	NBK1514	
treatment of malignancies in a standard fashion	1	NBK1514	
treatment follows routine practices for insulin-dependent diabetes mellitus	1	NBK4144	
wfs	1	NBK4144	
low-frequency sensorineural hearing loss (lfsnhl)	1	NBK4144	
psychiatric difficulties	1	NBK4144	
neurogenic bladder	1	NBK4144	
treatment of central diabetes insipidus follows routine practices	1	NBK4144	
treatment of gastroparesis and celiac disease follows routine practices	1	NBK4144	
(see celiac disease	1	NBK4144	
sleeping problems	1	NBK1183	
if no medical factors (e	1	NBK1183	
hepatic adenomas	1	NBK1183	
other structural anomalies (e	1	NBK1183	
cognitive/behavioral	1	NBK1249	
self-calming techniques can help manage anxiety	1	NBK1249	
hypertension is usually treated medically	1	NBK1249	
hypercalcemia	1	NBK1249	
management of hypercalcemia involves the following:	1	NBK1249	
hydration status should be assessed	1	NBK1249	
increase water intake as indicated	1	NBK1249	
but the serum concentration of calcium must be monitored	1	NBK1249	
vitamin supplements containing vitamin d should be avoided	1	NBK1249	
refractory hypercalcemia may be treated with oral steroids	1	NBK1249	
eye, ear, nose, and throat	1	NBK1249	
hyperopia is treated with corrective lenses	1	NBK1249	
dacrostenosis is treated as in the general population	1	NBK1249	
recurrent otitis media may be treated with tympanotomy tubes	1	NBK1249	
dental care may require assistance with daily brushing and flossing	1	NBK1249	
orthodontic referral should be considered for treatment of malocclusion	1	NBK1249	
infants often benefit from feeding therapy	1	NBK1249	
urinary tract abnormalities	1	NBK1249	
hypothyroidism is treated with oral thyroxine therapy	1	NBK1249	
treatment is life long, including during pregnancy	1	NBK1512	
d-penicillamine (chelator)	1	NBK1512	
pyridoxine must be given along with d-penicillamine	1	NBK1512	
zinc (metallothionein inducer)	1	NBK1512	
antioxidants	1	NBK1512	
, vegetarians) consult with a trained dietitian	1	NBK1512	
no specific treatment exists for wss	1	NBK378974	
all treatment is symptomatic	1	NBK378974	
note: standard replacement hormonal treatment will not promote fertility	1	NBK378974	
low igf-1	1	NBK378974	
standard treatment	1	NBK378974	
l-thyroxine replacement therapy	1	NBK378974	
ectodermal	1	NBK378974	
treatment is symptomatic and cosmetic only	1	NBK378974	
movement disorders	1	NBK378974	
benzodiazepines, especially clonazepam	1	NBK378974	
its use in wss has not been documented	1	NBK378974	
dysarthria	1	NBK378974	
consultation with a speech therapist may be helpful	1	NBK378974	
nutritional management by a knowledgeable nutritionist is helpful	1	NBK378974	
treatment is symptomatic and should be tailored to each patient	1	NBK55062	
orthopedic management of leg length discrepancy	1	NBK55062	
surgical correction of polydactyly	1	NBK55062	
cataract extraction and correction of vision	1	NBK55062	
dermatologic management of skin lesions	1	NBK55062	
hypohidrosis	1	NBK1112	
some individuals may benefit from "cooling vests	1	NBK1112	
hypodontia	1	NBK1112	
orthodontics may be necessary	1	NBK1112	
dental implants in adults can support aesthetic and functional dentition	1	NBK1112	
lubrication eye drops can be helpful for dry eyes	1	NBK1112	
no formal management guidelines exist	1	NBK1406	
the following are general considerations	1	NBK1406	
hypogammaglobulinemia is treated with ivig	1	NBK1406	
treatment with antiepileptic agents	1	NBK1213	
many individuals with periventricular nodular heterotopia have dyslexia	1	NBK1213	
pharmacologic treatment of dystonia	1	NBK1489	
anticholinergic agents and benzodiazepines	1	NBK1489	
the benzodiazepine associated with the best response is clonazepam	1	NBK1489	
zolpidem	1	NBK1489	
risperidone seems less effective than haloperidol in controlling dystonia	1	NBK1489	
pharmacologic treatment of parkinsonism	1	NBK1489	
surgical treatment of dystonia and parkinsonism	1	NBK1489	
optical devices	1	NBK3822	
pharmacologic	1	NBK3822	
total parenteral nutrition may be required	1	NBK1402	
institute appropriate antimicrobial therapy for infections	1	NBK1402	
treat lymphomas and gi cancer	1	NBK1402	
the following treatments are recommended:	1	NBK1449	
early intervention programs and special education for developmental delays	1	NBK1449	
premalignant lesions (e	1	NBK1397	
this involves electrodesiccation/curettage or surgical excision	1	NBK1397	
calcification of ligaments and tendons	1	NBK1397	
however, no controlled studies have been reported	1	NBK1397	
recurrent bacterial infections are treated with standard antibiotics	1	NBK349624	
standard management is recommended for the following:	1	NBK349624	
behavioral and psychiatric problems	1	NBK349624	
kyphoscoliosis	1	NBK349624	
eye problems	1	NBK349624	
testosterone-replacement therapy	1	NBK1416	
gynecomastia	1	NBK1416	
regression of gynecomastia may occur with testosterone replacement therapy	1	NBK1416	
